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Abstract/Summary 
The innate immune system is a vital part of the body‟s defences against viral pathogens. 
RIG-I and MDA5 belong to the retinoic acid inducible gene-I (RIG-I)-like receptors 
(RLRs) family and function as cytoplasmic PRRs that are involved in the elimination of 
actively replicating RNA viruses. Their location and their differential responses to RNA 
viruses emphasises the complexity of the innate detection system. RIG-I and MDA5 
contribute to antiviral signalling in different ways depending on the virus involved.  
Coxsackieviruses are positive sense, single-stranded RNA viruses belonging to the 
Enterovirus genus of the Picornaviridae family. They cause many serious diseases, 
including viral myocarditis (which can lead on to dilated cardiomyopathy), aseptic 
meningitis, and pancreatitis.  In order to identify which RLR recognises these viruses 
and which RNA species triggers RLR activation during Coxsackievirus infection, viral 
ssRNA and replicative intermediates of Coxsackievirus RNA as well as synthetic 
dsRNA were used in this study. The results revealed that MDA5 recognises not the 
genomic ssRNA but the dsRNA generated by the replication of these viruses. Confocal 
microscopy provided unique evidence between the relationship of viral dsRNA and 
MDA5 while cytokine assays using HEK-MDA5 cells showed a strong immune 
response to Coxsackievirus and the dsRNA intermediates. This shows very strong 
evidence that MDA5 is a key sensor of the dsRNA intermediate of Coxsackieviruses. 
As RIG-Is role in Coxsackie recognition still needs to be verified Huh7 and Huh7.5.1 
cells were used and showed no difference in immune response in the absence of RIG-I 
to Coxsackievirus infection, as well as the isolated ssRNA, suggesting that the VPg 
group present on the RNA blocks recognition. Furthermore immunoprecipitation 
experiments showed that in response to Coxsackievirus stimulation, RLRs 
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homodimerise as well as heterodimerise with LGP2, potentially upregulating their 
activity as a possible mechanism for viral detection. 
The data presented here show a much clearer role for RLRs in Coxsackievirus infection, 
while opening new questions as to MDA5s role in the diseases caused by 
Coxsackieviruses, as well as the specifics behind dimerisation of the RLRs. 
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Chapter 1: Introduction 
1.1: Coxsackie Virus 
Coxsackieviruses are part of the enterovirus genus in the picornavirus family, along 
with Poliovirus, Echovirus and others. Infection with enteroviruses usually results in an 
asymptomatic infection without causing any significant disease. However infection can 
lead to serious illness, especially in infants and immuno-compromised individuals. 
In 1948 an unknown virus was isolated from the faeces of a child with febrile illness 
during a poliomyelitis epidemic in the Hudson River town of Coxsackie, New York 
[5;6]. The isolates were obtained by inoculating suckling mice with the virus and 
showed a pathogenesis clearly different of that of Poliovirus, replicating readily in the 
mice [7]. The virus was named Coxsackievirus and later became part of the group A 
Coxsackieviruses (CVA). The following year the first Coxsackievirus group B (CVB) 
member was isolated from a case of aseptic meningitis [8]. The isolated CVA caused 
myositis with flaccid hind limb paralysis in newborn mice, while the new isolate was 
separated into the new group CVB as it resulted in spastic paralysis and generalised 
infection with myositis as well as involvement of the heart, pancreas, brain and brown 
fat [9]. The two groups were separated primarily by the ability to induce flaccid 
paralysis in suckling mice (Group A), or not (Group B). 
1.1.1: Symptoms and Diseases Associated with CVB 
Enterovirus transmission is via the faecal oral route or respiratory. The faecal-oral route 
is more likely in areas with poor sanitary conditions, while respiratory transmission is 
more prominent in more developed countries. While the major route of CVB infections 
in infants and children is faecal-oral, vertical transmission from mother to the infant is 
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also possible [10]. CVB infections in humans range from asymptomatic infections to 
chronic, debilitating diseases and are associated with inflammatory disorders of the 
heart, pancreas and central nervous system (CNS) and are mostly associated with 
pleurodynia and myocarditis [11]. The specific symptoms and their rate of occurrence 
of CV in infants include lethargy, vomiting, anorexia, fever (90%), aseptic meningitis 
(50%), irritability (35%), non-specific rash (20%) and encephalitis, myocarditis, 
pancreatitis and pneumonia (1-3%) [12]. Of all enteroviruses CVB causes 20-30% of 
neonatal infections in industrialised countries [13]. 
In the heart CVB3 can produce myocarditis that can lead to chronic dilated 
cardiomyopathy. Myocarditis is inflammation of the myocardium associated with 
damage unrelated to ischemic injury. Evidence that CVB causes myocarditis comes 
from isolation of the infectious virus as well as its nucleic acid from hearts of patients 
with myocarditis, in particular neonatal and paediatric cases [14;15]. Lesions on the 
heart appear to be due to both direct viral lysis and the immune response to the virus. 
Persistent viral infection triggers an immune response that damages the cells and leads 
to myocarditis. Auto-antibodies and auto-reactive T-cells have both been implicated in 
heart disease induced by enteroviruses, with cases of pathogenic immune responses 
being directed at myocytes that contain the virus as well as antigenic mimicry. In 
antigenic mimicry T-cells or B-cells that are directed against the virus cross-react with 
cardiac antigens that are exposed later in the infection. Lymphocytes that recognise 
virus-positive cardiocytes may also play an important role in myocardial injury [16]. 
The damage contributed by viral lysis and the immune response varies between cases. 
The CVB3 RNA persists in the heart of patients with chronic myocarditis even in the 
absence of the virus. It is hypothesised that the non-productive genome of the virus 
remains in the myocardium until a subsequent insult associated with cellular 
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proliferation activates gene expression [17]. Viral myocarditis can also mimic acute 
myocardial infarction by producing direct inflammation o the myocardium [18]. 
Acute viral myocarditis leads to dilated cardiomyopathy in a significant number of 
cases. The infecting virus initiates the disease and then persists, inciting ongoing cardiac 
damage [19]. Part of what may cause dilated cardiomyopathy in CVB infection is that 
the CVB 2A protein cleaves dystrophin, a key protein component in the heart muscle 
that is frequently mutated in inherited forms of cardiomyopathy. In dilated 
cardiomyopathy the heart becomes large with impaired function and leads to heart 
failure. One of the characteristics is little or no inflammation. Enteroviruses are capable 
of persisting in patients with developmental cardiomyopathy until the end stage of the 
disease and persists in the myocardium in a significant proportion of patients with end-
stage dilated cardiomyopathy in the absence of a continuing cell-mediated or humoral 
immune response [20]. CVB evolves into a slowly replicating form of the virus during 
infection capable of establishing a low-grade infection of the heart [21]. While one of 
the major symptoms associated with CVB, only 3.2% of CVB infections result in overt 
cardiac signs or symptoms. However children that die of CVB frequently have signs of 
myocarditis [22]. 
CVB3 infection also leads to acute and chronic pancreatitis in some patients and like 
myocarditis is due to both viral and host factors [23]. Infection of the pancreas induces a 
massive cellular infiltrate composed of natural killer cells, T-cells and macrophages and 
leads to the destruction of exocrine tissue. The physiological manifestations of 
pancreatic CVB infection are correlated to the viral tropism with the virus infecting 
acinar cells but sparing the islets of langerhans [24]. CVB3 can also infect neuronal 
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progenitor cells in the subventricular zone. This infection of the developing CNS leads 
to neurodevelopmental defects in foetal infection [25]. 
1.1.2: Structure of Picornaviruses 
Enteroviruses differ from other picornaviruses based on physical properties such as their 
buoyant density in caesium and stability in weak acid. They are resistant to common 
laboratory disinfectants, including 70% ethanol, isopropanol, dilute Lysol and 
quaternary ammonium compound. They are also insoluble to lipid solvents including 
ether and chloroform and soluble in detergents at room temperature. Enteroviruses can 
be deactivated by formaldehyde, gluteraldehyde, strong acid, sodium hypochlorite and 
free residual chlorine, as well as by UV light. They are also relatively thermostable and 
most are inactivated at 42°C [26]. 
Picornaviruses are amongst the simplest RNA viruses with a highly structured capsid 
spherical in nature with a diameter of around 30 nm. The protein shell contains a naked 
single positive stranded RNA genome. They lack lipid envelopes and as a result their 
infectivity is insensitive to lipid solvents. Picornaviruses must be acid stable enough to 
pass through the stomach to reach the intestine so retain infectivity at pH 3.0 and lower 
[27]. 
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The capsid of picornaviruses is composed of four 
structural proteins; VP1, VP2, VP3 and VP4, one 
copy of each together forming the protomer 
building block that makes the capsid. 60 copies of 
the four capsid proteins VP1-VP4 form an 
icosahedraly symmetric shell [28]. Each triangular 
protomer has VP1, VP2 and VP3 on the external 
face, with VP4 on the inner surface. While VP1, 
VP2 and VP3 show no sequence homology, they all 
have the same topology consisting of an 8-stranded 
anti-parallel β-barrel. At the 5-fold axis of symmetry in the icosahdral pattern there is a 
star-shaped plateau (or mesa) that is surrounded by a deep depression known as the 
canyon. There is also another protrusion at the 3-fold axis. The canyon of CVB3 is not 
as pronounced as that of Poliovirus and Rhinovirus. There is a large pocket factor at the 
base of the canyon that has been shown to contain a lipid in Coxsackieviruses and may 
be responsible for acid stability [29]. The main differences between VP1, VP2 and VP3 
are the loops connecting the β-sheets and the N and C-terminal sequences that extend 
from the β-barrel domain. These amino acid sequences give each picornavirus its 
distinct morphology and antigenicity. Upon receptor binding at physiological 
temperatures the virus undergoes a conformational change from 160S into an altered 
form known as the 135S or A Particle (S is the sedimentation property) [30]. The A 
particle is not infectious and conformationaly altered with both the VP4 and the N-
terminal of VP1 becoming externalised rather than being internal [31]. The antigenicity 
and sensitivity to proteases of the virus also changes [32]. The N-terminus inserts into 
the cell membrane, forming a pore through which its viral RNA can enter the cell, while 
Figure 1.1 - Structure of CVB3 VP1 – 
VP4. VP1 (blue) VP2 (turquoise) and 
VP3 (yellow) lie on the surface of the 
capsid, with VP4 (red) being internal [2].  
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VP4 also partitions into the membrane. After conversion to 135S a second 
conformational change occurs in which the viral RNA is injected into the cell leaving an 
empty particle that sediments at 80S [33;34]. 
 
Figure 1.2 - Structure of the capsid surface. The diagram shows the positioning of 
VP1, VP2 and VP3 with the canyon displayed as the shadowed area, the white dot the 
location of the entry to the hydrophobic pocket and the hydrophobic pocket shown by 
the white dotted line. Inside the hydrophobic pocket is the pocket lipid factor [35]. 
 
The genome of picornaviruses is a single positive stranded RNA molecule that is 
infectious because it is translated into viral proteins required for viral replication upon 
entry into the cell. The length of picornaviruses genomes varies between 7209 to 8450 
bases depending on the virus. The CVB genome is 7.4 kb in length and functionally 
equivalent to eukaryotic messenger RNA (mRNA) [36]. The picornavirus RNA is 
unique in that it has a Virion Protein, genome linked (VPg) covalently linked at the 5‟ 
end. An O4-(5‟ uridylyl)-tyrosine linkage covalently joins the VPg cap to the 5‟ 
uridylate moiety with the tyrosine always being the third amino-acid from the N-
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terminus. The VPg molecule varies from 22-24 amino-acids in length and is not 
included in the viral mRNA which is the only difference to the genome. It is not 
involved in infectivity and is removed by a host protein called “unlinking enzyme”. It is 
also present on nascent RNA chains of the replicative intermediate and on negative 
stranded RNA, suggesting it may be a primer for RNA synthesis. There is a 5‟ non-
coding region of picornaviruses that is long and highly structured and contains 
sequences that control genome replication and translation. It also contains the internal 
ribosome entry site (IRES) that directs translation of the mRNA by internal ribosome 
binding. The 3‟ non-coding region is shorter and contains a pseudoknot that has been 
implicated in controlling viral RNA synthesis and a 3‟ poly(A) tail [37]. 
The viral protein is translated from a single open reading frame (ORF) to form a single 
200 kD polyprotein that is processed by proteolytic cleavages to generate individual 
viral proteins in equimolar amounts [38]. The polyprotein is cleaved during translation 
by viral encoded proteins so the full length product is never observed. The polyprotein 
is first cleaved into three sections, P1, P2 and P3. P1 contains the viral capsid proteins 
and P2 and P3 encode protein processing (2A
Pro
, 3C
Pro
 and 3CD
Pro
) and genome 
replication (2B, 2C, 3AB, 3B
VPg
, 3CD
Pro
 and 3D
Pol
) [39]. 
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Figure 1.3 - Diagram to show processing of picornavirus viral genome. Adapted 
from [40]. 
 
1.1.3: Coxsackievirus and its Receptors CAR and DAF 
The first step in viral infection is binding to specific receptors on cells and 
internalisation of viral components. CVB3 interacts with at least two receptors; 
Coxsackie-Adenovirus Receptor (CAR) and Decay Accelerating Factor (DAF also 
known as CD55). A receptor for CVB was first identified in 1985 by Mapoles et al 
which turned out to be CAR [41] and has since been determined as the main receptor for 
all 6 serotypes of CVB [42]. CAR is a member of the CTX family which promote cell 
adhesion and many of which are located in tight junctions so its role in the body appears 
to be in cell-cell contact formation [43]. In epithelial cells tight junctions control the 
flow of ions and macromolecules across the intact epithelium and divide the apical and 
basolateral compartments. CAR is absent from the apical surface of epithelial cells, but 
is located in these tight junctions where it associates with another tight junction protein 
ZO-1 [44].  Tight junctions are important as natural defence against invasion by 
microbial pathogens as many pathogens must breach the epithelial barrier to gain access 
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to the body and CARs location in the tight junction must act as an impediment to 
Coxsackie infection. The importance of localisation in the tight junction is highlighted 
by the number of pathogens that disrupt the tight junctions integrity such as Clostridium 
perfringens, Helicobacter pylori and Rotavirus [45]. CAR has high expression in the 
brain, pancreas and the heart with significant expression also in the testes and prostrate, 
which shows consistency with the tropism of CVB which infects via the GI tract and 
causes myocarditis, pancreatitis and meningeoencephalitis [46-48]. In the heart it is 
mainly expressed on intercalated discs, regions important to the hearts structural 
integrity and CAR is essential to normal development of the heart. Gene deletions lead 
to severe cardiac abnormalities and death in utero. It has also been suggested to be 
important in early development of the CNS and other tissues as well as being involved 
in cell proliferation [49]. There is a large amount of interest in CAR due its being a 
receptor for Adenovirus as increased expression could give greater sensitivity to Adeno-
viral mediated gene therapy and make it more efficient [50]. 
DAF is a member of the Regulator of Complement Activation (RCA) gene family, 
which play a role in down regulation of complement activity at the cell surface [51]. It 
has been shown to be a cell surface receptor for CVB1, CVB3 and CVB5, as well as 
CVA21 and Echovirus 7 [52-54]. Some enteroviruses can also bind DAF and cause 
haemaglutination due to DAFs expression on erythrocytes [55]. DAF is expressed on 
the surface of polarized epithelial cells and like CAR is expressed  in the heart [56;57]. 
Viral immunoprecipitation results have also shown that CVB3 and CVB5 can bind five 
other receptors, however, which receptors these are and their role in CVB infection 
remains unclear [59]. 
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Both of the receptors are involved in binding CVB to the cell surface but their roles 
differ in comparison to each other and depend on the strain of virus. Binding of CVB to 
CAR and DAF creates a tight association that prevents acid elution of the virus. 
However only binding to CAR leads to A-particle formation of the virus, not though 
binding DAF, suggesting that CAR and not DAF is capable of triggering the 
conformational change that leads to uncoating and RNA release from the viral capsid. 
While CVB bound to DAF does not elute, neither does it undergo any form of 
conformational change and remains in its intact infectious state. However binding to 
DAF does increase susceptibility to infection suggesting that once bound to DAF the 
virus becomes available for further interactions with CAR that lead to infection [60]. 
Interestingly in Adenovirus infection CAR is insufficient for viral uptake, but facilitates 
attachment and uptake through Integrins avβ3 and avβ5 [61]. Most picornaviruses use 
the canyon-like feature on their surface to bind to cellular receptors such as CAR. 
Binding in the canyon causes destabilisation of the virus and thus initiates the uncoating 
process [62]. DAF binds outside of the canyon, lying across it and interacting with VP2 
rather than entering the canyon and therefore does not cause the disruption required for 
uncoating to begin [63;64]. 
While CAR is the main receptor for binding and uncoating all strains of CVB, the role 
of DAF varies dependant on the strain. Rhabdo-myosarcoma (RD) cells are a cell line 
normally resistant to CVB3 infection, however passing CVB3 through RD cells creates 
a new strain (CVB3-RD) that is capable of infecting RD cells while still maintaining the 
ability to infect HeLa cells [65]. CVB3-RD is capable of binding DAF, while the wt 
CVB3 strain Nancy cannot bind DAF transfectants. As well as this, the use of anti-DAF 
does stop CVB3-Nancy from binding HeLa cells which have both DAF and CAR 
[66;67]. Haemaglutinating CVB3 (CVB3-HA) can be bound by CHO transfected with 
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DAF, while wt CVB3 does not become bound and in neither cases does infection occur, 
further demonstrating the importance of CAR in infection [68]. However strains of 
CVB that can bind DAF infect polarised cells more efficiently than those unable to 
attach to DAF [69]. The DAF binding ability of CVB strains appears to correlate with 
the presence of an epitope on the VP2 capsid protein [70]. 
CAR is a 46 kDa transmembrane glycoprotein of 365-amino acids in length with a short 
leader, a 222-amino acid extracellular domain, a single membrane spanning helical 
domain and a 107 amino acid intracellular domain [71;72]. The intracellular domain 
contains a site for palmitylation, potential sites for phosphorylation and furin cleavage 
and a C-terminal hydrophobic peptide motif that interacts with PDZ-domain proteins. 
The extracellular domain is composed of two immunoglobulin (IG)-like domains, D1 
and D2 [73]. Both Coxsackie virus and Adenovirus bind the N-terminal D1 domain, 
however they recognise different parts of D1 [74]. It is the D1 domain that is inserted 
into the canyon of CVB [75] with capsid proteins VP1, VP2 and VP3 all interacting 
with D1, with the majority of the interactions being through VP1 [76]. The extracellular 
domain of CAR with the membrane tether  is sufficient for CAR to support CVB 
infection [77]. DAF has 5 domains, four of which are short consensus repeats (SCRs) 
and a C-terminal serine/threonine (S/T)-rich region ending in a glycosylphosphatidyl 
inositol (GPI) anchor. The N-terminal SCR1 does not appear to be involved in CVB 
binding, while the other four domains are necessary. The S/T region is required for 
binding but does not bind the virus itself. SCR2 and SCR3 form the main interaction 
with VP2, with VP3 also mainly crossing the canyon. SCR4 also binds the virus at the 
carboxyl end [78;79]. 
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1.1.4: Picornavirus and Coxsackievirus Replication and Life Cycle 
Replication occurs in the cytoplasm so once the virus has bound CAR, become 
uncoated and its RNA genome inserted into the cell, the viral replication process can 
start. The single positive stranded RNA is copied to create a negative stranded 
intermediate and then additional positive strands are copied from the negative strand to 
build up the quantity of RNA for translation. There are three forms of RNA in 
picornavirus infections, single-stranded RNA (ssRNA), replicative intermediate (RI) 
and replicative form (RF). ssRNA is almost exclusively positive, negative stranded 
ssRNA has never been detected. RI is full length positive stranded RNA from which 6-8 
nascent negative strands are attached, although a negative strand with positive nascent 
strands has also been detected. RF has a double stranded structure with one copy each 
of a positive and negative strand. This is essentially a dsRNA intermediate in the 
replication process. 3D
Pol
 is a primer-dependant enzyme that copies enterovirus RNA in 
the presence of an oligo (U) primer and VPg. Translation occurs through the 40S 
subunit binding the IRES. Both translation and replication of the mRNA into negative 
strands and the polyprotein can happen at the same time. It is hypothesised that 
cloverleaf structures in the 5‟ non-coding region regulate which occur with 3CDPro 
binding the cloverleaf and blocking translation while promoting RNA synthesis. 
However despite this there is evidence that the two mechanisms do occasionally collide 
[80]. 
The viral proteins are synthesised from the polyprotein precursor, which is cleaved 
nascently by 2A
Pro
 and 3C
Pro
 or 3CD
Pro
. Among the proteins synthesised are viral RNA-
dependant RNA polymerase and accessory proteins for genome replication and mRNA 
synthesis. P1 is cleaved to form the immature protomers which assemble to form a 
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pentamer structure. New single positive stranded RNA associates with the pentamer to 
form an infectious virion. The overall life cycle is around 5 to 10 hours depending on 
the virus. As the cell loses its integrity the new viruses are released [81]. 
During the life cycle the host cell undergoes certain changes induced by the virus to 
create a more efficient state for viral replication. Proliferation and rearrangement of 
intracellular membranes in infected cells leads to the destruction of the endoplasmic 
reticulum (ER) and the Golgi as well as causing the cytoplasm to fill with double 
membrane vesicles. RNA replication occurs on the surface of these vesicles and 
localisation there ensures high levels of the replication components in the same location 
and promotes oligomerisation. Three CVB3 proteins inhibit protein secretion, 2B and 
2BC by inhibiting protein trafficking through the Golgi while 3A also destroys the 
Golgi. This occurs early in the viral life cycle, with 2BC having stronger anti-secretory 
effects than 2B suggesting it may be important in early immune evasion [82]. 2B, when 
expressed, localises to the ER and also to the Golgi, although to a lesser extent. It 
modifies intracellular Ca
2+
 homeostasis by decreasing the Ca
2+
 of both the ER and 
Golgi without affecting is uptake [83]. 2B does this by forming pores in the ER and 
Golgi membranes resulting in conditions that favour the virus as well as suppressing 
apoptotic responses [84]. By disrupting the Golgi complex, viral protein 3A shuts of 
antograde MHC trafficking and the MHC class I not stopped by 3A are rapidly 
internalised which is induced by 2B and/or 2BC. This causes down regulation and 
inhibition of MHC Class I while leaving MHC Class II presentation relatively 
uninterrupted [85;86]. eIF4G is cleaved resulting in the termination of host mRNA 
translation as well as eIF4F modulation. Viral RNA translation continues unaffected 
due to the IRES. Host RNA synthesis is inhibited via inhibition of specific transcription 
factors such as TFIID, TFIIC, and TFIIIC. Nuclear import of proteins is inhibited due to 
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proteolysis of two components of the nuclear pore complex (Nup153 and p62). 
Transport of secretory and plasma membrane proteins is blocked through viral proteins 
2B and 2BC which block protein secretion from the Golgi, and 3A which blocks 
vesicular traffic from the ER [87]. 
CVB3 causes cell arrest at G1 or G1S indicated by reduced host DNA synthesis, 
decreased cyclin D1, cyclin E, CDK2 and CDK4, and reduced phosphorylation of Rb. 
This cell arrest creates an ideal environment for CVB3 replication due largely to CVB3s 
effect on the ubiquitin/proteosome system (UPS) [88;89].  CVB3 infection results in 
increased levels of ubiquitin activating enzyme E1A/E1B and ubiquitin-conjugating 
enzyme UBCH7, as well as decreasing de-ubiquitinating enzyme UCHL1. This leads to 
increased polyubiquitination and a subsequent decrease in free ubiquitin levels. 
Blocking the changes to the UPS that CVB3 causes by siRNA, proteosome inhibitors or 
Pyrrolidine dithiocarbonate (PDTC inhibits the ubiquitin/proteosome pathway) all lead 
to decreased viral replication and highlight the importance of the UPS [90-92]. One of 
the major determinants of the severity of the disease is due to the balance of pro and anti 
apoptopic pathways. CVB3 uses several methods of inhibiting the pro-apoptopic 
pathway so that it can continue to replicate before the cell undergoes full apoptosis. Akt 
is phosphorylated in a PI3K dependant mechanism during CVB3 infection modulating 
downstream signalling involving cell survival, proliferation, differentiation, migration 
and apoptosis. Inhibiting Akt during infection leads to enhanced cleavage of both 
caspase-3 and PARP, indicating its strong anti-apoptopic role in CVB3 infection [93]. 
Phosphorylation and activation of the extracellular signal-regulated kinase (ERK 1/2) 
participates in viral replication and suppresses caspase activity, protecting the cell from 
apoptosis and is necessary for efficient viral replication [94-96]. Cytopathic effects 
include condensation of chromatin, nuclear blebbing, proliferation of membrane 
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vesicles, changes in membrane permeability, leakage of intracellular components and 
shrivelling of the entire cell [97]. 
1.2: Pattern Recognition Receptors 
Charles Janeway in the now famous paper “Approaching the Asymptote: Revolution 
and Evolution in Immunology”, in 1989, coined two very important terms when dealing 
with the innate immune system. The first was the idea of Pattern Recognition Receptors 
(PRRs), molecules which would be capable of recognising pathogens. The second term 
was used to describe the molecules from the pathogens that the PRRs recognised, 
Pathogen Associated Molecular Patterns (PAMPs). He suggested that the PAMPs would 
be produced by broad classes of pathogens so that PRRs could recognise them [98]. As 
well as PAMPs a newer term has been coined, Danger-Associated Molecular Patterns 
(DAMPs), which are endogenous ligands associated with inflammation, which can also 
cause an immune response through certain PRRs. Recognition of PAMPs, or DAMPs 
by PRRs initiates signalling pathways that start the innate immune response necessary 
in killing infectious microbes. 
Toll-Like Receptors (TLRs) were the first group of PRRs to be discovered as part of the 
hosts innate immune response to pathogens. They are a family of type I transmembrane 
proteins that have a large range of PAMPs as their ligands. There are 10 human TLRs 
that can be separated into two groups; cell surface TLRs that largely recognise bacterial 
and fungal PAMPs as well as viral capsid proteins, and cell surface TLRs that mainly 
recognise nucleic acid PAMPs. 
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The next major group are Retinoic Acid-inducible Gene (RIG)-Like Receptors (RLRs), 
whose main function is to recognise viral RNA. This is a family of cytosolic PRRs that 
is made up of RIG-I, Melanoma Differentiation-Associated Gene 5 (MDA5) and LGP2. 
Nod-Like Receptors (NLRs) are a more diverse group of receptors that can be separated 
into either those that can form the inflammasome, or those that can‟t. The NLRs have 
been shown to recognise a large array of PAMPs, particularly highlighted in NLRP3 
which has been suggested to recognise DAMPs caused by various pathogens or defects, 
rather than specific PAMPs. 
1.2.1: Toll-Like Receptors 
Toll was first discovered in the Drosophila in 1985 by Nusslein-Volhard et al  as an 
important part in developing dorsal-ventral polarity in the embryo [99]. At the time it 
was not linked at all to immunity, however in 1991 Gay et al showed that the 
cytoplasmic domain of Drosophila toll was related to that of human inerleukin-1 
receptor (IL-1R), a protein involved in human inflammation [100]. The question arose, 
why would a protein involved in dorsal-ventral development in a fly be similar to a 
protein involved in the innate immune system in humans? It wasn‟t until 1996 that 
Lemaitre et al discovered that in Drosophila Toll protects against fungi after Toll 
deficient adult flies were infected with Aspergillus fumigates and died after 2-3 days 
[101]. It appeared that Toll was involved in embryonic development as well as adult 
immunity. The first human homologue of Toll was discovered by Medhitzhov and 
Janeway in 1997, named hToll, then in 1998 Rock et al discovered 5 homologues of 
Toll, TLRs 1-5, the 4
th
 of which was hToll, TLR4 [102;103]. A major breakthrough 
occurred later the same year when Poltorak et al discovered that TLR4 was activated by 
lipopolysaccharide (LPS), a component of the outer membrane of gram negative 
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bacteria [104]. For the first time a molecular mechanism was revealed for inflammation 
during sepsis. TLR6 was discovered in 1999 by Takeuchi et al, followed by TLRs 7, 8 
and 9 in 2000 and TLR10 in 2001 by Chuang and Ulevitch [105-107]. Over the last 
decade the molecular components and pathways of the innate immune response through 
TLRs has developed significantly giving a much more detailed view of this important 
system. 
TLRs are Type I transmembrane proteins, with their ectodomains containing leucine 
rich repeats (LRRs) that are responsible for recognising their ligand, a single 
transmembrane domain and an intracellular Toll-intereukin-1 receptor (TIR) domain for 
signalling. So far ten TLRs have been discovered in humans, while there are 12 TLRs in 
mice. TLR1 through TLR9 are conserved in both while TLR10 is non functional in 
mice due to a retroviral insertion. TLR11, TLR12 and TLR13 have been lost in the 
human genome [108]. Each TLR recognises a different set of PAMPs ranging from 
components of bacterial cell walls to viral nucleic acids. TLRs can be split into two 
groups, those that are expressed on the cell surface and those expressed in intracellular 
vesicles. TLR1, TLR2, TLR4, TLR5 and TLR6 are all cell surface receptors and largely 
recognise microbial components. TLR3, TLR7, TLR8 and TLR9 are all expressed on 
intracellular vesicles and recognise pathogenic nucleic acids. Once the TLR binds its 
ligand it dimerises, either with itself or another TLR, and recruits a single, or 
combination of, TIR domain containing adaptor proteins. The signalling cascade that 
ensues results in the production of proinflammatory cytokines as well as type-I 
interferon (IFN) with some TLRs [109]. 
TLRs are widely expressed throughout the body, including immune cells such as 
dendritic cells (DCs), T cells, B cells and macrophages. However this does not mean 
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expression is uniform throughout all cell types, even within subsets of immune cells 
expression can vary. As an example Myeloid DCs express TLR1 through TLR9, while 
plasmacytoid DCs (pDCs) express TLR7 and TLR9 strongly, while TLR2 and TLR4 
are only expressed weakly [110]. 
1.2.2: Cell Surface TLRs and their Ligands 
There is a large list of PAMPs for TLR2 including lipoproteins from both gram-positive 
and negative bacteria, lipotechoic acid (LTA), peptidoglycan, fungal phospholipo-
mannans and zymosan as well as viral components such as haemaglutinin from measles 
virus [108;109]. TLR2 functions mainly by forming heterodimers with either TLR1 or 
TLR6. The TLR1/2 heterodimer recognises triacylated lipopeptides as its main PAMP, 
while the TLR2/6 heterodimer recognises diacylated lipopeptides [108;110]. Some 
PAMPs require accessory molecules to be detected, for example in TLR2s case CD36 
and Dectin1 have been shown to be required. Upon ligand binding the TLR2 
heterodimers, the receptor complex is translocated to lipid rafts where it associates with 
CD36, a double-spanning membrane protein and class B scavenger receptor. CD36 is 
required for recognition of LTA as well as diacylated lipopeptide MALP-2. Dectin1 
binds fungal β-glucans such as zymosan and enhances TLR2s response to the PAMP 
[111]. Interestingly TLR2 does not cause type-I IFN response in macrophages and DCs, 
but does in inflammatory monocytes when infected with Vaccinia virus. This highlights 
that not only does expression of TLRs vary between cell types, but the specific role of 
certain TLRs may also vary [108]. 
As mentioned earlier TLR4 was identified as the PRR for LPS, a component of the 
outer-membrane of gram-negative bacteria that is associated with septic shock. Like 
TLR2 it appears to have a large range of PAMPs including LPS, fusion protein of 
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respiratory Syncytial virus, envelope protein of Mouse mammary tumour virus, fungal 
mannans and zymosan and glycoinositolphospholipids from the parasite Trypanosoma 
[108;109;112]. TLR4 forms a complex on the cell surface with a soluble protein called 
MD-2 in order to recognise LPS. TLR4 does not appear to bind LPS directly, rather 
MD-2 binds LPS and then binds itself to TLR4. Also involved in LPS detection is 
CD14, a glycosylphosphatidylinositol (GPI) anchored protein expressed on the cell 
surface, and LPS binding protein (LPB) a soluble plasma protein. CD14 binds LPS and 
facilitates its transfer to the TLR4/MD-2 complex, while LBP also binds CD14 and LPS 
[111]. 
Another accessory molecule is RP105, a type-1 transmembrane protein with 22 LRRs, 
which was the first LRR containing receptor reported on the B-cell surface. RP105 is 
required for both TLR2 and TLR4 signalling in B-cells and RP105 deficient B-cells 
have defective TLR2 and TLR4 responses. It associates with MD-1, a homologue of 
MD-2. The RP105/MD-1 complex is assumed to positively regulate the responses of 
both TLR2 and TLR4, however negative regulation has been reported in response to 
LPS in macrophages and DCs [111]. 
TLR5 detects flagellin of bacterial flagella. Mouse TLR11 is a close relative of TLR5 
and recognises uropathogenic bacterial components and protozoan parasite proteins. 
Human TLR11 is non-functional due to a stop codon in the gene [109]. 
1.2.3: Intracellular TLRs and their Ligands 
The intracellular TLRs recognise pathogenic nucleic acids, DNA, ssRNA and dsRNA. 
TLR3 is responsible for dsRNA recognition including genomic RNA from dsRNA 
viruses and dsRNA intermediates created during replication of ssRNA viruses as well as 
some dsDNA viruses [109;113]. ssRNA is recognised by TLR7 and TLR8. They were 
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originally identified as recognising imidazoquinoline derivatives and guanine 
analogues, they also recognise ssRNA from RNA viruses including Vesicular stomatitis 
virus, Influenza A virus and Human immunodeficiency virus. TLR7 is highly expressed 
in pDCs in order to produce large quantities of type-1 IFN upon RNA virus infection as 
well as cytokine production. In DCs TLR7 recognises bacterial RNA to induce type-1 
IFN. TLR8 is expressed highly in monocytes and mediates recognition of R-848 as well 
as viral ssRNA [108;109]. TLR9 detects CpG-DNA, fungal DNA as well as hemozoin 
from parasites [109]. 
Expression of nucleic acid sensing RNAs in intracellular vesicles aids in distinguishing 
between host and pathogen nucleic acids. Cellular nucleic acids present in the 
extracellular environment are rapidly degraded by nucleases and thus do not access the 
vesicles. Localisation in the intracellular vesicles also enables recognition of viruses as 
soon as uptake of the virus occurs. Viruses fuse with the membrane and are taken up 
into endosomes by autophagy. Once a virus is mature it may also use endosomes for 
uptake and release. Uptake of microbes into the endocytic pathway occurs via receptor-
mediated endocytosis, phagocytosis or on-specific fluid phase endocytosis [113]. 
Other ways of avoiding self nucleic acid recognition are still debatable. The CpG DNA 
motif that TLR9 recognises is four times less abundant in mammalian DNA than in 
bacterial or viral DNA. However it has been shown that the 2‟ deoxyribose phosphate 
backbone is recognised by TLR9, not necessarily specific sequences such as CpG DNA. 
It could be that compartmentalisation of TLR9 in vesicles is still the main way of 
avoiding self DNA recognition [113]. With TLR3 it is possible that it avoids self 
dsRNA, partially because dsRNA is very rare in mammalian cells, but also because it 
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can only bind dsRNA longer than 40bp, while any dsRNA that does occur in 
mammalian cells is shorter than this. 
Intracellular TLRs are present in the endoplasmic reticulum (ER) in unstimulated cells 
and are rapidly trafficked to endolysosomes upon infection via the common secretory 
pathway through the Golgi. A 12-membrane spanning protein, Unc93B interacts 
directly with the transmembrane domain of TLR3, TLR7 and TLR9 mediating their 
translocation to the endolysosome [111;113]. PRAT4A, a TLR4-binding chaperone that 
translocates it to the plasma membrane and also associates with TLR1, is required for 
immune responses from both TLR7 and TLR9, but not TLR3. It has been shown to be 
required for TLR9s translocation to lysosomal compartments. TLR9 translocation is 
also facilitated by High-mobility group box1 protein (HMGB1). Gp96 is a more general 
chaperone for TLRs, both cell surface and intracellular, and associates with TLRs in the 
ER and acts as a chaperone for protein folding as well as being required for TLR 
maturation [111]. 
1.2.4: TLR Signalling Pathways 
Once their particular PAMP has been recognised TLRs form a homodimer or, in the 
case of TLR1, TLR2 and TLR6, a heterodimer. This is believed to bring together the 
TIR domains of the TLRs which allows recruitment of TIR domain containing 
accessory molecules such as Myeloid differentiation primary response gene-88 
(MyD88), TIR-domain-containing adapter-inducing interferon-β (TRIF), TIR-domain 
containing adaptor protein (TIRAP) and TRIF-related adaptor molecule (TRAM). 
MyD88 is used by all of the TLRs except TLR3 and activates Nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinases 
(MAPKs) to induce inflammatory cytokine production. This pathway is known as the 
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MyD88-dependant pathway. The other pathway used by TLRs is the TRIF-dependant 
pathway. TRIF is used by TLR3, as well as by TLR4, which can utilize both pathways. 
As well as leading to NF-κB and inflammatory cytokines, it also leads to Interferon 
regulatory factor 3 (IRF3) activation and type-I IFN production. TLR4 also requires 
TRAM to use the TRIF pathway and both TLR2 and TLR4 use TIRAP to recruit 
MyD88. TLR4 is the only TLR to use all TIR accessory molecules and both pathways. 
It recruits TIRAP at the plasma membrane which facilitates recruitment of MyD88 
leading to the usual activation of NF-κB and MAPKs. Then, via dynamin dependant 
endocytosis, TLR4 is trafficked to endosomes where it recruits TRAM and TRIF and 
activates the TRIF-dependant pathway. This leads to IRF3 as well as MAPKs and NF-
κB. Both pathways appear to be necessary for TLR4 to activate expression of 
inflammatory cytokines [108]. 
1.2.5: MyD88-Dependant Pathway 
After MyD88 activation by TLRs it recruits IL-1 receptor-associated kinases IRAK4, 
IRAK1, IRAK2 and IRAK-M. MyD88 contains an N-terminal death domain (DD) that 
interacts with the DD of IRAK4. IRAK4 then phosphorylates IRAK1 and IRAK2, 
which go on to activate TNF receptor associated factor 6 (TRAF6). IRAK-M is an 
inhibitor of TRAF6. TRAF6 is an E3 ubiquitin ligase which, along with Ubc13 and 
Uev1A, catalyses the synthesis of polyubiquitin linked to Lys63 on target proteins 
including itself and IRAK1. The poly-ubiquitin chains then bind to novel zinc finger-
type ubiquitin-binding domains of TAK1 binding protein 2 and 3 (TAB2 and TAB3) 
which are the regulatory components of TGF-β activated kinase 1 (TAK1), activating 
TAK1. As well as binding and activating TAK1, the Lys63 polyubiquitin chains also 
bind the ubiquitin binding domain of NF-κB essential modulator (NEMO), a regulatory 
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component of the IKK complex required for NF-κB activation. As TRAF6 binds both 
the IKK complex and the TAK1 complex, the two are brought together and TAK1 
phosphorylates IKKβ of the IKK complex. This leads to IκB phosphorylation and 
subsequent degradation of the protein and the resultant NF-κB nuclear translocation and 
activation. The IKK complex also phosphorylates p105, which becomes degraded 
leading to the activation of MAP3K8. This activates MKK1 and MKK2, which then 
activate extracellular single related kinases (ERK) 1 and 2, as well as Jun Kinases 
(JNKs). TAK1 also activates mitogen-activates kinase (MAPKs) leading to 
phosphorylation of JNKs, p38 and CREB. Together this culminates in transcription 
factors AP-1 and the IRFs activation and with NF-κB induces gene transcription of 
proinflammatory cytokines [108;113;114]. 
1.2.6: TRIF-Dependant Pathway 
Once TLR3 binds its ligand, or TLR4 is internalised after ligand binding, TRIF is 
recruited to the TLR. TRIF associates with TRAF3 and TRAF6 as well as receptor-
interacting proteins (RIP) 1 and 3. TRAF6 and RIP1 are required to activate TAK1, as 
well as other adaptors such as TRADD and Pelino-1, which bind RIP1. TRAF6 is 
thought to bind TRIF in the same ubiquitin-dependant mechanism as it binds MyD88. 
RIP1 binds TRIF through its RIP homotypic interaction motif and also undergoes Lys36 
polyubiquitination. Once activated TAK1 goes on to activate NF-κB and MAPKs and 
the subsequent induction of proinflammatory cytokines in the same manner as in the 
MyD88-dependant pathway. As well as this pathway TRIF also recruits the IKKs, 
TBK1 and IKKi through TRAF3. This causes phosphorylation and activation of IRF3, 
leading to IFNβ production [108;113].  
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Figure 1.5 - Diagram to show the signalling pathways of the TLRs. Shown are both 
the MyD88 dependant pathway leading to NF-κB, AP1 and IRF3 and the TRIF 
dependant pathway utilized by TLR3 and TLR4. Adapted from [115;115]. 
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1.2.7: Structure of the TLRs 
TLRs are type-I integral membrane receptors with an N-terminal ligand recognition 
domain, known as the ectodomain, a single transmembrane helix and a C-terminal 
cytoplasmic signalling domain. The signalling domain is known as the TIR domain due 
to its homology with the signalling domain of the interleukin-1 receptor family 
members. The TIR domain (as mentioned above) is also found on many adaptor 
proteins and homotypic interactions between the TIR domains of the TLRs and the 
adaptors are the first step of signalling.  The TIR domain is approximately 160 amino 
acid residues in length and the primary sequence is characterised by three conserved 
sequence boxes known as Box 1, Box 2 and Box 3. The transmembrane domain is 
typically an alpha helix of around 20 amino acid residues that are uncharged and mostly 
hydrophobic.  
The N-terminal, or ectodomain, of the TLRs are either extracellular or in endosomes 
and are glycoproteins of around 550-800 residues in length. It is in this region that the 
TLRs bind their specific PAMPs and thus an important region in understanding how 
TLRs bind their ligand. The ectodomain is made up of leucine-rich repeats (LRRs), 
which are typically 20-30 amino acids in length. They consist of a conserved 
“LxxLxLxxNxL” motif and a variable region. Typically in LRR structures there are 
around 24 LLRs in a row, each LRR forming a loop structure with consecutive LRRs 
forming a “solenoid” structure. Side chains of conserved leucines point inwards, 
creating a stable hydrophobic core. The conserved asparagines are important in 
maintaining the overall shape of the protein. Beta sheets built by parallel beta strands 
provided by the “LxxLxLxxN” motif are more compact than the rest of the LRR loop 
structure and cause the solenoid shape to form a distinctive “horseshoe” shape, with the 
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beta sheet forming the concave part. A characteristic feature of TLR ectodomains is that 
there are often more than the standard 24 LRRs in a row, producing loops that protrude 
from the horseshoe structure, most commonly on the concave side. This is most 
noticeable in TLR7, TLR8 and TLR9. There are also “cap” structures on the C and N 
terminals of the ectodomain, cysteine rich regions known as LRR-CT and LRR-NT 
respectively. The LRR-CT is connected directly to the transmembrane domain. 
Dimerisation of TLRs occurs at the C-terminal of the ectodomain, with the N-terminals 
extending in opposite directions creating a characteristic 
“M” shape. Dimerisation of the ectodomains would 
likely bring together the TIR domains as well, with TIR 
domain containing adaptors recognising the 
dimerisation of the TLR TIR domains. 
As would be predicted the ectodomain varies between 
each TLR as each binds a different and specific set of 
PAMPs. TLR2 forms heterodimers with TLR1 or TR6 
with the binding site being where the convex curved 
edges meet (Figure 1.6-A+B.). The lipid binding pocket 
of the TLR2/6 complex is half the length of the TLR1/2 
complex, explaining why there is selectivity of 
diacylated over triacylated lipopetides. There is also 
the possibility that TLR2 can form homodimers, 
however this has yet to be confirmed. 
Unlike TLR2, TLR4 does not interact with its ligand 
directly, instead it forms a complex with MD-2. MD-2 
Figure 1.5 - Diagram to show 
ectodomain structure of TLRs. A. 
Conserved LxxLxLxxN motif and 
variable region. B. Loop structure of 
LRR with beta sheet. C. Horseshoe 
structure of the ectodomain with 
betas heets making the concave 
backbone [3]. 
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binds LPS in a large hydrophobic pocket and then binds TLR4 allowing TLR4 to 
recognise LPS. Dimerisation of TLR4 only occurs when its ligand is recognised, 
forming a TLR4/MD-2/LPS dimer. Five lipid chains of LPS are contained within the 
MD-2 hydrophobic pocket, while a sixth chain is presented to TLR4 and forms 
hydrophobic interactions with the second TLR4 in the homodimer. LPS phosphate 
groups form ionic interactions with positively charged residues on both MD-2 and 
TLR4. As well as this MD-2 interacts with the second TLR4s ectodomain upon ligand 
stimulation, further stabilising the complex. The TLR4s also interact with each other in 
the homodimer complex. The structure of the complex and its binding sites can be seen 
in Figure 1.6-C with MD-2 binding the concave side of the “horseshoe” structure. 
TLR3 is a monomer in solution and forms a homodimer upon ligand binding, forming 
the typical “M” structure. It interacts with dsRNA at two sites on each ectodomain as 
can be seen in Figure 1.6-D once near the C-terminal and once near the N-terminal of 
the ectodomain. Once dsRNA has bound the TLR3s interact with each other at the 
LRR-CT, positioning the four binding sites to correctly bind dsRNA. All three of the 
ectodomain binding sites (two for dsRNA, one to form the dimer) are required for stable 
dsRNA binding and signalling. The site at the LRR-CT at which the TLR3s bind each 
other is minimal, suggesting that dsRNA binding is the main dimerisation force. 
Interestingly TLR3 binds the phosphate backbone of the dsRNA which explains the 
lack of specificity between dsRNAs. It also means that mutation of the RNA sequence 
to avoid detection is not a factor and prevents escaping detection by mutation. There is 
also a distance of 120Å between the two N-terminal binding sites, which means that any 
dsRNA shorter than 40bp is incapable of being bound by the TLR3 dimer. As most 
„self‟ dsRNA is rarely longer than 25bp this would seem a likely mechanism to avoid 
recognition of „self‟ dsRNA. 
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Figure 1.6 – Diagrams to show the 3D structure from the side and from above of 
TLRs in their dimers binding their ligands. A. TLR1/2 complex binding Triacylated 
lipopeptide. B. TLR2/6 complex binding diacylated lipopeptide. C. TLR4/MD-2 
complex binding LPS. D. TLR3 binding dsRNA. [116] 
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No structure is available for TLR5, but its ectodomain is estimated to contain 20 LRRs 
with an important role of the 9
th
 LRR in flagellin recognition. Likewise there has been 
no structure reported for TLR7, TLR8 and TLR9. Their amino acid sequence suggests 
that they are noticeably different from TLR3. The ectodomain of each of the three TLRs 
contains 25 LRRs and importantly have stretches of amino acids around 40 residues in 
length between LRRs 14 and 15 that have an undefined structure. It has been reported 
that TLR9 undergoes conformational change upon ligand binding that could be 
dependent on this undefined region as well as evidence that TLR9 may be cleaved in 
this region between LRRs 14 and 15,. Both cleavage and conformational change could 
be required for TLR9 to be active; something which it seems is not required by TLR1, 
TLR2, TLR3, TLR4 and TLR6 [3;116;117]. 
1.3.1: Nod-Like Receptors 
Nod-Like Receptors (NLRs) can be considered as another part of the trinity of pathogen 
sensors as suggested by Creagh and O‟Neill [118] alongside the TLRs and RLRs and 
like the RLRs are located in the cytosol. The NLRs can be split into four different 
groups based on their structure, or two separate groups based on their function. There 
are 23 different NLRs known within the human genome, while there are over 34 in mice 
[119] and they can be defined by a nucleotide binding/oligomerisation domain (NBD, or 
NACHT) followed by a leucine rich repeat (LRR) domain. The C-terminal is the LRR 
domain, which like TLRs is thought to be the ligand binding domain, although this has 
yet to be proven, as well as having an auto-repression function when not binding a 
ligand [120]. The NBD is the central domain capable of binding ribonucleotides which 
regulates oligomerisation of the NLRs.  The N-terminal is more variable and is the 
domain through which the NLRs can be separated into sub families through their 
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structure, known as NLRA, NLRB, NLRC and NLRP. This domain is the effector 
domain and mediates homotypic protein-protein interaction for downstream signalling. 
NLR Class II Transactivator (CIITA) is the only NLRA in humans and has an acid 
transactivation domain as it N-terminal. NLRBs contain a baculovirus inhibitor repeat 
(BIR) domain and in humans the only NLRB is NAIP. NLRCs have a caspase 
recruitment domain (CARD) and include Nulceotide-binding Oligomerisation Domain-
containing (NOD) 1, NOD2, NLRC3, NLRC4, NLRC5 and NLRX1. The final group, 
NLRPs, have a pyrin domain (PYD) and include 14 members, NLRP1 through to 
NLRP14 [121-124]. Functionally NLRs can be separated on their ability to form a 
complex known as the inflammasome. Inflammasome formation mainly leads to IL-1β 
activation, while other NLRs lead to NF-κB, MAPK activation and type-I IFN 
induction. 
1.3.2: Inflammasome forming NLRs 
The inflammasome was named due to its similarity to the apoptosome and its ability to 
cause inflammation [125] and can be activated by members of the NLRs as well as 
certain PYTHIN protein families. Like the apoptosome, which activates apoptotic 
caspases, the inflammasome complex controls the release of inflammatory caspases 
upon formation and activation [126]. As well as caspase activation the inflammasome 
can lead to pyroptosis, a form of inflammation induced cell death. The basic 
components of the inflammasome are the activated receptor molecule, apoptosis-
associated speck-like protein containing CARD (ASC) and pro-caspase-1 [127]. It has 
been suggested that pyroptosis is mediated by direct CARD-CARD interaction between 
CARD containing NLRs and pro-caspase-1 without the involvement of ASC. In these 
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cases activation of caspase-1 requires ASC and the formation of a larger inflammasome 
complex [128]. 
In their inactive state the NLR is kept inactive by the fold-back of its LRR domain onto 
the NDB. They are kept in this inactive state with the help of chaperone proteins SGT1 
and HSP90, which help stabilise the fold-back, while at the same time leaving the NLR 
capable of recognising and binding its ligand. Once the NLR binds its specific ligand a 
conformational change occurs releasing the LRR from the NBD, allowing a 
ribonucleotide (ATP or NTP) to bind a Walker A motif on the NBD. This enables NLR 
oligomerisation and recruitment of other members of the inflammasome complex [129]. 
NLRs bind ASC through either PYD-PYD homotypic interaction or through CARD-
CARD homotypic interaction, while NLRCs can also interact directly with pro-caspase-
1 through their CARD domains. ASC then binds pro-caspase-1 via CARD-CARD 
homotypic interactions. The inflammasome activates caspase-1 by bringing the inactive 
pro-caspase-1 together in the complex, which undergoes proximity induced 
dimerisation and autocatalytic activation by cleavage [130-132]. The main role of 
caspase-1 is to cleave the inactive pro-IL-1β into the active IL-1β inflammatory 
cytokine. This is the second step in the activation of IL-1β, the first (priming signal) is 
the transcription and expression of the pro-IL-1β gene which is promoted by TLR and 
RLR recognition of their ligands, as well as other NLRs. Pro-IL-18 is also cleaved into 
its active form, however unlike IL-1β, it is constitutively expressed and doesn‟t need a 
priming signal. Caspase-1 activation also results in the release of leaderless proteins that 
may facilitate in tissue repair [133]. 
It has been shown that NLRP1, NLRP2, NLRP3, NLRP6, NLRP12, NLRC4, NOD2 as 
well as the PYTHIN receptor Absent in Melanoma-2 (AIM2) can activate caspase-1 and 
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lead to IL-1β processing when over expressed with pro-caspase-1 and ASC, suggesting 
roles in inflammasome formation. While certain NLRs have definitively been shown to 
form an inflammasome, such as NLRP1, NLRP3, NLRC4 and AIM2, other NLRs roles 
in inflammasome formation remain more unclear. 
 
Figure 1.7 - Diagram to sow the structure of certain inflammasomes. NLRP1, 
NLRP3 and AIM2 use ASC through PYD-PYD interactions to bind Pro-caspase-1 
through CARD. NLRP1 can also bind Pro-caspase-1 as well as pro-caspase-5 directly 
through a CARD domain on its C-terminal. NLRC4 (incorrectly labelled s the NLRP4 
inflammasome) can bind directly Pro-caspase-1, or via ASC [134]. 
 
In 2002 Tschopp et al discovered a caspase-1 activating multimolecular complex that 
contained caspase-1, caspase-5, ASC and NLRP1, which they called the inflammasome 
[135]. NLRP1 was the first NLR to be shown to form an inflammasome. It was shown 
by Reed et al that the minimum components of the NLRP1 inflammasome were 
NLRP1, pro-caspase-1 and NTP and not ASC, however ASC enhanced assembly. They 
also showed that NLRP1 recognised diacyl muramyl dipeptide (MDP) from bacterial 
peptidoglycan and suggested that upon binding MDP, NLRP1 undergoes a 
conformational change that allows binding and hydrolysis of NTP by the NBD causing 
self-oligomerisation [136]. Other stimuli for NLRP1 are Bacillus anthracis via its lethal 
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toxin and Toxoplasma gondii [137;138]. NLRP1 is not widely expressed, with its main 
expression being in T-cells and Langerhans cells, with a lower expression level in 
stomach epithelial cells, gut and lungs [139]. 
It is a unique member of the NLRP sub-family as, in addition to its PYD domain at its 
N-terminal, it has a FIIND motif and a CARD at its C-terminal. While it can interact 
with ASC through PYD-PYD homotypic interactions it can also bind caspase-1 and 
caspase-5 in an ASC independent manner through its C-terminal CARD [140;141]. The 
interaction with caspase-5 may contribute to IL-1β processing in human cells. 
Surprisingly, despite being the first NLR discovered that could form the inflammasome, 
it is one of the least studied and understood. This is likely due to its differences between 
itself and its three murine homologues, NLRP1a, NLRP1b and NLRP1c. The murine 
homologues only have the CARD domain at the C-terminal and lack the PYD domain. 
As well as this the human NLRP1 has been shown, as mentioned above, to recognise 
MDP, a trait that has not been shown in the murine homologues [142]. NRLP1s ability 
to recognise very distinct ligands such as MDP and lethal toxin also raises questions as 
to how it can detect such differing ligands.  
NLRP3 has a more standard structure than NLRP1, with the atypical LRR C-terminal, 
NBD and PYD N-terminal. Its NBD binds ATP upon stimulation causing the receptor 
to oligomerise and recruit ASC via its PYD. This then activates caspase-1 resulting in 
IL-1β and IL-18 processing and can lead to pyroptosis [143;144]. NLRP3 is not 
expressed in most tissues, except peripheral blood leukocytes. NLRP3 RNA expression 
is highest in monocytes with detectable levels in T-cells and granulocytes, as well as 
expression in brain microglia, lungs and testes [145]. 
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Figure 1.8 - Diagram showing the inflammasome which forms a pentamer or 
heptamer structure. Inflammasome activators can be separated into sterile or 
pathogen activators. The majority of these are capable of activating NLRP3 [146]. 
 
There are a plethora of different NLRP3 activators including viral, bacterial, fungal and 
protozoan PAMPs, as well as DAMPs, all very different in physical and chemical 
structure. NLRP3 can also act as a sensor for tissue damage. Following cell death after 
tissue damage, ATP can appear extracellularly and is sensed by the P2X7 receptor, 
activating NLRP3. Cell death can also release uric acid into the extracellular 
environment which can precipitate to form monosodium urate (MSU) crystals that are 
capable of activating NLRP3. MSU crystals can also cause gout as well as chronic 
arthritis, thus NLRP3 may have a role in the inflammation in these diseases. The 
NLRP3 inflammasome also activates in response to fibrillar ameyloid-β undergoing 
phagocytosis by microgilia. The resultant release of pro-inflammatory cytokines and 
neurotoxic factors could play an integral role in the pathogenesis of Alzheimer‟s 
disease. Cholesterol crystals are also recognised, forming early in atherosclerotic lesions 
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and leads to severe inflammation. As well as these self-derived activators, 
environmental hazards that form crystals or inorganic fibrils such as asbestos and silica 
crystals can cause the NLRP3 inflammasome to become activated leading to pulmonary 
fibrosis and silicosis. It also appears to become active due to UVB in sunburn and skin 
irritants in contact hypersensitivity. There is also a link to type-II diabetes and obesity 
due to the fact that NLRP3 can function as a sensor of glucose levels, islet amyloid 
polypeptide (IAPP) deposits and saturated fatty acids from high-fat diets. With all these 
diseases, mice lacking components of the NLRP3 inflammasome have milder forms of 
the disease. However, the detrimental role of NLRP3 in these disease contrasts with its 
necessary involvement in protection against certain pathogens as well as its protective 
role in inflammatory bowel disease (IBD) and colorectal cancer [147;148]. It would be 
impossible for the LRR of NLRP3 to detect all of these very different stimuli, so direct 
binding of any of these activators seems unlikely. Instead it would seem indirect 
recognition would be more likely with three main hypotheses on how NLRP3 activates. 
The first of these hypotheses is that NLRP3 recognises Potassium efflux. In 1994 
Perregaux et al demonstrated that efficient secretion of active IL-1β in response to 
LPS/ATP or LPS/nigericin required a K
+
 efflux. The physiological homeostatic K
+ 
concentration within a cell does not allow the NLRP3 inflammasome to form, but 
requires the P2X7 receptor to form pores upon sensing extracellular ATP, as occurs in 
tissue damage [149]. Recognition of most bacteria by NLRP3 is also likely due to pore 
forming bacterial toxins causing a K
+
 efflux [150]. This appears to be a common 
initiator for the inflammasome as several NLRs are inhibited by hyperosmotic K
+ 
[151]. 
The second hypothesis suggests that reactive oxygen species (ROS) can activate NRLP3 
and adding reactive oxygen compounds such as hydrogen peroxide can induce the 
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formation of the NLRP3 inflammasome. Inhibiting or scavenging of ROS has also been 
shown to suppress NLRP3.  It is unclear whether ROS is sensed directly or indirectly by 
NLRP, as it could be possible that ROS directly modifies NLRP3, or NLRP3 recognises 
a ROS-modified or induced intermediate molecule. Certain PAMPs, including some 
recognised by TLRs, known to activate ROS are insufficient for inflammasome 
formation. For example fungal pathogens can cause IL-1β cleavage in response to ROS 
as well as K
+
 efflux [152]. It has also been shown that over expression of ROS can also 
inactivate caspase-1 by oxidation and glutathionylation, suggesting a very tightly 
controlled method of caspase-1 control through ROS [153]. ROS is also involved in the 
priming stages as well, promoting proinflammatory cytokines and up-regulates NLRP3, 
prerequisites of NLRP3 inflammasome formation [154]. 
Cathepsin B release upon lysosomal damage activating NLRP3 is the third hypothesis 
[155]. Lysosomal damage is possible with all NLRP3 activators and pharmacological 
disruption of lysosomes has been shown to activate NLRP3. Furthermore proton pump 
inhibitors used to prevent lysosomal acidification, which in turn inhibits acid dependant 
proteases, completely stops NLRP3 inflammasome activation and lack of just cathepsin 
B, a lysosomal protein, causes substantial inhibition of the NLRP3 inflammation [156]. 
Recognition of asbestos silica in silicosis by NLRP3 has been shown to be dependent on 
ROS, however silicosis has also been shown to cause lysosomal damage [157]. It is 
possible that more than one of the three hypotheses may be required in certain cases and 
it certainly seems that all three are involved to some degree. 
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Figure 1.9 - Diagram to show the three models of NLRP3 activation, as well as the 
priming and activation stage. Other PRRs result in the expression of Pro-IL-1β in 
response to stimuli, known as the Priming stage. The activation stage involves the 
cleavage of Pro-IL-1β by caspase-1 into IL-1β. This occurs in response to either ROS 
production, potassium efflux, or release of cathepsin B in response to lysosomal damage 
and causes inflammasome assembly with NLRP3, pro-caspase-1 and ASC [158]. 
 
NLRC4 is the only NLRC currently known to form an inflammasome. As its N-terminal 
structure contains a CARD, not a PYD it is capable of recruiting pro-caspase-1 via 
CARD-CARD homotypic interactions without recruiting ASC. However in order to 
actually form an inflammasome and for a full and more robust IL-1β response ASC is 
required, which it binds through its CARD domain [159-161]. It is expressed 
predominately in hematopoietic tissues and cells as well as in the colon epithelia 
[162;163]. The main ligand for NLRC4 is flagellin, a major component of bacterial 
flagella. The receptor has been shown to recognise S. Typhimurium, Shigella flexneri, 
Pseudomonas aeruginosa and Legionella pneumophilia all of which are gram-negative 
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bacteria. In order to deliver virulence factors into the cell P. aerugiosa, S. Typhimurium 
and S. Flexneri use a type III secretion system (T3SS) while L. Pneumophilia uses a 
type IV secretion system (T4SS). As well as flagellin NLRC4 is able to recognise the 
T3SS basal body rod component that is believed to be secreted by accident into the host 
cytoplasm by active T3SS and T4SS [164;165]. There is evidence that NAIP5 may 
work alongside NLRC4 in order to recognise flagellin [166-168]. As with the other 
inflammasomes NLRC4 activation leads to IL-1β and IL-18 processing and pyroptosis. 
AIM2 is an interferon inducible gene and a member of the PYTHIN family that is 
localised in the cytosol [169] and is expressed in the small intestine, spleen and 
peripheral blood leukocytes [170]. AIM2 does not have an NBD, but has a HIN200 
domain and a PYD through which it can interact with ASC to form an inflammasome 
[171]. It senses dsDNA through its HIND200 domain from both bacteria and viruses. 
Interestingly it does not appear to recognise all dsDNA viruses, recognising 
Cytomegalovirus, but not Adenovirus, whose recognition is dependent on NLRP3. It is 
possible that the dsDNA viruses that are not recognised by AIM2 have a life cycle that 
keeps its DNA out of the cytosol and thus away from AIM2 [172]. With no NDB, 
AIM2 forms oligomeric complexes due to clustering of AIM2 when binding dsDNA 
and through ASC. As with the NLR inflammasomes, the AIM2 inflammasome converts 
pro-caspase-1 into the active caspase-1 and processes IL-1β and IL-18 and can cause 
pyroptosis. 
Other inflammasome forming NLRs include NLRP6 which can form an inflammasome 
with ASC. The NLRP6 inflammasome is important in the colonic epithelium where it is 
essential in preventing recurring colitis and is protective against IBD and colorectal 
cancer. Its role in these conditions can be explained by the fact that it controls the 
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composition of gut microbiota, preventing harmful bacteria from colonisation as well as 
suppressing proliferation of intestinal epithelial cells following injury [173;174]. 
NLRP12, like NLRP6, has been shown to co-localise with ASC and both can induce 
capase-1 dependent IL-1β secretion [175]. 
1.3.3: Non-Inflammasome forming NLRs 
Nod1 and Nod2 were the first NLRs that were discovered to regulate NF-κB and 
MAPK. Both recognise fragments of peptidoglycan from the bacterial cell wall. Nod1 
recognises meso-diaminopimelic acid (DAP) found in gram-negative bacteria and some 
gram-positive. It has also been demonstrated that Nod1 contributes to host defence 
against Trypanosoma cruzi which is a protozoan parasite and does not have 
peptidoglycan so Nod1 must be capable of recognising another PAMP, or maybe even 
DAMP. Like NLRP1, Nod2 recognises MDP, which forms a part of peptidoglycan in 
both gram-positive and gram-negative bacteria, making Nod2 a more general bacterial 
sensor than Nod1. Nod2 appears to be more adapted to recognising bacteria such as M. 
tuberculosis that convert their MDP from its N-acetylated form to its N-glycosylated 
form, which is a stronger activator of Nod2. Nod2 may also have a role in sensing 
ssRNA from viruses as Nod2 deficient mice were shown to be more susceptible to 
respiratory syncytial virus (RSV) due to a less robust type-I IFN response. It has also 
been implicated in the initiation of autophagy which results in bacterial confinement to 
autphagosomes and restriction of infection [176;177]. 
After the peptidoglycan PAMPs are internalised through bacterial membrane vesicles, 
bacterial secretion systems, or host cell mediated pH-dependant endocytosis, Nod1 and 
Nod2 are translocated to the plasma membrane at the site of ligand entry. As Nod1 and 
Nod2 are NLRCs their structure consists of an LRR which binds the ligand, an NBD 
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and CARD through which they recruit RIP2. This causes autophosphorylation of RIP2 
to occur as well as Lys63 ubiquitin chain formation via the E3 ubiquitin ligase cIAP1/2 
allowing recruitment of the TAK1-TAB2/3 complex. Nemo is also recruited to RIP2, 
bringing together the IKK complex (of which Nemo is a part) close to the TAK1 
complex. This causes phosphorylation of IKKβ by TAK1 and its subsequent activation. 
IκB is then phosphorylated by IKKβ and degraded, allowing the release of NF-κB 
[178;179]. 
RIP2 can also recruit TRAF3 which activates TBK1 and IKKi. This leads to type I IFN 
production through IRF3 and IRF7 activation. While Nod2 has been shown to use this 
pathway it only appears to be in response to infection with ssRNA viruses such as RSV, 
VSV and influenza A virus. Nod2 also appears to interact, when translocated to the 
mitochondria, with MAVS, a signalling molecule downstream of the RLRs located at 
the mitochondria. Although not very well described or understood, Nod2 appears to 
utilise a RIP2-independant mitochondrial signalling complex, at the core of which is 
MAVS, and is not known to be used by any other PRR [180]. However while Nod2 
does appear to interact with MAVS, it is unclear as to whether it directly or indirectly 
associates with viral ssRNA. It is possible that immunoprecipitation of Nod2 only has 
ssRNA present due to co-immunoprecipitation of RIG-I through MAVS [181]. 
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Figure 1.10 - Diagram to show the NF-κB activation pathway after Nod2 is 
activated. Nod2 recruits RIP2 through CARD-CARD homotypic interaction. cIAP 
forms a ubiquitin chain on RIP2 that allows association with the TAK1 complex. The 
IKK complex binds RIP2 directly through Nemo. Tak1 then phosphorylates IKKβ 
allowing the IKK complex to phosphorylate IκB. IκB is then ubiquitinated causing it to 
undergo proteasomal degradation. This frees NF-κB to move to the nucleus and start 
transcription of genes. 
 
Other non-inflammasome NLRs include NLRX1, a unique NLR due to its 
mitochondrial targeting sequence at its N-terminal which causes it to be located at the 
mitochondria. Its N-terminal effector domain is similar to CARD or PYD but can‟t 
quite be categorised as either. It has been shown to interact with MAVS, impeding its 
association with RIG-I, and thus acting as a negative regulator in viral responses. It also 
positively regulates ROS production in response in intracellular bacterial pathogens 
[182-184]. NLRC5 has also been shown to act as a negative regulator. Like NLRX1 its 
N-terminal bears no similarity to other NLRs, however its LRR and NBD are most 
similar to those of Nod1 and Nod2. It has been shown to negatively regulate NF-κB 
through IKKα/β and type-I IFN through RIG-I and MDA5 [185]. 
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1.4.1: RIG-Like Receptors 
RIG-Like Receptors (RLRs) are PRRs located within the cytosol and have been shown 
to have an important role in sensing pathogenic nucleic acids. There are three members 
of the RLRs, Retinoic-acid Inducible Gene-I (RIG-I), Melanoma Differentiation-
Associated-gene 5 (MDA5) and Laboratory of Genetics and Physiology 2 (LGP2). The 
RLRs belong to the superfamily 2 (SF2) helicases/ATPases and contain a C terminal 
domain, believed to be the main ligand recognition site, a central DExD/H box helicase 
domain with ATPase activity and two N-terminal CARDs. LGP2 differs from the other 
two RLRs in that it lacks the two CARDs in its structure. 
RIG-I was originally identified as a gene that was induced in retinoic acid-treated acute 
promyelocytic leukaemia [186] and was first associated with viral infection when a 
porcine homolog was displayed to be induced by porcine reproductive and respiratory 
syndrome virus [187]. In 2004 RIG-I was shown to activate IRF-regulated reporter gene 
expression in response to Poly(I:C), a synthetic dsRNA and known strong inducer of 
IFN. RIG-I knock-out mice showed RIG-I as being essential for virus-induced type-I 
IFN expression in fibroblasts and conventional DCs and is thus critical in regulation of 
adaptive immunity as well as its major role in innate immunity [188]. MDA5 was 
originally isolated as a gene induced by mezerin, an IFN and protein kinase C activating 
compound, in a melanoma cell line [189]. LGP2 was first identified  as the gene 
adjacent to the STAT3/5 locus [190]. All three have since been shown to have vital 
importance the production of type I IFNs and inflammatory cytokines in the innate 
immune response to viral pathogens, although their roles do differ and each recognises a 
different set of viruses and nucleic PAMP structures. 
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1.4.2: RLRs and their Ligands 
Both RIG-I and MDA5 have been shown to recognise viruses and cause an innate 
immune response due to their ligands, but the viruses recognised differ. LGP2s role is 
more complicated as it has been shown to be both a negative and positive regulator in 
response to viral infection. RIG-I detects both negative and positive stranded RNA 
viruses including Japanese Encephalitis virus, Sendai virus (SeV), Vesicular stomatitis 
virus (VSV), Influenza virus, Hepatitis C virus (HCV), Respiratory syncitial virus 
(RSV) and Newcastle disease virus (NDV). Mice deficient in RIG-I show no production 
of proinflammatory cytokines or type I IFNs in response to any of these viruses, while 
MDA5 knock-outs still show normal responses. RIG-I can also be activated by the 
DNA virus Epstein-Barr virus. MDA5 has been demonstrated to recognise 
Picornaviruses such as Encephalomyocarditis virus (EMCV), Mengo virus and Theilers 
virus, while the similarity in viral structure would suggest that other Picornaviruses, 
including CVB3, are recognised by MDA5 as well. Norovirus also appears to be 
primarily recognised by MDA5 as well as some other Hepatitis viruses. These viruses 
all showed diminished response in MDA5-deficient mice, but not RIG-I deficient mice. 
Both can detect Rotavirus, Paramyxoviruses, Herpes simplex virus and Flaviviruses 
while Reovirus is recognised by MDA5 but also slightly by RIG-I [191;192]. Over-
expression of LGP2 causes lowered IFN production in response to viral infection, 
however LGP2 knock-out cells have an attenuated IFN response to VSV and EMCV, 
suggesting, that while it probably can‟t signal downstream due to its lack of CARDs, it 
may co-operate with MDA5 and RIG-I [193]. 
The synthetic dsRNA Poly(I:C) has been known to be a potent inducer of IFN for a 
relatively long time and is a ligand for TLR3 as well as the RLRs. It was initially 
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thought that MDA5 was the main RLR that recognised Poly(I:C), however it has since 
been shown that both RIG-I and MDA5 bind Poly(I:C) but differ in specificity based on 
the length of the Poly(I:C). Long Poly(I:C) (around 2 kbp) is recognised by MDA5, 
while shorter Poly(I:C) (around 70 bp) is recognised by RIG-I [194]. As most 
commercial Poly(I:C) is approximately 4-8 kbp this would explain why it was initially 
thought that MDA5 was the main Poly(I:C) receptor, however partial digestion by 
RNaseIII leads to smaller fragments of Poly(I:C) of roughly 300 bp that can be 
recognised by RIG-I and not MDA5 [195]. This would suggest that the same is true of 
viral nucleic acids and that long dsRNA is primarily bound by MDA5 and shorter 
dsRNA by RIG-I. dsRNA in most viruses is likely to be a replication intermediate or 
secondary structures formed such as hairpin structures. It is also possible that dsRNA in 
some viruses is not an intermediate but generated by defective interfering particles [196-
198]. The ability to distinguish between different lengths of dsRNA and structures of 
RNA may be due to the ability of MDA5 to form a cooperative filamentous assembly 
along the length of the dsRNA. The filament is suggested to be a dynamic structure that 
uses ATP hydrolysis to determine its stability [199]. 
 RIG-I also differs from MDA5 in that it recognises RNA with a 5‟triphosphate (5‟ppp) 
end. 5‟ppp viral RNA is selectively recognised by RIG-I [200;201]. Host RNA is almost 
always either capped (such as adding a 7-methyl-guanosine cap in mRNA) or post-
translationally modified to remove the 5‟ppp (tRNA and rRNA), therefore recognising 
5‟ppp RNA is an excellent way of avoiding “self”-RNA recognition, while 5‟ppp RNA 
is still common in the genomes of most RNA viruses recognised by RIG-I [202;203]. 
The 5‟ppp facilitates dsRNA recognition but is in itself not sufficient for RNA binding 
by RIG-I. The 10-20bp region behind the 5‟ppp is also thought to be essential in 
recognition by RIG of the viral RNA [204]. Certain viruses avoid RIG-I detection by 
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removing the 5‟ppp structure or by having a cap structure instead. Hantaan virus 
(HTNV), Crimean Congo hemorrhagic fever virus (CCHFV) and Borna disease virus 
(BDV) all have the 5‟ppp structure removed in infected cells [205], while 
Picornaviruses have a VPg molecule attached to the 5‟ end of the viral RNA, blocking 
the 5‟ppp and thus preventing RIG-I from recognising its RNA [206]. As well as the 
5‟ppp RNA, RIG-I also requires dsRNA to either be blunt ended or have a 5‟ overhang. 
3‟ overhang RNA becomes unwound and is unable to cause an IFN response, while the 
blunt end and 5‟overhang appear to be resistant to helicase activity, preventing 
unwinding and can generate an efficient IFN response [207]. Findings on whether RIG-I 
recognises base sequence vary, with some studies showing that RIG-I recognising 
Hepatitis C virus requires AU rich sequences, while other groups have shown no 
involvement of the base sequence of the viral RNA whatsoever [208-210]. RIG-I has 
also been demonstrated to recognise RNase L cleavage products during viral infections 
including 5‟ and 3‟monophosphate dsRNAs [211;212]. RIG-I is also capable of 
detecting DNA viruses through RNA polymerase III-derived 5‟ppp RNA that can be 
generated from viral non CpG DNA [213;214]. 
As mentioned earlier initial reports showed LGP2 as a negative regulator of RIG-I, most 
likely through competitive inhibition and is not required for synthetic RNA ligands such 
as Poly(I:C). It has since been shown that LGP2 is required for IFN production in 
response to certain viruses recognised by RIG-I and MDA5. The CTD of LGP2 has 
been shown to bind the terminus of dsRNA regardless of the presence of 5‟ppp and with 
higher affinity than which it is capable of binding 5‟ppp ssRNA. It has been suggested 
that LGP2 may work by making the viral RNA more accessible for binding by RIG-I 
and MDA5 by removing protein from viral ribonucleoprotein complexes, or by 
unwinding of the viral RNA [215-217]. 
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Both RIG-I and LGP2 appear to have auto-repression, most likely through the CTD 
blocking the ATPase/helicase activity as well as the CARDs on RIG-I. The same 
regions thought to be the repressor domain in LGP2 and RIG-I do not show any auto-
repression function in MDA5. It seems likely that the viral RNA ligand binding RIG-I 
causes it to undergo a conformational change in the presence of ATP that releases the 
CARDs for downstream signalling [218;219]. Thus the ATPase activity appears to be 
required for conformational change rather than helicase activity [220]. CARD 
interaction with the CARD of downstream factors is also reliant on the conjugation of 
Lys63 linked ubiquitin to RIG-I by E3 ubiquitin ligase tripartite motif protein 25 
(TRIM25) [221]. As with auto-regulation this TRIM25 dependant ubiqutination does 
not occur with MDA5 suggesting that there is differential regulation of RLRs [222]. 
However both MDA5 and RIG-I are both dependant on the formation of Lys 63 
polyubiquitin chains for IRF3 activation [223]. RIG-I then forms an oligomer (possibly 
a tetramer [224]) allowing its CARDs to interact with the CARDs of Mitochondrial 
antiviral signalling (MAVS) on the outer membrane of the mitochondria [225]. 
1.4.3: MAVS and Downstream Signalling 
The adaptor molecule for the RLRs, used by both RIG-I and MDA5, was discovered in 
2005 by four different groups who identified a CARD containing adaptor molecule 
located on the mitochondrial outer membrane. Each group gave the molecule a different 
name, Mitochondrial antiviral signalling (MAVS) [226], Interferon-β promoter 
stimulator-1 (IPS-1) [227], Virus-induced signalling adaptor (VISA) [228] and CARD 
adaptor inducing IFN-β (Cardif) [229]. MAVS contains an N-terminal CARD domain, a 
proline rich region in its centre and a transmembrane domain at its N-terminal. The 
transmembrane domain is attached to the outer membrane of the mitochondria and 
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MAVS localisation there appears to be critical. Both forced translocalisation to the ER 
or plasma membrane as well as C-terminal truncation result in signal activation being 
stopped [230]. Both RIG-I and MDA5 form oligomeric complexes with MAVS through 
CARD-CARD interaction upon activation. MAVS was thought to form a dimer which 
is crucial to its signalling and Baril et al showed that blocking MAVS oligomerisation 
inhibits signal transduction [231]. In 2010 Onoguchi et al [232] showed data to suggest 
that MAVS may form an aggregate in response to viral infection. New data from Hou et 
al [233] demonstrated that upon viral infection MAVS does indeed aggregate on the 
mitochondrial membrane and that aggregation is required for IRF3 activation. Upon 
Lys63 bound CARD terminals from RIG-I or MDA5 binding the MAVS CARD 
domain, the CARD of MAVS forms protease-resistant and prion-like fibrils. This 
causes aggregates to form in a progressive manner, with the MAVS aggregates formed 
from binding the RLR CARDs being capable of inducing other MAVS molecules to 
form these prion-like aggregates. Of note is that the RIG-I CARD can form Lys63 
polyubiqutin chains, which the MAVS CARD is incapable of forming and that the 
MAVS CARD can form the prion-like fibrils, which the RIG-I CARD is incapable of. It 
is thought that the region between the CARD and the trans-membrane domain is 
responsible for recruiting downstream signalling factors.  
Once this has occurred MAVS recruits tumour necrosis factor (TNF) receptor 
associated factor 3 (TRAF3), an E3 ligase for Lys63-linked polyubiquitination which 
interacts with the TRAF-interacting motif (TIM) in MAVS proline rich region.  This 
then activates two IκB kinase (IKK) related kinases, IKKi and TANK-binding kinase 1 
(TBK1) which phosphorylate IRF3 and IRF7 causing their translocation from the 
cytoplasm to the nucleus. Once activated and in the nucleus IRF3 and IRF7 activate 
transcription of genes encoding Type I IFNs and IFN-inducible genes. TRAF3 also 
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signals to the IKK complex which consists of IKKα, IKKβ and NF-κB essential 
modulator (NEMO) which phosphorylates IκB. This phosphorylation signals IκB for 
proteosome dependant degradation and allows functional NF-κB to translocate to the 
nucleus and activate transcription of cytokines. Other molecules that are involved are 
TRAF2 and TRAF6 which may interact with MAVS in a similar manner to TRAF3.  
Fas-associated death domain (FADD and receptor interacting protein 1 (RIP1) are both 
death domain (DD) containing molecules and are both involved by interacting with 
MAVS at the C-terminal and activate NF-κB through caspase 8 and caspase 10. 
Another DD molecule, TNFR-associated DD (TRADD), also forms a complex with 
MAVS, TRAF3, TANK, FADD and RIP1 and is involved in activation of both NF-κB 
and IRF3 and 7 [234-236]. 
Type-I IFNs play a crucial role in antiviral responses in the host by inducing 
transcription of IFN-induced genes (ISGs). Type-I IFNs consist of IFNβ, multiple sub-
types of IFNα as well as IFNκ and IFNω. Type-I IFNs activate the transcription of ISGs 
by engaging the IFNα receptor 1/2 (IFNAR1/2) heterodimer which are present on most 
cell types and induces the JAK-STAT pathway. There are more than 1000 ISGs, many 
of which are uncharacterised, however many have shown to possess antiviral effects 
such as ISG15, myxovirus resistance 1, the 2‟-5‟ oligodenylate synthetases/ribonuclease 
L system that induces RNA breakdown and protein kinase R (PKR) that phosphorylates 
the eukaryotic translation initiation factor 2α, resulting in the inhibition of protein 
synthesis. In addition, Type-I IFNs also enhance the immune response by inducing 
maturation of dendritic cells, activation of monocytes and natural killer cells, and by 
promoting T-cell responses and antibody production [237;238]. 
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Figure 1.11 - Diagram to show signalling from MDA5 and RIG-I. The RLRs create 
a signalling cascade through MAVS (IPS1) to activate IRF3 and NF-κB, leading to the 
release of Type-I IFNs and pro-inflammatory cytokines. Adapted from [115]. 
57 
 
1.4.4: RLR Signalling Pathway Regulation by Host and Viruses 
There are numerous ways through which both the host and the virus can affect the RLR 
signalling cascade. Firstly RIG-I and MDA5 are themselves ISGs and are induced by 
Type-I IFNs. As mentioned earlier TRIM25 aids in RIG-I binding MAVS through 
polyubiquitination, dependant on caspase 12. Another caspase, caspase 8, while 
involved in NF-κB activation also cleaves RIP-I and negatively regulates RIG-I, 
possibly acting as a negative feedback mechanism. Stimulator of interferon genes 
(STING) appears to have a role in RIG-I signalling as STING deficient mice are more 
susceptible to VSV, normally recognised by RIG-I. STING is located on the ER and 
appears to aid RIG-I recognising viral RNA from ER-attached ribosomes and the 
subsequent association with MAVS [239]. STING also facilitates in recruitment of 
TBK1 and phosphorylation of IRF3. STING interacts with RIG-I, but does not bind 
MDA5 [240]. 
Other molecules that induce IFNs are also capable of inducing the RLRs due to their 
being ISGs. On top of the NLRs and TLRs that cause Type-I IFN expression there are 
also DNA sensors such as the cytoplasmic DNA-dependant activator of IFN-regulatory 
factors (DAI). DAI is highly cell specific in its role, but can detect pathogenic DNA and 
lead to Type-I IFN production. IFI16, a PYTHIN member like AIM2, detects non-AT 
rich DNA like VACV DNA and another DExD/H box-containing helicase DHX36 
selectively binds CpG-A and both elicit Type-I IFN production in pDCs. 
Many viruses have methods of evading detection by the RLRs. V proteins of 
paramyxoviridae including NDV and SeV can interact with MDA5 and interfere with 
its activity to transmit a signal. While RIG-I is the usual receptor to detect SeV, and 
hence the reason for evading MDA5 may seem strange, defective interfering (DI) 
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particles of SeV contain dsRNA species as a result of abnormal copy back genome 
synthesis and could be detected by MDA5 if SeV did not utilise this evasion strategy. 
With Influenza A non-structural protein 1 (NS1) has been reported to interact and 
inhibit RIG-I. It may also bind RNA sequestering it from RLR recognition. NS3/4a of 
HCV inhibits RIG-I mediated IRF3 activation by cleaving MAVS and disrupting its 
mitochondrial activation [241]. Ebola virus VP35 protein serves as a competitor for 
dsRNA, disrupting RIG-I mediated Type-I IFN production, while SeV V protein 
selectively binds MDA5 and inhibits dsRNA induced activation of Type-I IFNs [242]. 
1.4.5: Picornaviruses and RLRs 
Finberg et al [243] have shown that Type-I IFN production in response to CVB3 is 
reliant on MAVS, while the cytokine production is not. This is due to MDA5 being 
essential for the IFN response, although it is probably aided to some degree by TLR3, 
while other PRRs may have a larger role in cytokine production than MDA5. They 
showed an increased mortality rate and disrupted Type-I IFN response pathway in 
MAVS-MDA5 deficient mice. However they did not show whether RIG-I played a role 
(even if small), or the method by which the RLRs detected CVB3. 
The role of TLR3 and MDA5 in Picornaviruses seems to be non-redundant, but rather a 
complementary role in controlling infection by RNA viruses, by each being 
predominant in differing cell tissues. TLR3 is required for the survival of mice infected 
with CVB, with TLR3 deficient macrophages in mice resulting in increased cardiac and 
liver damage during an acute infection. Loss of MDA5 resulted in faster viral 
replication, increased liver and pancreas damage and heightened mortality. The IFN 
response, particularly IFNα, appears to be MDA5 dependant. Results with EMCV-D 
which causes severe heart pathology showed increased viral titers in the heart and 
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elevated troponin levels in the serum in MDA5 deficient mice. TLR3 deficient mice 
have only moderately augmented viral titers in the heart, suggesting MDA5 has the 
dominant role in protecting against myocarditis in EMCV-D infection. TLR3 appears to 
be more prominent than MDA5 in the pancreas where it has been shown that TLR3 
deficient mice develop diabetes. Mice deficient in MDA5 die due to severe myocarditis 
before diabetes can occur, but MDA5
+/-
 mice do develop transient hyperglycemia [244]. 
The MDA5 gene is also a strong candidate for a gene locus associated with type-I 
diabetes, which would suggest the involvement of MDA5 in auto-immune disorders 
[245]. 
Picornaviruses also have evasion strategies to avoid RLR detection. Cleavage of RIG-I 
by 3C
Pro
 from Picornaviruses has been demonstrated with cleavage products appearing 
6 hours post infection for Poliovirus, Echovirus type-I and EMCV. The cleavage 
product was only detected after 14 hours post infection for Rhinovirus type 16 [246]. 
Cleavage of MDA5 was also found in Picornaviruses with MDA5 cleavage starting at 4 
hours post infection with Poliovirus causing a gradual decline in MDA5 levels. The 
same was not found in Rhinovirus type 16 or Echovirus type 1. For Rhinovirus type 1 
and EMCV levels of MDA5 started to decline 6 hours post infection. The cleavage 
involves caspases and the cellular proteosome.  In Poliovirus infection MDA5 has been 
shown to undergo caspase-dependant cleavage in cells induced to enter apoptosis. 
Whether this is part of the pathway leading to apoptosis or whether poliovirus induces 
apoptosis and MDA5 cleavage is a result is unknown [247]. MAVS can also be cleaved 
by Picornaviruses as Hepatitis A cleaves it though its 3ABC protease [248]. 
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1.4.6: Structure of RLRs and MAVS 
The RLRs comprise of three main domains, the CTD, the helicase domain and the two 
tandem CARDs. The two main RNA binding sites are contained in the CTD and the 
helicase domain and binding in the CTD is required for the molecule to undergo a 
conformational change that both releases the CARDs for downstream signalling and 
activates the ATPase activity in the helicase domain. RIG-I is a 925 residue, 106 kDa 
protein, while MDA5 is 117 kDa and LGP2 is 60 kDa. 
The helicase domain of RIG-I is comprised of two Hel domains, Hel1 (242-456) and 
Hel2 (458-469, 609-745). The region in the centre of Hel2 is an insertion domain 
known as Hel2i (470-608). The C-terminal of Hel1 links to Hel2, while a bridging 
domain from Hel2 links to the CTD. The bridging domain is an elbow like helical 
structure, forming a long alpha helix that bridges back to Hel1 before connecting the 
CTD. Without the presence of an RNA ligand Hel2 and Hel2i form a single rigid 
structure. However upon ligand presentation Hel1, Hel2 and Hel2i all move in relation 
to each other with Hel1 rotating 60‟ and Hel2i by around 23‟ if Hel2 is taking as the 
stable position. This brings together two RecA domains creating mature dsRNA and 
ATP binding sites as well as causing disordered loops in the RecA domains to become 
more structured so that they can take part in ATP binding. The bridging domain also 
becomes involved in stabilising ATP binding. The helicase domain preferentially binds 
the 3‟ end of dsRNA forming a 1:1 dsRNA/RIG-I complex for short dsRNA (around 
20bp), while longer dsRNA can form a 2:1 complex with a separate RIG-I binding each 
end of the dsRNA. The helicase binds the dsRNA with the 3‟ backbone coming into the 
most contact with RIG-I [249]. 
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The tandem CARDs are linked directly to one another and most likely form a rigid 
structure. They are bound to the Hel2i domain of the helicase with CARD2 bound to 
Hel2i and in close proximity to Hel1. The close proximity to these Hel domains means 
that there is enough steric hindrance to stop polyubiquitin chains from forming on the 
CARDs by TRIM25 [250]. 
 
 
Figure 1.12 - Diagram to how the structure of RIG-I. (A) Domain structure of RIG-
Is helicase and CARD domains. (B) Ribbon diagram of the RIG-I helicase and CARD 
structure. Colours are from A. The Bridging Domain links the helicase domain to the 
CTD. (C) Tandem CARDs of RIG-I with the linker between the two CARD coloured 
straw [251]. 
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The CTD interacts primarily with the 5‟ strand of the dsRNA, with the opposite strand 
making only very limited contributions to the binding of the RNA. This could explain 
why RIG-I is capable of binding ssRNA as well as dsRNA. There are three groups of 
residues on the CTD that bind RNA, the first interacting with the 5‟ppp, the second 
binds the phosphate backbone and the third interacts with exposed bases at the dsRNA 
terminus as well as forming hydrogen bonds with the phosphate backbone. The first 
only interacts with 5‟ppp RNA, while the second two interact with both 5‟ppp and blunt 
end RNA. While RIG-I can recognise 5‟ppp ssRNA, dsRNA and 5‟ppp dsRNA it has a 
stronger binding affinity for 5‟ppp dsRNA [252]. So while the helicase domain binds 
the 3‟ end of the dsRNA, the CTD binds the 5‟ end including the triphosphate group. 
Essentially the binding sites in the CTD and helicase domain complement each other 
and the receptor encircles the RNA. Unlike the rest of the protein, which is rigid when 
no ligand is present, the CTD is more flexibly linked to the helicase domain without 
strong interactions with the rest of the protein so remains available for binding dsRNA. 
Auto-regulation appears to work through the CARDs which are bound to Hel2i in such 
a way that it blocks the dsRNA binding site on the helicase domain. dsRNA competes 
with CARD for the binding site so once dsRNA binds the CTD it can compete with the 
CARD for the binding site causing the conformational change that releases the CARDs 
and allows ATP to bind [253]. 
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Figure 1.13 - Model from Kowalinski et al [254] to show the structure of RIG-I 
without its ligand and the conformational change upon binding the ligand. (A) 
RIG-I in an auto-repression state. (B) 5‟ppp dsRNA binds the CTD of RIG-I. (C) ATP 
binding as well as ligand binding causes a conformational change that exposes the 
CARDs. The CARDs become polyubiquinated leading to (D). The helicase domain also 
becomes exposed allowing the dsRNA to bind fully. (D) Polyubiquitination allows 
downstream signalling to MAVS. (E) ATP hydrolysis leads to re-opening of RIG-I 
either for further use or degradation. 
 
The CTD of RIG-I structure consists of three-leafed β-sheet structure with short 
connecting helices. The three leaves create a shallow groove on the concave side of the 
CTD carrying a positive electrostatic potential and forms the main binding site for the 
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RNA 5‟ terminus, mainly interacting with the phosphate backbone. The MDA5 CTD 
consists of two four stranded β-sheets, one at the end terminus and one in the centre of 
the CTD and linked by a β-hairpin.  They are also joined by four highly conserved Cys 
residues that coordinate a zinc ion crucial in maintaining the CTDs fold. A long loop 
known as the specificity loop between β-strands 5 and 6 is similar between RIG-I and 
MDA5, but absent in LGP2 and is responsible for recognising the RNA end structures. 
The β-sheet containing β5-8, the β hairpin, the specificity loop and loops between β8-9 
and β9 to the C-terminal helix have a positive charge and thus form the RNA binding 
site in MDA5 similar to RIG-I and LGP2. RIG-I contains an extra positively charged 
area that could be responsible for binding the 5‟ppp, counteracting the negative charge 
of the triphosphate moiety [255;256]. There is also a CTD binding loop that is critical in 
P2 and RIG-I but less so in MDA5 that could also explain why MDA5 binds slightly 
different ligands to RIG-I and LGP2 [26]. 
MAVS consists of an N-terminal CARD, a proline rich domain involved in protein 
interactions and a c-terminal transmembrane domain. It has three TRAF interacting 
motifs (TIMS), with the first two being in the proline rich region, one that binds TRAF6 
and one that binds TRAF2. The third TIM is located close to the C-terminal and binds 
both TRAF6 and TRAF3. Both the C-terminal and N-terminal binding sites are required 
for TRAF6 to bind and for TRAF6 mediated activation of NF-κB. The C-terminal TIM 
binding of TRAF3 is essential for mediating the induction of IFN and ISG expression 
[257]. 
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1.3: Aims and Objectives 
While Finberg et al have shown that MDA5 is the RLR that recognises and creates a 
Type-I IFN response to CVB3, it remains unclear as to RIG-Is role in Coxsackievirus 
recognition, whether the same is true of CVA viruses and what the specific ligand is. 
Using both CVA9 and CVB3 the aim is to isolate RNA structures from both viruses and 
determine if any are recognised by either RLR and if in doing so activate the type-I IFN 
response. 
It has been shown that during the Coxsackievirus life cycle, as well as the positive 
ssRNA genome of the virus, there are also the RF dsRNA intermediate and the RI 
dsRNA which is a single strand of RNA with nascent strands attached. By isolating 
these and infecting cells it should be possible to determine which of the natural 
Coxsackievirus RNAs activates the RLRs. By infecting cells with synthetic dsRNAs it 
will also be possible to determine the effect of having end-group structures on dsRNA. 
Using confocal microscopy should allow visualisation of any PAMP/PRR binding that 
may occur, while the innate immune response can be determined by measuring the 
activation of IRF3 or NF-kB and through cytokine assays. It is expected that as MDA5 
recognises poly(I:C) that the RF form of the dsRNA intermediates will cause an 
immune response, while the ssRNA will not be bound by the RLRs. Due to its partial 
dsRNA, partial ssRNA structure, the RI could potentially be recognised by either RLR, 
however is most likely bound by MDA5 if at all.  
Using Huh7 (wt) and Huh7.5.1 cells which have a mutation causing a defective RIG-I it 
can be determined whether the removal of RIG-I has any effect on the immune response 
to Coxsackie virus. While the most plausible outcome is that RIG-I is prevented from 
binding the ssRNA due to its VPg end group, its role needs to verified. Specifically the 
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possibility that the VPg end group is removed during replication allowing RIG-I to bind 
the ssRNA, but also whether any of the dsRNA intermediates are recognised. The RI 
may allow RIG-I to bind its nascent strands for example. 
Other PRRs have been shown to form dimers, or large oligomeric structures (such as the 
inflammasome), as well as evidence that MAVS forms a homodimer. The same may 
therefore be true of the RLRs and using immunoprecipitation of the RLRs from infected 
cells may allow an insight,  not just into whether RLRs form oligomeric structures, but 
also into the role of LGP2. The main aim is to see whether LGP2 binds RIG-I or MDA5 
before and during Coxsackie infections, as well as looking for RIG-I or MDA5 
homodimerisation. 
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Chapter 2: Materials and Methods 
2.1: Chemicals 
All fine chemicals were obtained from Sigma (UK). The mAb J2 used for dsRNA 
detection recognises double-stranded RNA (dsRNA) provided that the length of the 
helix is greater than 40 bp. dsRNA-recognition is independent of the sequence and 
nucleotide composition of the antigen [258]. The J2 antibody was obtained from 
English & Scientific Consulting Bt (Hungary). Alexa 488-Ulysis reagent was obtained 
from Molecular Probes Inc (Cambridge Biosciences, Cambridge, UK). Viral RNAs 
were labelled with Alexa-488-Ulysis reagent according to the manufacturer‟s 
instructions.  
Synthetic RNAs: 
The Synthetic RNAs used were the following:  
 Poly (I:C) purchased from Invitrogen USA 
 5‟OH-dsRNA 25-mer has a 5‟OH modification, molecular weight of 8.31 kDa 
and a GCAGAGGGUGGCGCUCCCGACAAGC sequence. Purchased from 
Eurogentec. 
 5‟ppp-dsRNA has a 5‟ppp modification, molecular weight of 6.47 kDa and a 
GCAUGCGACCUCUGUUUGA sequence. Purchased from Eurogentec. 
Antibodies: 
The antibodies used were the following: 
 Donkey Anti-Goat IgG (H+L) TRITC (Rhodamine), purchased from Jackson 
Immuno Labs 705-025-003. 
 IRF-3 (FL-425) Rabbit Polyclonal IgG, purchased from Santa Cruz 
Biotechnology sc-9082. 
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 LGP2 Goat pAb to DHX58, purchased from Abcam ab82151. 
 LGP2 (H-159) Rabbit Polyclonal IgG, purchased from Santa Cruz 
Biotechnology sc-134667.  
 MAVS (T-20) Goat Polyclonal IgG, purchased from Santa Cruz Biotechnology 
sc-70096. 
 MDA5 (C-16) Goat Polyclonal IgG, purchased from Santa Cruz Biotechnology 
sc-48031. 
 MDA5 (H-61) Rabbit Polyclonal IgG, purchased from Santa Cruz 
Biotechnology sc-134513. 
 Phospho-IkappaBalpha (Ser32) (14D4) Rabbit mAb, purchased from Cell 
Signaling Technology #2859L. 
 Rabbit Anti-Goat Polyclonal Immunoglobulins FITC, purchased from DAKO 
F0250. 
 RIG-I (C-15) Goat Polyclonal IgG, purchased from Santa Cruz Biotechnology 
sc-48929 . 
 RIG-I (H-300) Rabbit Polyclonal IgG, purchased from Santa Cruz 
Biotechnology sc-98911. 
 Streptavidin-HRP conjugate, purchased from Amersham Biosciences 1058765. 
 Swine Anti-Rabbit Polyclonal Immunoglobulins FITC, purchased from DAKO 
F0205. 
 Swine Anti-Rabbit Polyclonal Immunoglobulins HRP, purchased from DAKO 
P0217. 
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2.2: Tissue Culture  
The following basic tissue culture techniques were used on all the cell lines utilised 
throughout the project. All tissue culture (TC) was performed in a Microflow Class 2 
laminar flow hood in a sterile environment. Aqueous Virkon was used to clean the work 
area before use, and to clean all the equipment before placing it inside the cabinet, to 
ensure sterility. A lab coat and disposable gloves and shoes were worn. 25cm
2 
Nunclon
TM
 Surface Flasks and Nunc Falcon tubes were used throughout.  
2.3: Cell Lines  
2.3.1: Human Cardiac Cell Line 
Human Cardiac (Girardi) cell line (ECACC – European Collection of Animal Cell 
Cultures), maintained in 1g/L Glucose Dulbecco‟s Modified Eagle‟s Medium (DMEM), 
containing GlutaMAX, 10% heat-inactivated Foetal Calf Serum (FCS), and 1% non-
essential amino acids (Invitrogen (UK)).  
2.3.2: Huh 7.0 and Huh 7.5.1 Cell Lines  
Human Hepatocellular (Huh) 7.0 cell line (Kindly donated by Dr Chisari, Scripps 
Research Institute, USA), maintained in 4.5g/L glucose DMEM, containing GlutaMAX, 
10% heat-inactivated FCS, and 1% non-essential amino acids (Invitrogen (UK)).  
Huh 7.5.1 cell line (Kindly donated by Dr Chisari, Scripps Research Institute, USA), 
maintained in 4.5g/L glucose DMEM, containing GlutaMAX, 10% heat-inactivated 
FCS, and 1% non-essential amino acids (Invitrogen (UK)). They contain a RIG-I 
mutation that leads to a defect in IFN production.  
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2.3.3: Human Embryonic Kidney (HEK) 293 Cell Line  
HEK 293 cell line (ECACC), maintained in 1g/L DMEM, containing GlutaMAX, 10% 
heat-inactivated FCS, and 1% non-essential amino acids (Invitrogen (UK)).  
Transfections of HEK/MDA5 and HEK/RIG-I cells with puno-hMDA-5, or puno-RIG-I 
(Invivogen) were performed using Lipofectamine 2000 according to the manufacturer‟s 
recommendations. HEK/MDA5 and HEK/RIG-I were maintained in DMEM containing 
4.6 g/L glucose with 10% FCS and 100g/ml Ampicillin. 
2.3.4: HEK-Blue IFN-α/β Cells  
HEK-Blue IFN-α/β cells were purchased from Invivogen USA and maintained in  
DMEM, 4.5 g/l glucose, 2-4 mM L-glutamine, 10% (v/v) fetal bovine serum, 50 µg/ml 
penicillin, 50 μg/ml streptomycin, 100 μg/ml Normocin. 
These cells allow the detection of human type I IFNs by monitoring the activation of the 
ISGF3 pathway. These cells were generated by stable transfection of HEK293 cells with 
the human STAT2 and IRF9 genes to obtain a fully active type I IFN signalling 
pathway. The other genes of the pathway (IFNAR1, IFNAR2, JAK1, TyK2 and 
STAT1) are naturally expressed in sufficient amounts. The cells were further transfected 
with a SEAP reporter gene under the control of the IFN-α/β inducible ISG54 promoter. 
Stimulation of HEK-Blue IFN-α/β cells with human IFN-α or IFN-β activates the 
JAK/STAT/ISGF3 pathway and subsequently induces the production of SEAP. Levels 
of SEAP in the supernatant can be easily determined with QUANTI-Blue.  
QUANTI-Blue is a colorimetric enzyme assay developed to determine any alkaline 
phosphatase activity (AP) in a biological sample, such as supernatants of cell cultures. It 
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detects and quantifies secreted embryonic alkaline phosphatase (SEAP), a reporter 
widely used for in vitro and in vivo analytical studies. 
In the presence of alkaline phosphatase, the colour of QUANTI-Blue changes from pink 
to purple/blue. The intensity of the blue hue reflects the activity of AP. The levels of AP 
can be determined quantitatively using a spectrophotometer at 620-655 nm. 
2.3.5: Primary Cardiac cells  
Primary human cardiac cells were obtained from an adult male (TCS cell works) and 
maintained in the cell medium provided from TCS. 
2.3.6: LLC Cell Line  
LLC (Lewis Lung Carcinoma) cell line (ATCC – American Type Culture Collection), 
maintained in 1g/L DMEM, containing GlutaMAX, 10% heat-inactivated FCS, and 1% 
non-essential amino acids (Invitrogen (UK)). The LLC is a monkey cell line that is 
susceptible to nearly all viruses so it is extensively used for virus propagation. 
2.4: Coxsackievirus B3 (CBV3) / Coxsackievirus A9 (CAV9) 
2.4.1: Propagating CBV3/CAV9 
A prototype strain of CBV3 (Nancy strain) or CAV9 (Griggs strain) was obtained from 
the ATCC, and propagated on LLC cells. 100 µl of virus was added to a flask of 1.5 ml 
LLC cells and incubated at 37
o
C 5% CO2 for approximately 24 hours. Once all the cells 
had been killed, the flasks were freeze-thawed three times, to break open the cells and 
release the virus. The cell supernatant was then transferred to 50 ml Falcon tubes and 
centrifuged at 12,000 rpm for 5 minutes at RT. The supernatant containing the virions 
was then added to fresh 50ml Falcon tubes and frozen at -80
o
C.  
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2.4.2: Purifying CBV3 and CAV9 using a Sucrose Density Gradient  
Both of the viruses were purified using a sucrose gradient purification procedure, 
prepared in 40 ml Beckmann SW28 ultra-centrifuge tubes. The sucrose solutions were 
layered into the tubes in the following order (with the boundary between them marked): 
7 ml 60% sucrose in PBS; 6 ml 30% sucrose in PBS; and 3 ml 10% sucrose in PBS.    
15 ml virus was gently loaded onto the gradient, and the tubes were centrifuged at 
25,000 rpm for 90 minutes at 4
°
C. The virus settles in a band at the interface between 
30% and 60% sucrose. The top layers of sucrose were carefully removed, and the 
purified virus was pipetted into 15 ml Falcon tubes and frozen at -80
°
C.  
2.4.3: Isolating Single-Stranded RNA (ssRNA) from Purified virus  
In tissue culture, 300 µl of purified CBV3 or CAV9 was added to sterile eppendorfs. 
Each eppendorf will end up containing 80 µl ssRNA, enough for two indirect 
immunofluorescence stimulations of 40 µl each. From this point on, all work was 
performed in a fume hood with sterile eppendorfs and tips, to ensure the purity of the 
ssRNA.  
2 µl vanadyl ribonuclease complex (an RNase inhibitor, which stops the breakdown of 
RNA) was added to each eppendorf, followed by 300 µl ultra-pure phenol (the bottom 
layer). Phenol dissolves any proteins present. After vortexing for 5-10 seconds, the 
eppendorfs were centrifuged at 13,000 rpm for 10 minutes at RT. The upper layer was 
then transferred to new eppendorfs. 300 µl chloroform / isoamyl alcohol (chloroform 
dissolves lipids present, and isoamyl alcohol ensures deactivation of RNase) was added 
to each eppendorf, followed by another round of vortexing and centrifugation. The 
upper layer was again transferred into new eppendorfs. 15 µl (1/20
th
) sodium acetate 2M 
pH 6.5 and 750 µl (2.5x vol) of 95% ethanol were added, mixed, and the eppendorfs 
73 
 
were then frozen at -80
o
C for at least 60 minutes. Afterwards, the eppendorfs (straight 
from the freezer) were centrifuged at 13,000 rpm for 30 minutes at RT. The excess 
supernatant was removed, the eppendorfs were centrifuged at 13,000 rpm for a further 
minute, and the remaining supernatant was removed, leaving just a pellet of ssRNA. 80 
µl sterile water (ddH2O), or LAL water, was added to each eppendorf, and the ssRNA 
was frozen at -80
o
C.  
2.4.4: Isolation of dsRNA 
The replicative intermediate dsRNA and the high order RI-RNA containing dsRNA 
with nascent ssRNA strands of CAV9 or CBV3 was isolated from infected cells, where 
the infection had proceeded for 5 hrs and dsRNA was purified from the cytoplasm of 
these cells using a protocol similar to Richards and Ehrenfeld [259-261]. Girardi cardiac 
cells (5x10
8) 
were infected with virus at a multiplicity of 50 PFU/cell. Cells were lysed 
with lysis buffer (0.5% Nonidet P-40, 10 mM Tris-Hcl, 10 mM NaCl, 1 mM MgCl2, 0.5 
mM CaCl2. Cell debris was removed and the supernatant was extracted with an equal 
volume of buffer A (0.15 M NaCl, 0.01 M Tris-HCl pH 8.3, 5 mM EDTA in saturated 
phenol). After centrifugation the aqueous phase was removed and again treated with 
buffer A. The aqueous layer was removed and precipitated with 0.2 M sodium acetate 
and 95% ethanol at -20
o
C. The ethanol precipitate was dissolved in 10 mM EDTA-1% 
SDS and fractionated in 2 M LiCl at -20
o
C. The suspension was centrifuged at 16,000 
and the LiCl soluble fraction containing replicative dsRNA and RI-RNA was 
chromatographed through a CF11 cellulose column. The material eluted was ethanol 
precipitated and further purified by analytical zonal sedimentation in a 15% to 30% 
sucrose gradient (On 15% to 30% sucrose gradients RF RNA sedimented at 20S and 
banded at a density of 1.63g/ml, whereas viral ssRNA sedimented at 35S and banded at 
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a density of 1.68 g/ml). The precipitated RNA from appropriate fractions was further 
fractioned on a FPLC Superdex 200 column. The fractions containing dsRNA were 
pooled and ethanol precipitated. 
2.5: Indirect Immunofluorescence  
Immunofluorescence is a technique that uses a 
fluorescent dye (fluorochrome) conjugated to an 
antibody that binds a specific protein or antigen [262]. 
For example in these experiments fluorescein 
isothiocyanate (FITC) was used as the fluorescent dye. 
There are two major types of immunofluorescence, 
direct and indirect. In direct immunofluorescence the 
antibody that binds the antigen/protein is directly 
conjugated to the fluorochrome. In indirect 
immunofluorescence a primary and a secondary 
antibody are used. This method can be seen in Figure 
2.1 and was the type used in these experiments. The 
primary antibody binds the antigen/protein for which it 
is specific, but does not have a fluorochrome conjugated 
to it (A). Any unbound primary antibody is then washed 
away, leaving just the primary antibody bound to the 
specific antigen/protein (B). The secondary antibody is 
specific for the primary antibody and does have a 
fluorochrome conjugated to it, binding the primary 
antibody that is bound to the antigen/protein (C). Again 
Figure 2.1 - Diagram to show 
the mechanics of indirect 
immunofluoresence. 
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unbound secondary antibody is washed away (D). Finally a laser is used to excite the 
fluorochrome and causes it to emit a different wavelength light which can be detected 
(E). The main advantage of indirect over direct is that several of the secondary 
antibodies can bind each primary antibody thus creating a brighter fluorescence than in 
the direct method [263].  
The fluorochrome absorbs and emits different wavelengths of light as follows. At a 
normal temperature a molecule is at its ground state, however upon excitation using a 
photon of light an electron can jump to an excited state. Collision with surrounding 
molecules dissipates some of the excited energy however it quickly undergoes 
spontaneous emission, losing the remaining energy by emitting light of a longer 
wavelength. Fluorescein for example emits a green light upon being excited by blue 
light. This allows specific labelling of certain proteins within a sample as well as 
labelling different proteins by using molecules that absorb and thus emit different 
wavelengths of light from each other [4]. 
 
 
 
Figure 2.2 – Diagram of fluorochrome 
absorption and emission. The dotted lines show 
quantum energy levels within a molecule. Upon 
absorption of a high energy photon the energy 
level of the molecule is raised to an excited state. 
The red arrow indicates the dissipation of some 
of the energy by colliding with surrounding 
molecules, causing the molecule to be in a lower 
energy excited state. The green arrow shows the 
spontaneous emission of a longer wavelength 
light causing the molecule to fall back to its 
ground state energy level [4].  
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2.6: Flow Cytometry 
Flow cytometry is a way of measuring 
characteristics of a single cell at a time as 
they flow past detectors using means such 
as light excitation, light scattering and 
fluorescence [264;265]. In order to 
measure a single cell at a time the sample 
of cells is injected into a sheath flow 
known as the fluidics system [1]. The 
fluidics system has a central core section 
through which the sample is passed and a 
surrounding section of sheath fluid which 
is travelling in the same direction at a higher speed. As well as this the diameter of the 
flow is reduced forcing the cells into the centre of the stream [265]. Together this 
creates a drag effect on the sample in the central core and changes its velocity causing 
the cells to be arranged in a single file [1]. This allows the cells to pass one at a time 
through a laser. As the cells pass through the laser they scatter light as well as 
fluorescing if labelled with fluorochrome molecules. The fluoresced light wavelength 
depends on the fluorochrome used [265].  
Light scattered in the forward direction is detected by a photomultiplier tube (PMT) that 
converts the intensity of light into voltage. An obscuration bar is placed in front of the 
PMT stopping the intense light from the laser beam reaching the PMT, only the forward 
scatter light that is scattered around the obscuration bar reaches the PMT and is 
detected. The forward scatter detected correlates to the size of the cell with small cells 
Figure 2.3 - Diagram of the mechanics by 
which the flow cytometer uses sheath fluid to 
force cells to pass before the laser one cell at a 
time [1]. 
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producing a small amount of forward scatter and with larger cells creating larger 
amounts of forward scatter [266]. 
The side scatter produced is dependent on the granular content and structural 
complexity of the cell [1]. The side scatter is detected by a different PMT than the 
forward scatter (often at 90‟ to the laser) and is focused via a lens system [266].  
Combining the forward and side scatter data allows differentiation between different 
types of cells within the cell sample population. For example in a blood sample the 
lymphocytes, monocytes and neutrophils can be distinguished from one another. 
As in our experiments only one cell type was used at a time the amount of fluorescence 
is of more interest. As explained before when the laser hits the cell it causes the 
fluorochrome antibody to emit light of a different wavelength. The emitted light travels 
along the same path as the side scatter light and passes through a series of dichroic 
mirrors and filters, separating different wavelengths of light for detection. The intensity 
of fluoresced light is detected by a PMT and converted to voltage. There are three major 
types of filter used, long pass which allows light of a wavelength above a certain point 
to pass through, short pass which allows light of a wavelength below a certain point to 
pass through and band pass which allows only a narrow range of wavelengths to pass 
through [1]. These filters absorb the light not of the permitted wavelength while the 
dichroic mirrors are set at a 45‟ angle to the light. Dichroic mirrors permit a certain 
wavelength or range of wavelengths through however instead of absorbing the non-
permitted light it is reflected. Thus a specific wavelength of light can be separated and 
detected by a PMT and the fluoresced light from each cell measured.  
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Figure 2.4 - A diagram of the overall setup of a flow cytometer. The fluidics system 
channels the cells so they pass through the laser one at a time. The forward scatter light 
is detected by a PMT (labelled FSC) and the side scatter is detected by a second PMT 
(labelled SSC). The fluoresced light passes through a range of dichroic mirrors 
reflecting first shorter wavelength light for detection, then longer and longer 
wavelengths so that each range of wavelengths is detected by a separate PMT. They 
also pass through a filter to make sure the correct wavelength light is being detected. 
The voltages created upon detected are sent to a computer and processed as data [1]. 
 
2.6.1: Determining RIG-I and MDA5 Expression Levels  
Indirect immunofluorescence followed by flow cytometry was used to investigate the 
expression levels of RIG-I and MDA5 before and after stimulation. Confluent cells 
were stimulated with either 5 moi CBV3 or 20 g/ml ssRNA, dsRNA or synthetic 
RNAs and incubated for 1, 2, 4, or 6 hours. Three flasks were needed per stimulation 
per time point. At each time point, 2 ml of the supernatant was added to screw-top 
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eppendorfs and frozen at -20
°
C, for use in the Cytometric Bead Array assay. The cells 
were then scraped off, washed with PBS and fixed with 4% Paraformaldehyde (PFA).  
After centrifuging at 13,000 rpm for 2 minutes at RT, the cells were resuspended in       
1 ml PBS / 0.02%(w/v) Bovine Serum Albumin (BSA) / 0.02%(w/v) Saponin / 0.02%(w/v) 
Sodium Azide (NaN3). BSA is used as a carrier protein to antibodies and as a general 
protein blocking agent. The amphipathic nature of Saponin makes it act as a surfactant, 
enhancing the penetration of proteins through the cell membrane. NaN3 prevents the 
internalisation of surface antigens, which could produce a loss of fluorescent intensity. 
The cells were then centrifuged and the supernatant aspirated off again, followed by 
resuspension in 100 µl PBS / BSA / Saponin / NaN3, and incubation with 2 µl of 
primary antibody (MDA5 (C-16) Goat pAb or RIG-I (C-15) Goat pAb) for one hour or 
greater at RT.   
After incubation in primary antibody, the cells were washed and resuspended in 100 µl 
PBS / BSA / Saponin / NaN3, followed by incubation with 2µl of secondary antibody 
(pAb Rabbit anti-Goat FITC) for 45–60 minutes in the dark (to prevent photobleaching) 
at RT. The cells were then washed twice in PBS / BSA / Saponin / NaN3, then 
resuspended in 500 µl PBS and transferred to flow tubes and run on the 
FACSCalibur
TM
. 10,000 cells not gated were analysed for each sample.  
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2.7: SDS-PAGE and Western Blotting to detect pIκB, total IκB and 
IRF3 
2.7.1: SDS-PAGE  
SDS-PAGE stands for Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis. 
Electrophoresis is the separation of macromolecules in an electric field [267]. SDS is an 
anionic detergent used to denature proteins leaving them in their primary structure. The 
negative charge of SDS destroys most of the protein bonds as well as giving the protein 
a uniform negative charge making the protein travel to the positive pole in an electrical 
field [267;268]. The denaturation of the protein into its primary state is caused by 
heating the sample in a buffer containing soluble thiol reducing agent (such as β-
mercaptoethanol in this case), which destroys all disulphide bonds on cysteine residues 
as well as SDS [269]. This results in proteins being separated by their primary structure 
size alone, having been given a uniform negative charge and removing all secondary, 
tertiary and quaternary structure of the proteins.  
If the proteins are all denatured and with equal charge they will move in an electrical 
field towards the positive pole at the same rate. For this reason the medium used 
through which the protein moves is polyacrylamide. Polyacrylamide is porous and 
allows smaller molecules to pass through faster than larger ones, thus separating 
proteins based on their molecular mass [267]. The more concentrated the acrylamide, 
the smaller the pores in the gel are and the slower the proteins move through the gel. 
Polyacrylamide is a polymer of monomeric acrylamide, crosslinked with N,N‟-
methylene-bis-acrylamide (BIS). Together they do not polymerise but require 
ammonium persulphate (APS) for free radicals and -N,N,N‟,N‟-tetramethylethyline 
diamine (TEMED) as a catalyst to start polymerisation [269].  
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When setting up a gel, a resolving gel is created and then a stacking gel on top. The 
reason for this is that the stacking gel, to which the proteins are loaded, is a low 
concentration polyacrylamide gel and so all the proteins move through it quickly and at 
relatively the same speed. When they reach the boundary of the resolving gel, the 
resolving gel is a higher concentration and essentially forces the protein to line up at the 
border and start moving more slowly through the higher concentration gel. It is in the 
resolving gel that the proteins are separated based on mass, when an electrical current is 
passed through the gel.  
2.7.2: Western Blotting  
Western blotting is a technique used to transfer the proteins that have been separated by 
SDS-PAGE onto a nitrocellulose membrane, and then probe them with antibodies for 
further analysis. Using the electroblotting method, a sandwich of the gel (with the 
stacking gel trimmed off) and the nitrocellulose membrane was compressed in a cassette 
between two layers of blotting paper and pads pre-soaked in transfer buffer. The gel 
holder cassette was then placed into a tank transfer system together with an ice block, 
and the tank filled with transfer buffer. A constant current of 210 mA was applied for 60 
minutes, electrophoretically transferring the proteins from the gel to the membrane 
[270;271] 
2.7.3: Immuno-Blotting membranes with Antibodies  
A blocking reagent is used on the membrane, usually a source high in protein (in this 
case a milk powder solution), to prevent the antibodies from binding parts of the 
membrane which do not have protein bands. As nitrocellulose has a high binding 
affinity for all proteins, antibodies would naturally bind to it, however by using a 
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protein rich liquid, protein will bind the rest of the membrane „blocking‟ the antibodies 
from binding [270]. 
Once blocked the membranes are incubated first with a primary antibody specific for 
the protein being detected and then with a secondary specific for the primary and 
conjugated to horseradish peroxidise (HRP). To detect the bands the membrane has 
electrochemiluminescence (ECL) reagent added to it causing the HRP to emit light. In a 
dark room the membrane has photographic film placed onto it which forms dark bands 
where there has been luminescence after developing. 
2.8: Immunoprecipitation of RIG-I, MDA5 and LGP2 
Immunoprecipitation is used to isolate an antigen using a specific antibody, usually 
from a complex solution such as cell lysate. The lysate is incubated with the antibody, 
before an insoluble support is added (in this case protein-A sepharose beads) which 
immobilises the antibody and bound antigen. Before adding the antibody, the cell lysate 
was mixed with protein-A sepharose beads as a pre clear. Pre-clearing is used to remove 
proteins that bind the immunoglobulin non-specifically, lowering the background and 
signal to noise ratio [272]. The sample is mixed thoroughly before being centrifuged. 
The supernatant is removed and new lysis buffer added and then the cycle repeated so 
that all the non-bound parts of the lysis have been washed out, leaving only the antibody 
and bound protein with the protein-A sepharose beads. The lysis buffer used is 
dependent on the target protein being immunoprecipitated and has many important 
functions including stabilising the native protein conformation, inhibiting enzymatic 
activity, minimising denaturation of the antibody binding site and increasing protein 
release from the cell lysate [273]. Once washed the protein is eluted using the reducing 
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sample buffer used in SDS-PAGE and once the sample buffer had been left for 15 min 
it can be added to the SDS-PAGE set up to be run. 
To test whether RIG-I, MDA5, and LGP2 homo- or heterodimerise together, 
immunoprecipitation experiments were performed. The technique can be used to isolate 
a particular protein, as well as determine if dimerisation between two proteins has 
occurred. In this project, RIG-I, MDA5, or LGP2 antibodies were used to precipitate out 
their respective protein, and SDS-PAGE was then used to detect a different protein, i.e. 
precipitate out MDA5 and perform SDS-PAGE to detect LGP2.  
Cardiac cells were stimulated with CBV3 for 1, 2, 4, and 6 hours, or left unstimulated (0 
hour). At each time point, the cells were washed, lysis buffer was added for over 2 
hours, followed by centrifugation and transferral of the supernatant to new eppendorfs. 
The cell lysate was then pre-cleared twice in Protein A Sepharose (PAS) beads, to 
prevent non-specific binding of the antibody to unwanted proteins, followed by 
incubation with primary antibody and more PAS beads. 
The reason Protein A is used is that it binds specifically to the heavy chains in the Fc 
region of antibodies. This results in the antibody being oriented so that the antigen 
binding site faces outwards, immobilising the antibody while also allowing it to 
effectively bind the antigen [273]. 
After washing the resulting pellet in lysis buffer, the samples were analysed using SDS-
PAGE and western blotting, using X2 SDS-PAGE Non-Reducing Sample Buffer.  
2.9: Confocal Microscopy  
Confocal microscopy is a technique used to visualise the interaction and location of 
different proteins within cells. A confocal microscope can create sharp images of 
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specimens by excluding out-of-focus light in specimens which are thicker than the focal 
plane by using a spatial pinhole. This increases the micrograph contrast and enables 
reconstruction of three-dimensional images.  
Originally developed by Minsky in 1955 it sequentially focused a point of light across a 
specimen, point by point, and collected the returning rays. He reduced background light 
by firstly only focusing light on a single point and also by passing the collected light 
through a second pinhole aperture that removed unwanted light. To scan the specimen 
the stage that held the specimen moved, rather than the light source. 
In fluorescence confocal microscopy a molecule absorbs light of one frequency and 
emits light at a different frequency. The sample is dyed and a suitable wavelength light 
is used to illuminate it. The resulting emitted light is collected and an image is formed. 
A dichroic mirror is used that reflects lower wavelength light buts transmits longer 
wavelength light. This allows light from the source to be reflected through the objective 
onto the sample, while the fluorescent light passes through the objective and the mirror 
as it is a longer wavelength. This method is called epifluorescence. 
At a basic level, confocal microscopy works by having two lenses that focus the light 
from the focal point of one lens to the focal point of the other. The aim is to see only the 
focal point of one of the lenses on the specimen so a pinhole is created at the focal point 
of the other lens stopping light from any other point than the focal point from passing 
through. The specimen is also only illuminated by a single beam of light at the focal 
point using a pinhole system, reducing the amount of light from out of focus parts. This 
is unlike fluorescent microscopy where the entire section of the specimen is illuminated.  
The focal point forms an image at the pinhole thus the two points are known as 
conjugate points. The pinhole is conjugate to the focal point, hence „confocal‟.   
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In Figure 2.5 it can be seen that the laser emits a blue light, which is reflected off the 
dichroic mirror and onto a pair of scanning mirrors, one horizontal the other vertical. 
These are motor driven and scan the laser across the specimen creating a full 2D image. 
The laser excites the fluorescent molecule in the specimen and the green light is 
emitted, which is descanned by the same mirrors that scan the excitation light (the blue 
laser) and passes through the dichroic mirror. It is then focused onto the pinhole and the 
light that passes through is detected, such as by a photomultiplier tube. The detector is 
connected to a computer that creates a full image from all the points one pixel at a time. 
[4;274;275;275] 
 
Figure 2.5 - Diagram to demonstrate how a confocal microscope works. This shows 
the path of the laser in the confocal microscope (blue) as it is reflected off the dichroic 
mirror and then the rotating (scanning) mirrors. This is then focused onto the specimen 
via the microscope lenses. The green line indicates the path of light emitted by the 
fluorescent label in the specimen, as it passes back through the microscope and is 
descanned by the rotating mirrors. It then passes through the dichroic mirror and then 
the light from the focal plane of the lenses passes through the pinhole and can be 
detected [4]. 
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2.9.1: Labelling procedure for confocal microscopy 
Cardiac cells grown on microchamber culture slides (Lab-tek, Gibco), were incubated 
with Alexa 488-ssRNA (20 µg/ml) or dsRNA for different time points, and were 
subsequently rinsed twice in PBS/0.02% BSA, prior to fixation with 4% formaldehyde 
for 15 min. The cells were fixed in order to prevent potential re-organisation of the 
proteins during the course of the experiment. Cells were permeabilised using 
PBS/0.02% BSA/0.02% Saponin and labelled with antibodies for RIG-I, MDA5 and 
MAVs directly labelled with the appropriate fluorophore. Cells were imaged on a Carl 
Zeiss, Inc. LSM510 META confocal microscope (with an Axiovert 200 fluorescent 
microscope) using a 1.4 NA 63x Zeiss objective. The images were analysed using LSM 
2.5 image analysis software (Carl Zeiss, Inc.). 
2.10: Cytometric Bead Array / IFN assays 
A cytometric bead array (CBA) human soluble protein flex set bead system (Becton 
Dickinson) was used to quantitatively measure IFN-β production in cells. The flex set 
bead system is a bead-based immunoassay capable of measuring soluble IFN-β in cell 
culture supernatant samples. The beads, of known size and fluorescence, are coated with 
a capture antibody specific for IFN-β. The detection reagent is a mixture of 
phycoerythrin (PE)-conjugated secondary antibodies, which provides a fluorescent 
signal in proportion to the amount of bound IFN-β. When the beads are incubated with 
cell supernatant, sandwich complexes (capture bead, IFN-β, and PE) are formed, and 
can be measured using flow cytometry.  
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2.10.1: IFN Assay Procedure  
The standards and detection reagents were prepared according to the BD CBA Human 
Soluble Protein Master Buffer Kit manual. 50 µl of the tissue culture supernatant 
prepared previously was added to flow tubes, followed by the addition of 50 µl of the 
IFN-β beads, mixed, and incubated for 1 hour at RT. 50 µl of the PE detection reagent 
was then added and mixed, followed by a further 2 hour incubation at RT in the dark. 
1ml of Wash Buffer was added to each tube, centrifuged at 200 g for 5 minutes, and 
then the supernatant was carefully aspirated off and discarded. The bead pellets were 
resuspended in 300 µl of Wash Buffer, and the samples were analysed using flow 
cytometry, with the data acquired being analysed using the FCAP Array software 
(Becton Dickinson).  
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Chapter 3: Determining the RNA Ligand for MDA5 using CAV9 
3.1: Introduction 
Human Coxsackieviruses are divided into two subgroups, Coxsackie B viruses (CBV) 
and Coxsackie A viruses (CAV). Subgroup division is mainly based on the 
pathogenicity of the virus serotypes in experimental animals. CAVs cause flaccid 
paralysis in newborn mice in contrast to CBVs which induce spastic paralysis. CAVs 
affect striated muscle while CBVs replicate in several tissues including the central 
nervous system [276]. 
Coxsackieviruses are obligate intracellular pathogens that need to hijack the host‟s 
machinery in order to produce progeny of viruses, but this is often limited by the host‟s 
antiviral response. Successful sensing of the viruses by the host leads to a rapid innate 
immune response. Viral RNA seems to be a molecular signature that the host recognises 
and is a potent inducer of the innate host response. Viral RNA is recognised by TLRs or  
RLRs, which are the two main families of pattern recognition receptors (PRRs) that 
play a key role in sensing viral RNA and activate inflammatory cytokines and type I 
interferons (IFNs) [277;278]. 
TLR7 and TLR8 have been shown to detect genomic ssRNA from Coxsackie B viruses 
as well as from Human Parechoviruses which are related to Enteroviruses and trigger a 
cytokine response [279;280]. Furthermore studies utilising mice have shown that 
MDA5 recognises Coxsackie B viruses and triggers Interferon type I production but do 
not reveal the specific RNA ligand recognised [281]. 
RLRs have been recently discovered to play a key role in sensing RNA virus invasion. 
They recognise viral RNA independently of TLRs and unlike TLRs, which are found 
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either on the cell surface or endosomes, RLRs are found in the cytoplasm [282]. The 
two main RNA helicases are RIG-I and MDA5. 
RLRs were initially thought to recognise the same ligand, dsRNA, but it has since 
become apparent that the two receptors possess distinct virus specificities. It has been 
shown that RIG-I and MDA5 recognise different viruses and different viral RNAs 
[283;284], with RIG-Is main ligands being single-stranded RNA (ssRNA) containing a 
terminal 5 -triphosphate (ppp) [285], as well as linear dsRNA no longer than 23 
nucleotides [286]. MDA5 recognises long strands of dsRNA but the mechanism by 
which this occurs is less clear [286]. 
RIG-I recognises negative sense ssRNA viruses including Influenza virus, Newcastle  
disease virus, Sendai virus as well as Hepatitis C virus, while positive sense ssRNA 
viruses such as Picornaviruses, and more specifically Encephalomyocarditis virus and 
Coxcackievirus B3  have been shown to activate MDA5 and trigger IFN response 
[281;283;284]. 
Despite the wealth of information on the types of viruses and RNA that can activate 
RIG-I and MDA5, the natural ligand responsible for triggering the response remains 
unclear. RNA recognition by RIG-I seems to require the presence of a free 5‟-
triphosphate structure [285;287;288], but much less is known about the nature of the 
RNAs that act as ligands for MDA5. It has been suggested that higher order RNA viral 
structures are required in order to activate MDA5 [289], but the specific agonist has not 
been identified. Using biochemical methods, Pichlmair et al [289] concluded that 
MDA5 does not recognise the replicative intermediate dsRNA but higher order RNA 
structures. Their results suggest that MDA5 activation requires an RNA web rather than 
simply long molecules of dsRNA, however that fails to explain why MDA5 can sense 
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Poly:I:C, which is an equivalent of long dsRNA or dsRNA viruses such as Reoviruses 
[286] or why it cannot sense Picornavirus genomic ssRNA that contains highly ordered 
secondary structures and tertiary RNA structures in the 3‟ and 5‟UTR regions. Since not 
all MDA5 agonists seem to fit the model of an RNA web, or branches of RNA, there is 
a pressing need to identify what is the exact MDA5 ligand. Revealing how MDA5 
becomes activated during infection will lead to the future development of new therapies 
to combat viral disease. 
In order to identify the specific ligand for MDA5, we chose to utilise Coxsackie A9 
virus which is genetically similar to Coxsackie B viruses which belong to the 
Picornavirus family. Although members of the family have been shown to trigger the 
innate immune response via TLRs [280;290;291] and by MDA5 [281;283;284], little is 
known about the exact ligand. In addition there is not a lot of information about CAV9 
innate immune recognition so far.  
3.2: Results 
3.2.1: Studies with Different Types of RNA  
Enteroviruses are positive-sense ssRNA viruses thus their replication follows a strategy 
common for all positive-sense RNA viruses. The viral genome is transcribed into 
complementary RNA (negative strand) which in turn is used as a template to synthesize 
new strands forming double-stranded RNA (dsRNA), replicative intermediate forms 
(RF), and a complex partially double stranded RNA intermediate (RI) which has double 
stranded core to which nascent strands of ssRNA are attached. Therefore during an 
Enteroviral infection, the host‟s innate immune system will be presented with a pool of 
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foreign RNA, such pools would contain whole viral genomes, viral transcripts as well as 
replication intermediates.  
In order to determine whether viral replication is essential for MDA5 recognition and to 
characterize the RNA species responsible for MDA5 activation in cells infected with 
positive stand RNA viruses such as CAV9, cardiac cells were infected and the full 
length genomic ssRNA as well as the viral dsRNA replicative form (RF) and the high 
molecular weight RI-RNA were isolated from the cytoplasm of these cells using 
modified purification procedures for the isolation of viral ssRNA and poliovirus 
replicative intermediates (RF) and (RI) similar to Richards and Ehrenfeld [261;292] and 
purified by Fast Performance Liquid Chromatography (FPLC) (Figure 3.1).  
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Figure 3.1 - Purification of RNA by size exclusion chromatography. (A) The 
standard elution curves for RNA oligonucleotides of various lengths on the Superdex 
200 column size exclusion column was used for calibration. The elution profile of viral 
ssRNA and viral RF and viral RI obtained from the size exclusion chromatography step 
on the Superdex 200 column is shown. (B) FPLC was performed at 3mL/min. CAV-9 
ssRNA (lane 1) and replicative intermediate RF-RNA (lane 2) and high order replicative 
intermediate RI-RNA (lane 3) were isolated and analysed by agarose gel 
electrophoresis. (C) The RNA samples ssRNA (lane 1) and RF-RNA (lane 2) were 
treated with pancreatic RNase (1g/ml). (D) ssRNA (lane 1) and RF-RNA (lane 2) were 
treated with DNase I (20g/ml). (E) RI-RNA was treated with with DNase I (20g/ml) 
(lane 1) or pancreatic RNase (1g/ml) (lane 2) and analysed by agarose gel 
electrophoresis. 
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The purified ssRNA was resistant to DNase I and digested by pancreatic RNase into 
two bands of 6,000 bases and 1,500 bases (Figure 3.1C). RF RNA was resistant to 
DNase I and over 99% resistant to pancreatic RNase indicating that there was no 
contamination by DNA or sensitive ssRNA (Figure 3.1D). The purified RI RNA was 
resistant to DNase I and over 50% resistant to pancreatic RNase (Figure 3.1E) 
 
3.2.2: RLR Involvement in Recognition of Enteroviruses 
In order to investigate the involvement of RIG-I and MDA5 in the innate recognition of 
enteroviruses, HEK-RIG-I and HEK-MDA5 cells were used. These cells were infected 
with CAV9 as well as Influenza A virus (IFVA) (a negative-sense RNA virus) as a 
control. MDA5 and RIG-I expression levels were tested at different time points after 
infection (Figure 3.2A, B). Our data demonstrated that MDA5 was up-regulated in 
HEK-MDA5 cells infected with Coxsackie A9 virus (CAV-9), but not Influenza A virus 
while as expected in HEK-RIG-I cells RIG-I was only up-regulated in cells infected 
with Influenza A virus. 
In order to determine the immuno-stimulatory effect of the viruses, IFN secretion in 
response to these viruses was also examined (Figure 3.2C, D). Our data demonstrated 
that CAV9 and IFVA viruses triggered a significant IFN response, confirming the 
involvement of RLRs in the sensing of RNA viruses. 
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Figure 3.2 - RIG-I/MDA5 expression in HEK cells. HEK-MDA5 and HEK-RIG-I 
cells were either not stimulated (0 hour) or stimulated with CAV9 or IFVA at different 
time points (5 moi). The cells were fixed and permeabilised, followed by antibody 
staining against MDA5 in HEK-MDA5 cells (A) and RIG-I in HEK-RIG-I cells (B) 
followed by incubation with the appropriate secondary antibody conjugated to FITC. 
The supernatants were harvested and assayed for IFNsecretion using the Flex set 
system (Becton Dickinson). In HEK-MDA5 cells (C) and HEK-RIG-I cells (D). 
Fluorescence was detected using a FACSCalibur (BectonDickinson). The data 
presented is the mean of three independent experiments. 
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3.2.3: MDA5 Senses the Viral Replicative Intermediate dsRNA  
In order to determine which RNA species triggers MDA5 activation and induction of 
IFNCAV-9 genomic ssRNA as well as the dsRNA replicative intermediates, RF-
RNA and RI-RNA, were isolated (see Materials and Methods section) and transfected 
into cardiac cells.  The data showed a small increase in IFN production when ssRNA 
was used possibly due to TLR7/8 detection and a very high IFN production in 
response to RF. The RI-RNA induced IFNresponse as well (Figure 3.3A), however it 
was lower than the response induced with RF-RNA. 
In order to determine whether MDA5 was responsible for the IFNresponse and to 
exclude other pattern recognition receptors such as TLR7 and TLR8 which recognise 
ssRNA or TLR3 which recognises dsRNA but trigger mainly IL6 and TNF secretion, 
we used RNA interference to knock down expression of RIG-I and MDA5 in cardiac 
cells (Figure 3.3B). Following confirmation of knockdown we stimulated the cells with 
ssRNA, RF-RNA (dsRNA) and RI-RNA which contains both dsRNA and ssRNA and 
measured IFN production (Figure 3.3C). Our results showed that by knocking down 
RIG-I there was no down-regulation on IFNresponse, while knocking down MDA5 
almost abrogated IFN production (figure 3.3C). These results confirmed that MDA5 
senses CAV9 and more specifically the dsRNA formed during their replication in the 
cell cytoplasm. 
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Figure 3.3 - IFNβ upregulation induced by viruses. Human cardiac cells were 
stimulated with different CAV9 RNAs, genomic ssRNA, replicative intermediate 
dsRNA (RF) and dsRNA-ssRNA replicative intermediate (RI). The supernatants were 
harvested and assayed for cytokine secretion using the Flex set system (Becton 
Dickinson). Fluorescence was detected using a FACSCalibur (BectonDickinson). 
IFNsecretion is depicted in graph (A), and (C). RNA interference for MDA5, RIG-I, 
TLR3, TLR7 and TLR8 in cardiac cells is also depicted (receptor expression levels were 
reduced by 85% by RNA interference panel (B). Human cardiac cells were silenced for 
either RIG-I or MDA5, and either not stimulated (white bar charts), or incubated with 
ssRNA with RF-RNA or RI-RNA. The supernatants were harvested and assayed for 
IFN secretion at 4hr using the Flex set system (Becton Dickinson). The data represents 
the mean of three independent experiments. 
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3.2.4: Visualisation of MDA5 and Viral RNA  
Our experiments revealed that MDA5 recognises not the genomic ssRNA but the 
dsRNA generated by the replication of these viruses. In order to confirm interaction 
between MDA5 and viral dsRNA intermediates we used confocal cell imaging. The 
ssRNA, dsRNA (RF), or RI-RNA were delivered directly into the cells‟ cytoplasm 
using streptolysin O (SLO), which is a pore-forming bacterial toxin, as a non endocytic 
delivery method in order to avoid TLR detection. This is a simple and rapid means of 
introducing nucleic acid into the cytoplasm of eukaryotic cells [293;294]. The ssRNA, 
dsRNA and RI-RNA were labelled with Alexa 488. MDA5 and RIG-I were labelled 
with Alexa 633-Fab goat specific Ig, while MAVs was labelled with Alexa 546-Fab 
rabbit specific Ig.  
When we investigated MDA5-viral RNA interactions using confocal microscopy, a high 
level of co-localisation of dsRNA with MAVs and MDA5 was observed, whereas we 
saw no co-localisation of dsRNA with RIG-I (Figure 3.4 A+B). Furthermore when we 
used RI-RNA co-localisation of RI-RNA with MAVS and MDA5 was also shown 
(Figure 3.4 C+D). Interestingly, when we used CAV9 ssRNA, we found no co-
localisation either with RIG-I or with MDA5 (Figure 3.5), suggesting that MDA5 does 
not engage the ssRNA of the viruses but only interacts and recognises the dsRNA 
intermediates that ae formed during the replication phase. As expected, when Influenza 
genomic 5‟ triphosphate ssRNA was used, we found co-localisation with RIG-I but not 
with MDA5 (Figure 3.6).  
98 
 
 
Figure 3.4 - Localisation of enteroviral dsRNA RF or RI-RNA and MDA5 in 
cardiac cells. Human cardiac cells containing CAV-9 ssRNA, dsRNA RF or RI-RNA 
directly conjugated to Alexa 488. MDA5 and RIG-I were labelled with Alexa 633-Fab 
goat specific Ig, while MAVs was labelled with Alexa 546-Fab rabbit specific Ig. The 
indicated regions in merged images are enlarged in panels A, B, C and D Yellow 
regions indicate localisation of MAVs with dsRNA RF and RI-RNA. White regions 
indicate localisation of MDA5, MAVs with dsRNA RF and RI-RNA. Bars 10 m. 
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Figure 3.5 - There is no localisation of enteroviral ssRNA either with RIG-I or with 
MDA5. Human cardiac cells containing CAV-9 ssRNA conjugated to Alexa 488. 
MDA5 was labelled with Alexa 546-Fab goat specific Ig. RIG-I was labelled with 
Alexa 546 Fab goat specific Ig. We see no degree of localisation in the displayed 
images. Bars 10 m 
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Figure 3.6 - Localisation of influenza ssRNA and RIG-I in cardiac cells. Human 
cardiac cells containing Influenza ssRNA (5‟ppp ssRNA) conjugated to Alexa 488. 
MDA5 was labelled with Alexa 633-Fab goat specific Ig. while MAVs was labelled 
with Alexa 546-Fab rabbit specific Ig. RIG-I was labelled with Alexa 633-Fab goat 
specific Ig. Yellow regions indicate localisation of MAVs and ssRNA. White regions 
indicate localisation of RIG-I, MAVs and ssRNA. Bars 10 m 
 
3.2.5: Picornavirus replication is essential for MDA5 sensing 
To gain more insight as to whether Picornavirus replication and the generation of 
dsRNA is a prerequisite for MDA5 sensing, confocal microscopy was once again used. 
This method helped us visualise dsRNA formed de novo during virus infection. Cardiac 
cells were infected with CAV9 for different time points during infection and the dsRNA 
was visualised using the monoclonal dsRNA-specific mouse antibody J2 Fab directly 
conjugated to Alexa 488. MDA5 and RIG-I were labelled with Alexa 546-Fab goat 
specific Ig, while MAVs was labelled with Alexa 546-Fab rabbit specific Ig. To verify 
that the dsRNA detected was indeed of viral not cellular origin, cells were also treated 
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with the DNA dependent RNA polymerase inhibitor actinomycin D and the dsRNA 
signal was still detected verifying that it was specific for viral dsRNA. 
The experiments were consistent with our previous studies and highlighted that dsRNA 
co-localises with MDA5 and MAVs but not RIG-I (figure 3.7).  
 
 
Figure 3.7 - Localisation of viral dsRNA and MDA5 in virus infected cardiac cells. 
Human cardiac cells infected with CAV-9 were stained with J2 Fab specific for dsRNA 
directly conjugated to Alexa 488. MDA5 and RIG-I were  labelled with Alexa 546-Fab 
goat specific Ig while MAVs was labelled with Alexa 546-Fab rabbit specific Ig, RIG-I 
was labelled with Alexa 546 Fab goat specific Ig. Nuclear stain TOPRO was also used 
to label the nucleus. Yellow regions indicate localisation of MAVs or MDA5 with viral 
dsRNA. Bars 10 m. 
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3.3: Discussion 
The RNA helicases, RIG-I and MDA5, have been defined as essential PRRs for host 
detection of a variety of RNA viruses and activation of type I interferons.  It has been 
widely known that RIG-I is a key sensor for negative strand ssRNA viruses such as 
Hepatitis C virus and Influenza viruses whereas induction of type I IFN by positive 
strand Picornaviruses, including Encephalomyocarditis virus, Theiler‟s virus and 
Mengo virus, is mediated by MDA5 and not RIG-I [283;284;295].  
A large research effort has focused on understanding the ligands that are recognized by 
each of these RLRs since these new insights will help in the development of improved 
vaccines and new antiviral therapeutics to control virus infections. 
Despite the wealth of information on the types of RNA that can activate RIG-I and 
induce IFN production there is not a lot of information on the viral RNA required for 
MDA5 activation. It has been shown that RIG-I recognizes single-stranded RNA 
(ssRNA) containing a terminal 5 -triphosphate (ppp), as well as linear dsRNA no longer 
than 23 nucleotides. MDA5 recognition is less clear, since it does not sense viral 
genomic ssRNA. It seems to recognise long strands of dsRNA but the mechanism by 
which this occurs has not been revealed. Pichlmair et al [289] using mainly biochemical 
methods had suggested that MDA5 senses high order structured RNA containing 
ssRNA and dsRNA, however that fails to explain why MDA5 can sense Poly(I:C), 
which is a synthetic long dsRNA, or dsRNA viruses such as Reoviruses [286] or why it 
cannot sense Picornavirus genomic ssRNA that contains highly ordered secondary 
structures and tertiary RNA structures in the 3‟ and 5‟UTR regions. The inherent 
problem with the study by Pichlmair et al is that they rely on immunoprecipitations with 
a dsRNA-specific antibody in order to isolate RNA/MDA5 complexes. Using this 
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method they demonstrated that infected cells contained not only dsRNA but also ssRNA 
of high molecular weight, which was found to be immunostimulatory. The problem is 
that such biochemical isolations rely exclusively on the specificity of the antibody used 
and they are prone to artefactual associations.  
The goal of the present study was to determine whether RIG-I or MDA5 participate in 
the induction of type I IFN in response to Coxsackie A9 virus infection and to 
determine the specific RNA ligand that was recognized and activated these sensors 
using non-invasive methods. 
CAV9 is a positive ssRNA virus therefore in addition to its ssRNA genome there are 
also substantial amounts of cytosolic dsRNA produced during the replicative life cycle 
of these positive ssRNA viruses. Thus during an Enteroviral infection, there is a pool of 
viral RNA that trigger the host‟s innate immune response, raising the question of which 
viral RNA species is responsible for MDA5 activation. CAV9 ssRNA as well as the 
replicative intermediate dsRNA (RF) and the high order replicative intermediate (RI), 
which is basically a dsRNA RF with a nascent ssRNA viral strand, were isolated and 
used in this study. The data showed that although RIG-I acts as a sensor triggering 
interferon production in the presence of negative ssRNA virus such as Influenza A virus 
it cannot recognise the replicative intermediate dsRNAs  of positive strand viruses. 
The experiments have shown that there was no interaction of MDA5 with the genomic 
ssRNA. However MDA5 recognised the dsRNA produced during the CAV9 replication 
as well as RI-RNA which has a dsRNA core, highlighting the importance of dsRNA in 
MDA5 recognition. Thus providing unique evidence between the relationship of viral 
dsRNA and MDA5 and confirming that the dsRNA replicative intermediate form of 
CAV9 is the effective agonist recognised by MDA5 (Triantafilou, K. 2012). 
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While the confocal data does not prove direct interaction, the difference in co-
localisation between MDA5 and RIG-I with the dsRNA intermediates and the 
difference between ssRNA localisation from CVA and IFVA with the RLRs is strong 
enough evidence to show interaction when combined with the IFN assay data.  FRET or 
other methods could be used to show proximity of molecules and could be performed as 
further work to show evidence that MDA5 binds the dsRNA intermediate . However the 
evidence presented here is significant without the further work being neccesary.  
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Chapter 4: RIG-Like Receptor Involvement in CVB3 Infection of Cardiac 
Cells  
4.1: Introduction    
One of the most severe of CVBs symptoms is myocarditis, an infection of the heart 
muscle [296]. The cardiac Girardi cell line is a human heart cell line of epithelial 
morphology that is susceptible to CVB [297] thus making it  a good base from which to 
understand the PRR response to CVB. 
Recognition of CVB3 is most likely through MDA5, as has been shown for other 
Picornaviruses, rather than RIG-I [298;299]. Evidence thus far indicates that MDA5 is 
the main candidate for CVB3 recognition of the RLR family [300], however the extent 
of its role in relation to other PRRs and the exact nature of its recognition of CVB3 have 
yet to be elucidated. It has already been demonstrated in Chapter 3 that MDA5 
recognises dsRNA intermediate when cells are infected with CAV9 and the same is 
likely true of CVB3, however this needs to be confirmed. To make matters more 
complicated there is evidence that suggests both RIG-I and MDA5 may be cleaved by 
the virus during its life cycle, likely towards the later stages of infection as has been 
shown in other Picornaviruses [301;302]. For this reason specific nucleic PAMPs have 
been used to stimulate the cells in order to determine specific structures that may 
influence MDA5 or RIG-I binding in CVB3 infections. Picornaviruses life cycle lasts 
from around 5 to 10 hours, with the Coxsackievirus life cycle estimated at around 6 
hours [303], so for each stimulation time points of 2, 4 and 6 hours were used to create 
an idea of changes through the life cycle, as well as giving insight to any possibly 
cleavage of the RLRs that may occur.  
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The innate immune system is a vital part of the body‟s defences against viral pathogens. 
RIG-I and MDA5 function as cytoplasmic PRRs that are involved in the elimination of 
actively replicating RNA viruses. Their location and their differential responses to RNA 
viruses emphasises the complexity of the innate detection system. In order to identify 
which RNA species triggers MDA5 activation during infection, viral ssRNA and the 
replicative intermediate dsRNA were isolated from CVB3. Furthermore dsRNAs such 
as Poly(I:C) which is a mismatched double-stranded RNA with one strand being a 
polymer  of inosinic acid, the other a polymer of cytidylic acid was used. Poly(I:C) is a 
known inducer of IFN response recognised by MDA5 [304]. It was later determined 
that MDA5 recognised Poly(I:C) around 2 kbp and RIG-I recognised cleaved Poly(I:C) 
products around 70 bp [305]. Viral dsRNA may follow the same rule of recognition 
with shorter dsRNA in secondary structures and the replicative intermediate and longer 
dsRNA in the replicative form which has a full copy of both the positive and negative 
strand RNA [306-309]. 
 In addition synthetic dsRNAs with altered end structures were also used to determine 
their effect on RLR binding. Synthetic 5‟ppp dsRNA was used as it has been linked as a 
possible factor in RIG-I binding to dsRNA structures [310], as well as RIG-Is known 
preference for 5‟ppp ssRNA [311;312]. The synthetic 5‟OH dsRNA was used as a 
second form of end structure for dsRNA. Using both could give a better insight into the 
end structures role in RLR recognition, whether changing the structure provides a better 
binding platform or acts as a hindrance. 
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To determine if CBV3 infection (and more specifically which CBV3 RNA constructs) 
triggers the innate immune response, cardiac cells were taken and stimulated with 
CVB3 as well as CVB3 ssRNA, CVB3 RF-RNA and synthetic RNA structures to 
determine which RNA constructs is immunostimulatory..  
Ligand binding to either of the RLRs leads to signalling through MAVS that results in 
activation of both NF-κB and IRF3 [313-315]. This leads to the expression of type-I 
IFNs, including IFNα and IFNβ, which activate IFN-induced genes (ISGs) through the 
receptor IFNAR1/2 and inducing the JAK/STAT pathway. Therefore the presence of 
IRF3 and phosho-IκB (P-IκB) in cardiac cells in response to different RNA constructs 
were investigated. 
P-IκB acts as a good determinant for the levels of NF-κB as the phosphorylation of 
total-IκB (T-IκB) releases NF-κB. For this reason T-IκB was also probed for as a 
control for the P-IκB.  
The ligands used to stimulate the cells were CVB3 (figure 4.1), ssRNA and RF-RNA 
(dsRNA) both extracted from CVB3 infectious cycle, the synthetic dsRNA homolog 
Poly(I:C) and two synthetic RNAs with specific RNA structures shown here as RNA1 
and RNA2 (see materials and methods). For each ligand the cells were stimulated for 2, 
4 or 6 hours and unstimulated cells were used as a control.  
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4.2: Results           
4.2.1: Immunostimulatory effect of CBV3 and different RNA constructs on cardiac 
cells 
 
Figure 4.1 – Immunostimulatory effect of CBV3 on cardiac cells. Cells were either 
not infected or infected with 5 moi CVB3 for 2, 4 and 6 hours The cell lysate from each 
stimulation was used for SDS-PAGE gel electrophoresis and western blot analysis using  
primary antibodies specific for IRF3, phospho-IκB or total-IκB and followed by the 
appropriate secondary antibodies conjugated to HRP. The data represent the mean of 
three independent experiments. 
 
 
Infection of cardiac cells with CVB3 triggers innate immune recognition since for IRF3, 
P-IκB and T-IκB were present upon viral infection This is consistent with previous 
studies showing CVB recognition by different PRRs such as TLR4, which recognises 
the virus capsid [290] as well as TLR7 and TLR8 which recognise CBV ssRNA [280] 
as well as MDA5 in CVB innate recognition [316]. 
To determine whether the CVB3 ssRNA is also immunostimulatory, CVB3 genomic 
RNA was used to stimulate cells (figure 4.2). 
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Figure 4.2 – Immunostimulatory effect of CBV3 ssRNA on cardiac cells. Cells were 
ustimulated or stimulated with 10 µg ssRNA for 2, 4 and 6 hours The cell lysate from 
each stimulation was used for SDS-PAGE gel electrophoresis and western blot analysis 
using  primary antibodies specific for IRF3, phospho-IκB or total-IκB and followed by 
the appropriate secondary antibodies conjugated to HRP. The data represent the mean of 
three independent experiments. 
 
As expected the data showed that CVB3 ssRNA is recognised by PRRs and triggers 
signalling cascades since IRF3, phospho-IκB or total-IκB are triggered upon ssRNA 
stimulation. 
 
Figure 4.3 - Immunostimulatory effect of CBV3 RF-RNA (dsRNA) on cardiac 
cells. Cells were unstimulated or stimulated with 10 g of CVB3 RF-RNA for 2, 4 and 
6 hours The cell lysate from each stimulation was used for SDS-PAGE gel 
electrophoresis and western blot analysis using  primary antibodies specific for IRF3, 
phospho-IκB or total-IκB and followed by the appropriate secondary antibodies 
conjugated to HRP. The data represent the mean of three independent experiments. 
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Stimulation with CVB3 RF-RNA appears to activate P-IκB evenly across all time 
points, but not IRF3, which appears to be expressed after 4 hours, indicating that it may 
utilise different PRRs for IRF3 and P-IκB (possibly TLR3 for P-IκB and MDA5 for 
IRF3). Again T-IκB is expressed uniformly across all time points (figure 4.3). 
To determine the RNA ligand which triggers signalling in cardiac cells, different RNA 
synthetic constructs were used. Poly(I:C) is a synthetic dsRNA and was used to 
stimulate cells for different time points (figure 4.4).  
 
Figure 4.4 - Immunostimulatory effect of Poly IC on cardiac cells. Cells were 
unstimulated or stimulated with 10 g of Poly IC for 2, 4 and 6 hours The cell lysate 
from each stimulation was used for SDS-PAGE gel electrophoresis and western blot 
analysis using  primary antibodies specific for IRF3, phospho-IκB or total-IκB and 
followed by the appropriate secondary antibodies conjugated to HRP. The data 
represent the mean of three independent experiments. 
 
Interestingly the results after stimulating cardiac cells with Poly(I:C) closely match 
those of stimulating with RF-RNA (dsRNA). Both have increased expression of IRF3 
from 4 hours and uniform expression of P-IκB and T-IκB. This resemblance between 
the results would suggest that despite Poly(I:C) being a synthetic analogue of dsRNA 
they are both recognised by the same PRRs leading to similar innate immune responses. 
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Following Poly(I:C) synthetic RNA analogues with different end groups were used, first 
5‟OH synthetic dsRNA (RNA1) (figure 4.5) and then 5‟ ppp dsRNA (RNA2) (figure 
4.6). 
 
Figure 4.5 - Immunostimulatory effect of 5’ OH dsRNA on cardiac cells. Cells were 
unstimulated or stimulated with 10 g of 5‟ OH dsRNA for 2, 4 and 6 hours The cell 
lysate from each stimulation was used for SDS-PAGE gel electrophoresis and western 
blot analysis using  primary antibodies specific for IRF3, phospho-IκB or total-IκB and 
followed by the appropriate secondary antibodies conjugated to HRP. The data 
represent the mean of three independent experiments. 
 
Stimulation with 5‟OH dsRNA creates a strong expression of P-IκB and T-IκB, 
however a diminished IRF3 response. This would suggest that unlike CVB3 ssRNA and 
RF-RNA it may not trigger all signalling cascades. 
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Figure 4.6 - Immunostimulatory effect of 5’ppp dsRNA on cardiac cells. Cells were 
unstimulated or stimulated with 10 g of 5‟ppp dsRNA for 2, 4 and 6 hours The cell 
lysate from each stimulation was used for SDS-PAGE gel electrophoresis and western 
blot analysis using  primary antibodies specific for IRF3, phospho-IκB or total-IκB and 
followed by the appropriate secondary antibodies conjugated to HRP. The data 
represent the mean of three independent experiments. 
. 
Like 5‟OH dsRNA, 5‟ppp dsRNA has a diminished IRF3 response, while still having a 
good P-IκB and T-IκB response. However the P-IκB decreases after 2 hours, leaving a 
far less significant response by 6 hours. 
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4.2.2: IFN-β Production   
Type I interferons IFNα/β are mainly triggered by RLRs such as RIG-I and MDA5. To 
determine the involvement of RLRs in CVB3 recognition IFNβ secretion was measured. 
Cardiac cells were stimulated with CVB3, CVB3 ssRNA, CBV3 RF-RNA, Poly(I:C) 
and synthetic 5‟OH dsRNA and 5‟ppp dsRNA. Time points of 2, 4 and 6 hours were 
used and the levels of IFNβ in the cells were measured.  
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Figure 4.7 - CBV3 infection activates RLRs. Cardiac cells were either not infected or 
infected with 5 moi of CBV3 Supernatant was collected at 2 hr, 4 hr, 6 hr post infection 
and analysed for IFN secretion using the Flex set system on a FACSCalibur (Becton 
Dickinson). The data represents the mean of three independent experiments. 
 
The results indicate an increase in IFNβ secretion (figure 4.7) when cells were infected 
with CVB3, thus implicating RLR involvement in CVB3 recognition. To determine the 
specific ligand that RLRs recognise, CBV3 ssRNA was used to stimulate cells (figure 
4.8). 
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Figure 4.8 - CBV3 ssRNA stimulation on cardiac cells. Cardiac cells were 
unstimulated or stimulated with 10 g of ssRNA. Cell Supernatant was collected at 2 hr, 
4 hr, 6 hr post infection and analysed for IFN secretion using the Flex set system on a 
FACSCalibur (Becton Dickinson). The data represents the mean of three independent 
experiments 
 
Expression levels of IFNβ are slightly elevated but are not as high as the expression 
levels triggered by CVB3. This probably suggests that ssRNA does not have as efficient 
an immunostimulatory effect on RLRs and the low levels of IFNβ are possibly triggered 
by TLR recognition. 
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IFN Production in  Cardiac Cells Stimulated With CVB3 dsRNA
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Figure 4.9 - CBV3 RF-RNA (dsRNA) stimulation on cardiac cells. Cardiac cells 
were unstimulated or stimulated with 10 g of CBV3 RF-RNA Cell Supernatant was 
collected at 2 hr, 4 hr, 6 hr post infection and analysed for IFN secretion using the Flex 
set system on a FACSCalibur (Becton Dickinson). The data represents the mean of 
three independent experiments. 
 
The stimulation with RF-RNA triggers high expression levels of IFNβ (figure 9), 
showing it to be a far greater inducer of the type-I IFNs than the viral ssRNA. The 
increase is nearly as high as the CVB3 results with a 25 fold increase over the 
unstimulated at 2 and 4 hours and a drop to just over 1000pg/ml at 6 hours. This 
indicates that the dsRNA intermediate is crucial in the PRR response to CVB3.   
Synthetic dsRNA constructs were also used such as PolyIC (figure 4.10), synthetic 
5‟OH dsRNA (figure 4.11) and synthetic 5‟ppp dsRNA (figure 4.12). 
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Figure 4.10 - Poly IC stimulation on cardiac cells. Cardiac cells were unstimulated or 
stimulated with 10 g of Poly IC. Cell supernatant was collected at 2 hr, 4 hr, 6 hr post 
infection and analysed for IFN secretion using the Flex set system on a FACSCalibur 
(Becton Dickinson). The data represents the mean of three independent experiments. 
 
The Poly(I:C) triggers IFNβ expression over time. Therefore confirming dsRNA 
recognition by RLRs. 
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IFN Production in  Cardiac Cells Stimulated With 5'OH dsRNA
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Figure 4.11 - Poly IC stimulation on cardiac cells . Cardiac cells were unstimulated 
or stimulated with 10 g of 5‟ OH dsRNA. Cell supernatant was collected at 2 hr, 4 hr, 
6 hr post infection and analysed for IFN secretion using the Flex set system on a 
FACSCalibur (Becton Dickinson). The data represents the mean of three independent 
experiments. 
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Figure 4.12 - 5’ppp dsRNA stimulation on cardiac cells. Cardiac cells were 
unstimulated or stimulated with 10 g of 5‟ppp dsRNA. Cell supernatant was collected 
at 2 hr, 4 hr, 6 hr post infection and analysed for IFN secretion using the Flex set 
system on a FACSCalibur (Becton Dickinson). The data represents the mean of three 
independent experiments. 
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In comparison with the other cardiac results, the 5‟ OH dsRNA construct triggers IFNβ 
production but not as high as Poly IC or RF-RNA. However 5‟ppp dsRNA has by far 
the least increase in IFNβ expression, thus indicating that 5‟ppp dsRNA does not have 
an immunostimulatory effect on RLRs. 
IFN Production in  Cardiac Cells Stimulated With a
Variety of  Viral  PAMPs
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Figure 4.13 - RNA stimulations on cardiac cells. Cardiac cells were unstimulated or 
stimulated with 5 moi of CBV3 or with 10 g of ssRNA, RF-RNA, Poly IC as well as 
5‟OH dsRNA or 5‟ OH dsRNA. Cell supernatant was collected at 2 hr, 4 hr, 6 hr post 
infection and analysed for IFN secretion using the Flex set system on a FACSCalibur 
(Becton Dickinson). The data represents the mean of three independent experiments  
 
An overview of the cardiac stimulations (figure 4.13) shows that along with CVB, the 
RF-RNA creates the largest IFNβ response. The ssRNA is recognised but is not as 
potent an inducer of the immune response as the dsRNA. The 5‟OH dsRNA is also 
clearly recognised while the 5‟ppp seems to nearly completely negate any IFNβ 
response. 
 
119 
 
4.3: Innate Immune Response to CBV3 Infection in HEK and HEK-MDA5 cells 
4.3.1: IFNβ Production in Stimulation with CBV3 and Genomic RNA as well as 
Synthetic RNA 
In order to determine the specific role of MDA5 on RNA ligand recognition HEK293 
cells transfected with MDA5 were also used. Measurements of IFNβ secretion 
determined the immunostimulatory effect of different RNA constructs (figure 4.14 and 
figure 4.15). 
IFN Production in HEK-wt Cells Stimulated With CVB3
and synthetic dsRNAs
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Figure 4.14 - RNA stimulations on HEK cells. HEK cells were unstimulated or 
stimulated with 5 moi of CBV3 or with 10 g of ssRNA, RF-RNA, Poly IC as well as 
5‟OH dsRNA or 5‟ppp dsRNA. Cell supernatant was collected at 2 hr, 4 hr, 6 hr post 
infection and analysed for IFN secretion using the Flex set system on a FACSCalibur 
(Becton Dickinson). The data represents the mean of three independent experiments 
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IFN Production in HEK-MDA5 Cells Stimulated With
CVB3 and synthetic dsRNAs
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Figure 4.15 - RNA stimulations on HEK-MDA5 cells. HEK-MDA5 cells were 
unstimulated or stimulated with 5 moi of CBV3 or with 10 g of ssRNA, RF-RNA, 
Poly IC as well as 5‟OH dsRNA or 5‟ppp dsRNA. Cell supernatant was collected at 2 
hr, 4 hr, 6 hr post infection and analysed for IFN secretion using the Flex set system on 
a FACSCalibur (Becton Dickinson). The data represents the mean of three independent 
experiments. 
 
Stimulation of HEK-wt cells showed no significant expression of IFNβ, as expected. 
However when HEK-MDA5 cells were used the data produced showed that the CBV3 
virus as well as the synthetic dsRNAs created a strong IFNβ response. The addition of 
the 5‟OH end group triggers an IFN response but obviously slightly lower than the RF-
RNA since it is not as long as RF-RNA. Therefore the 5‟OH end group may be a factor 
in dsRNA recognition. However The 5‟ppp end group is not very immunostimulatory to 
RLRs since it stimulates a response but not very significant.  
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4.3.2: IRF3 Production after Stimulation with CBV3 and Genomic RNA as well as 
Synthetic RNA 
The HEK cell line do not naturally express any PRRs so in order to determine the 
specific effect of MDA5 in recognising RNA constructs we used HEK-MDA5 cells. 
Both HEK-MDA5 and HEK-wt cells were stimulated with CVB3, ssRNA and RF-RNA 
(dsRNA) isolated from CVB3, Poly(I:C), 5‟OH dsRNA and 5‟ppp dsRNA for 2, 4 and 
6 hours as well as using unstimulated cells as the control. The cell extracts were 
analysed via SDS-PAGE electrophoresis and western blotting for the detection of IRF3 
as the downstream signalling target to determine the strength of the innate immune 
response.  
From the data (figure 4.16) we concluded that there is no IRF3 expression in HEK-wt 
type cells. However when HEK-MDA5 cells were used there was an IRF3 response to 
CVB3 infection as expected. Furthermore RF-RNA (dsRNA) as well as Poly(I:C) and 
5‟ OH dsRNA triggered IRF3 response. We show no response when ssRNA was used 
and a very weak response when cells were stimulated with 5‟ ppp dsRNA. 
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Figure 4.16 - IRF3 expression in rensponse to CBV3 and RNA constructs. Cells 
extracts from unstimulated HEK-wt or HEK-MDA5 cells as well as cells stimulated 
with 5 moi CVB3 (A) or with 10 µg of ssRNA (B), RF-RNA (C), as well as 5‟OH 
dsRNA (D) or 5‟ ppp dsRNA (E) or Poly IC (F) were analysed for the presence of IRF3 
by western blotting using an IRF3 Rabbit pAb and a Swine Anti-Rabbit Ig HRP 
secondary. The bands were visualised using the ECL procedure. The data represent the 
mean of three independent experiments. 
A B
C D
E F
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4.3.3: Detection of Expression Levels of IFNα/β using HEK- IFNα/β reporter cells 
As a second method of detecting the Type-I IFN response to CVB3 due to MDA5, 
HEK- IFNα/β reporter cells were used. One of the ISGs under the control IFNα and β 
causes expression of SEAP into the supernatant, which turns blue when Quanti-Blue is 
added. The more blue the supernatant, the more SEAP is expressed and the more IFNα 
and β are being expressed. A spectrophotometer was used to measure the level of SEAP 
at A630. Stimulations used CVB3, CVB3 ssRNA and dsRNA and the synthetic 
Poly(I:C), 5‟OH dsRNA and 5‟ppp dsRNA at 2, 4 and 6 hours. 
IFN / Activation in HEK-wt Cells Stimulated With Viral
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Figure 4.17 - IFN / response in HEK-wt cell infections. Supernatant from HEK wt 
infections with 5 moi of CVB3 as well as 10g of ssRNA, dsRNA, Poly(I:C), 5‟OH 
dsRNA or 5‟ppp dsRNA for 2, 4 and 6 hours was added to HEK IFN / reporter cells 
and incubated for 24 hours. Quanti-Blue was added and the levels of SEAP measured 
using a spectrophotometer at 630nm. The SEAP levels correspond to the expression 
levels of IFN/β. 
As with the cytokine assay, the data overall show a negligible Type-I IFN response, 
which verifies that no PRRs are present in HEK-wt that can induce an innate immune 
response. 
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IFN / Activation in HEK-MDA5 Cells Stimulated With
Viral  PAMPs using HEK-Blue Cells
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Figure 4.18 - IFN / response in HEK-MDA5cell infections. Supernatant from HEK 
MDA5 infections with 5 moi of CVB3 as well as 10g of ssRNA, dsRNA, Poly(I:C), 
5‟OH dsRNA or 5‟ppp dsRNA for 2, 4 and 6 hours was added to HEK IFN / reporter 
cells and incubated for 24 hours. Quanti-Blue was added and the levels of SEAP 
measured using a spectrophotometer at 630nm. The SEAP levels correspond to the 
expression levels of IFN/β. 
 
The overview of the HEK-MDA5 data shows that next to the expected strong response 
through MDA5 to CVB3, most of the dsRNAs create the next highest response. There is 
very little difference between the RF-RNA (dsRNA) and Poly(I:C) IFN expression 
levels when seeing the data. This indicates that the most crucial part of the viral dsRNA 
sensed by MDA5 is the double stranded nature of the RNA. The 5‟ppp structure on the 
dsRNA appears to prevent the major portion of a Type-I IFN response to dsRNA, while 
5‟OH appears to have an effect in triggering IFNα/β response. Furthermore the data 
conclusively shows that ssRNA is not recognised by MDA5. 
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4.4: Co-localisation of RLRs and CVB3  
Our experiments revealed that MDA5 recognises not the genomic ssRNA but the 
dsRNA generated by the replication of these viruses. In order to confirm MDA5 and 
viral RNA interactions we used confocal cell imaging.  
When we investigated MDA5-viral RNA interactions using confocal microscopy, 
Cardiac cells were infected with CVB3 for different time points during infection and the 
dsRNA was visualised using the monoclonal dsRNA-specific mouse antibody J2 Fab 
directly conjugated to Alexa 488. MDA5 and RIG-I were labelled with Alexa 546-Fab 
goat specific Ig, while MAVs was labelled with Alexa 546-Fab rabbit specific Ig.  A 
high level of colocalisation of dsRNA with MAVs and MDA5 was observed, whereas 
we saw no colocalisation of dsRNA with RIG-I (Figure 4.19). 
 
Figure 4.19 - Localisation of enteroviral dsRNA RF and MDA5 in cardiac cells. 
Human cardiac infected with CVB3 were stained with J2 Fab specific for dsRNA 
directly conjugated to Alexa 488. MDA5 and RIG-I were labelled with Alexa 633-Fab 
goat specific Ig while MAVs was labelled with Alexa 546-Fab rabbit specific Ig, 
Yellow regions indicate localisation of MAVs with dsRNA RF. White regions indicate 
localisation of MDA5, MAVs with dsRNA RF. Bars 10 µm. 
 
MAVS dsRNA MDA5 Merged 
dsRNA MAVS RIG - I Merged 
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4.5: Discussion 
Effective immune defence against viral infection depends on accurate and robust 
detection of viral RNAs by pattern recognition receptors in the innate immune system. 
RIG-I and MDA5 function as cytoplasmic PRRs that are involved in the elimination of 
actively replicating RNA viruses.  
Upon viral RNA recognition, RIG-I and MDA5 interact with a common signalling 
adaptor, MAVS and activate NF-kB and IRF3/7 signalling pathways, resulting in the 
expression of type I interferon and proinflammatory cytokines.  
Despite the wealth of information on the types of RNA that trigger RIG-I, much less is 
known about the nature of the RNAs that act as agonists for MDA5. In order to identify 
the specific ligand for MDA5, we chose to utilise CVB3, which is a member of 
Picornaviridae. In order to identify which RNA species triggers MDA5 activation 
during infection, we isolated viral ssRNA and replicative intermediate of RNA as well 
as using synthetic dsRNAs.  This work revealed that MDA5 recognises not the genomic 
ssRNA but the dsRNA generated by the replication of CVB3 and more specifically 
synthetic 5‟OH dsRNA appears to have an effect in triggering IFNα/β response. 
Furthermore, using fluorescent imaging, visualization of dsRNA and MDA5 is achieved 
providing unique evidence between the relationship of viral dsRNA and MDA5 and 
gives strong evidence that MDA5 is the key sensor for the dsRNA replicative 
intermediate form of positive sense ssRNA.  
Results from the cardiac cells are limited by the presence of other PRRs expressed 
within the cells and the SDS-PAGE data, while reliably showing expression of NF-κB 
or IRF-3, is not easily quantifiable. However alongside the IFN-assays, confocal work 
and the HEK-MDA5 data the evidence presented all points to the same conclusion. 
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Chapter 5: Determining the Role of RIG-I in CVB3 sensing using HUH 
Cells 
5.1: Introduction   
RLRs were initially thought to recognise the same ligand, dsRNA, but it has since 
become apparent that RIG-I and MDA5 possess distinct virus specificities. It has been 
shown that they each recognise different viruses and different viral RNAs [317;318]. 
RIG-I recognises single-stranded RNA (ssRNA) containing a terminal 5‟-triphosphate 
(ppp) [319], as well as linear dsRNA no longer than 23 nucleotides in length [320]. 
MDA5 recognises long strands of dsRNA, but the mechanism by which this occurs is 
less clear [321]. 
In order to determine the involvement of RIG-I in CBV3 recognition, Huh cells were 
used. The Huh7 cells are a well differentiated human hepato-carcinoma cell line [322] 
that can be used to compare cell lines with or without RIG-I. The Huh 7.5.1 cell line is 
derived from the wt Huh7s and contains a mutation within the RIG-I gene. The T551 
mutation within the gene is located in the CARD domain of RIG-I and prevents CARD-
CARD homotypic interactions. This prevents RIG-I from transducing a signal through 
MAVS and essentially means that the RIG-I pathway is completely inhibited [323].  
To elucidate the role of RIG-I in CVB3 infection both the Huh7 and Huh7.51 cell lines 
were used to compare the effect of a fully functioning RIG-I pathway. Stimulations 
used 2, 4 and 6 hour time points to cover the CBV3 life cycle and CVB3, CVB3 ssRNA 
and dsRNA and Poly(I:C) were used to infect the cells. The main point of interest is 
whether RIG-I plays any role in Coxsackievirus RNA recognition.  
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Phospho-IκB detection corresponds with NF-κB activation, which when coupled with 
IRF3 detection, gives an indication of MDA5 and RIG-I activity in response to different 
stimulations.  
Huh7 and Huh 7.5.1 cells were stimulated with CVB3, ssRNA and RF-RNA (dsRNA) 
isolated from CVB3 and Poly(I:C). The Huh cell lines were used with the aim of 
determining the immunological difference of having a working RIG-I pathway present. 
The strength of the innate immune response was measured by probing for IRF3, 
phospho-IκB and total-IκB through SDS-PAGE and detecting via ECL. For each 
stimulus the cells were left for either 2, 4 or 6 hours as well as an unstimulated sample 
as the control.  
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5.2: Results  
5.2.1.: Ligand recognition and Phospho-IκB and IRF3 signalling in Huh 7 and 
7.5.1 Cells   
 
Figure 5.1 - CBV3 recognition by HUH cells. Huh7 and Huh7.5.1 cells were either 
left unstimulated or stimulated with CBV3 virions, for 2, 4, or 6 hour time points. 
Discontinuous SDS-PAGE followed by western blotting using specific phospho-Iκb, T-
Iκb or IRF3 Rabbit pAb and a Swine Anti-Rabbit Ig HRP secondary antibody was used 
to detect their presence. The bands were visualised using the ECL procedure. This is a 
representative of three independent experiments. 
 
Stimulation of both cell lines of Huh cells with CVB3 causes strong expression of IRF3, 
P-IκB and T-IκB through all three time points. There appears to be very little difference 
between the presence of RIG-I or not, most likely due to the fact that CVB3 is also 
detected by other PRRs such as TLR4, TLR3, TLR7, TLR8 or MDA5 [324-326].  
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Figure 5.2 - CBV3 ssRNA recognition by HUH cells. Huh7 and Huh7.5.1 cells were 
either not stimulated or stimulated with, CBV3 ssRNA, for 2, 4, or 6 hour time points. 
Discontinuous SDS-PAGE followed by western blotting using specific phospho-Iκb, T-
Iκb or IRF3 Rabbit pAb and a Swine Anti-Rabbit Ig HRP secondary antibody was used 
to detect their presence. The bands were visualised using the ECL procedure. This is a 
representative of three independent experiments. 
. 
Unlike the stimulation with CVB3, where there is no difference between the two cell 
lines, there is a slight difference in the expression of P-IκB with ssRNA stimulation. We 
have already seen in cardiac cells that RIG-I is not involved in CVB ssRNA 
recognition. This data could suggest that perhaps another PRR, (probably TLR7 which 
has been shown to recognize CVB ssRNA [327]) is responsible for IRF3 and P-IkB 
expression and could be more upregulated in the presence of RIG-I. 
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Figure 5.3 - RF-RNA (dsRNA) recognition by HUH cells. Huh7 and Huh7.5.1 cells 
were either not stimulated or stimulated with, CBV3 dsRNA, for 2, 4, or 6 hour time 
points. Discontinuous SDS-PAGE followed by western blotting using specific phospho-
Iκb, T-Iκb or IRF3 Rabbit pAb and a Swine Anti-Rabbit Ig HRP secondary was used to 
detect their presence. The bands were visualised using the ECL procedure. This is a 
representative of three independent experiments. 
. 
Stimulation with RF-RNA (dsRNA) confirms that MDA5 is the main receptor for 
CVB3 and recognises the virus through its dsRNA intermediate as there is no difference 
in IRF3 and P-IkB expression in both cell lines. Huh7.5.1 cells lacking RIG-I still 
respond to dsRNA from CVB3. This data seems to corroborate that RIG-I is not 
important in CVB dsRNA recognition.  
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Figure 5.4 - Poly (IC) recognition by HUH cells. Huh7 and Huh7.5.1 cells were either 
not stimulated or stimulated with, Poly(I:C), for 2, 4, or 6 hour time points. 
Discontinuous SDS-PAGE followed by western blotting using specific IRF3, T-Iκb or 
P-IκB Rabbit pAb and a Swine Anti-Rabbit Ig HRP secondary antibody was used to 
detect their presence. The bands were visualised using the ECL procedure. This is a 
representative of three independent experiments. 
 
Again the Poly(I:C) results are similar to those of dsRNA stimulations, Since Poly (IC) 
is a known ligand for MDA5 this results confirm that MDA5 is functional on both cell 
lines and that it recognises Poly(I:C) which is synthetic dsRNA. 
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To verify that RIG-I was functional in HUH 7.5.1 cells, ssRNA from Influenza A virus 
(IFVA) was used. IFVA genomic ssRNA has been shown to be recognised by RIG-I 
and triggers a strong IFNα/β via IRF3 [328] so IFVA ssRNA was used to stimulate 
HUH cells (see Fig. 5.5).  
 
 
Figure 5.5 - IFVA ssRNA recognition by HUH cells. Huh7 and Huh7.5.1 cells were 
either not stimulated or stimulated with, IFVA ssRNA, for 2, 4, or 6 hour time points. 
Discontinuous SDS-PAGE followed by western blotting using IRF3 specific Rabbit 
pAb and a Swine Anti-Rabbit Ig HRP secondary antibody was used to detect the 
presence of IRF3. The bands were visualised using the ECL procedure. This is a 
representative of three independent experiments. 
 
The data showed that although IFVA ssRNA triggered IRF3 signalling in Huh7 cells, in 
cells that did not have a functional RIG-I like the Huh7.5.1 there was no IRF3 
signalling. Therefore confirming that RIG-I is functional in Huh7 cells and the data 
obtained for CVB3 were specific. 
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5.2.2: IFN-β Production  
To determine the effect of inhibiting the RIG-I pathway on IFNα/β production Huh7 
and Huh7.5.1 cells were used. They were stimulated with CVB3, CVB3 ssRNA and 
dsRNA for 2, 4 and 6 hours (Fig. 5.6) 
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Figure 5.6 - CBV3 infection activates RLRs. Huh7 and Huh7.5.1 cells were either not 
infected or infected with 5moi of CBV3. Supernatant was collected at 2hr, 4h, 6h post 
infection and analysed for IFNβ secretion using the Flex set system on a FACSCalibur 
(Becton Dickinson). The data represents the mean of three independent experiments. 
 
The difference between the IFN expression levels between the two cell lines is minimal 
which would suggest that RIG-I does not play a role in CVB3 recognition. The response 
is actually higher at 2 and 4 hours with 1000pg/ml over 915pg/ml for Huh7.5.1 and 
Huh7 at 2 hours respectively and 1115pg/ml over 910pg/ml for Huh7.5.1 and Huh7 at 4 
hours respectively.  
Cells were also stimulated with RF-RNA (dsRNA) for different time points (figure 5.7). 
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IFN Production in Huh Cells Stimulated With CVB3 dsRNA
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Figure 5.7 - CBV3 RF-RNA (dsRNA) stimulation on HUH cells. Huh7 and Huh7.5.1 
cells were unstimulated or stimulated with 10 µg of CBV3 RF-RNA. Cell supernatant 
was collected at 2hr, 4h, 6h post infection and analysed for IFNβ secretion using the 
Flex set system on a FACSCalibur (Becton Dickinson). The data represents the mean of 
three independent experiments. 
 
Stimulation with the CVB3 dsRNA creates IFNβ expression levels remarkably similar 
to those of the CVB3 stimulation. The Huh7 cells have a slightly lower expression when 
stimulated than the Huh7.5.1, verifying that RIG-I does not trigger a Type-I IFN 
response to CVB3 dsRNA,  
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IFN Production in Huh Cells Stimulated With CVB3 ssRNA
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Figure 5.8 - CVB3 ssRNA stimulation on HUH cells. Huh7 and Huh7.5.1 cells were 
unstimulated or stimulated with 10 µg of CBV3 ssRNA. Cell supernatant was collected 
at 2hr, 4h, 6h post infection and analysed for IFNβ secretion using the Flex set system 
on a FACSCalibur (Becton Dickinson). The data represents the mean of three 
independent experiments. 
 
The ssRNA isolated from CVB3 creates a much lower IFNβ than the full CVB3 virus 
and the dsRNA, with the highest expression still falling below 700pg/ml. This indicates 
that dsRNA is a far more prominent PAMP in CVB3 than the ssRNA. There is also very 
little difference between the IFNβ expression levels between the Huh7 and Huh7.5.1 
showing that RIG-I is not capable of recognising and creating an immune response to 
CVB3s ssRNA. 
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5.2.3: Detection of Expression Levels of IFNα/β using HEK-blue cells  
HEK IFNα/β reporter cells were also used to confirm the data obtained. Huh7 and 
Huh7.5.1 cells were stimulated with CVB3, CVB3 ssRNA and dsRNA and Poly(I:C) 
for 2, 4 and 6 hours and the IFNα/β measured using HEK-Blue cells.  
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Figure 5.9 - IFN α/β response in CBV3 infections. Supernatant from HUH cell 
infections with 5 moi of CVB3 for 2, 4 and 6 hours was added to HEK IFN α/β reporter 
cells and incubated for 24 hours. Quanti-Blue was added and the levels of SEAP 
measured using a spectrophotometer at 630nm. The SEAP levels correspond to the 
expression levels of IFNα/β. 
 
The Type-I IFNα/β response to CVB3 in both cell lines is strong, over 10 fold the 
unstimulated values for both in the first two time points. There is not much difference 
between expression levels at 2 and 4 hours (0.35/0.33 and 0.33/0.35 respectively) 
however by 6 hours there is a drop in expression levels on both the Huh7 and HUH7.5.1 
leaving a stronger IFN response in the Huh7.5.1. The Type-I IFN α/β response, despite 
the loss of the RIG-I pathway, is not affected and complements the cytokine assay data. 
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IFN / Activation in Huh Cells Stimulated
With CVB3 dsRNA using HEK-Blue Cells
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Figure 5.10 - IFN α/β response in RF-RNA (dsRNA). Supernatant from HUH 
stimulations with 10µg of dsRNA, for 2, 4 and 6 hours was added to HEK IFN α/β 
reporter cells and incubated for 24 hours. Quanti-Blue was added and the levels of 
SEAP measured using a spectrophotometer at 630nm. The SEAP levels correspond to 
the expression levels of IFNα/β. 
 
The dsRNA stimulations show an 8.5 fold increase in IFNα/β expression over the 
unstimulated for both the 2 and 4 hour time points in the Huh7 cells, with the Huh7.5.1 
having slightly lower IFNα/β levels, but a higher increase in terms of comparison to the 
unstimulated at over 10 times the unstimulated value. The 6 hour time point however 
shows a larger difference with a 5.5 fold increase for the Huh7 cells and much larger 10 
fold increase for the Huh7.5.1. This gain complements the cytokine assay data and 
shows further evidence that RIG-I is not essential to CVB3 dsRNA IFN α/β response 
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IFN / Activation in Huh Cells Stimulated
With Poly(I:C) using HEK-Blue Cells
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Figure 5.11 - IFN α/β response in Poly IC stimulations. Supernatant from HUH 
stimulations with 10µg of Poly(I:C), for 2, 4 and 6 hours was added to HEK IFN α/β 
reporter cells and incubated for 24 hours. Quanti-Blue was added and the levels of 
SEAP measured using a spectrophotometer at 630nm. The SEAP levels correspond to 
the expression levels of IFNα/β. 
 
The Poly(I:C) results are similar to the dsRNA results, although slightly lower. This 
data confirms that RIG-I does not appear to be involved in the recognition of Poly(I:C).  
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IFN / Activation in Huh Cells Stimulated
With CVB3 ssRNA using HEK-Blue Cells
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Figure 5.12 - IFN α/β response in CVB3 ssRNA stimulations. Supernatant from 
HUH stimulations with 10µg of CVB3 ssRNA, for 2, 4 and 6 hours was added to HEK 
IFN α/β reporter cells and incubated for 24 hours. Quanti-Blue was added and the levels 
of SEAP measured using a spectrophotometer at 630nm. The SEAP levels correspond 
to the expression levels of IFNα/β. 
 
As with the IFNβ results from the cytokine assay, the IFNα/β expression levels as 
detected through the HEK-Blue cells show very little difference between the Huh7 and 
Huh7.5.1. This confirms that RIG-I does not play a role in CVB3 ssRNA recognition 
and is incapable of creating an immune response. 
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Since RIG-I was shown to be ineffective in CVB3 and CBV3 RNA recognition, IFVA 
ssRNA was also used to stimulate HUH cells for different time points as a control 
(figure 5.13). 
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Figure 5.13 - IFN α/β response in IFVA ssRNA stimulations. Supernatant from HUH 
stimulations with 10µg of IFVa ssRNA for 2, 4 and 6 hours was added to HEK IFN α/β 
reporter cells and incubated for 24 hours. Quanti-Blue was added and the levels of 
SEAP measured using a spectrophotometer at 630nm. The SEAP levels correspond to 
the expression levels of IFNα/β. 
 
As expected since IFVA ssRNA is a ligand for RIG-I, the data showed that there is an 
obvious difference between the two cell lines. The IFNα/β response is diminished in 
Huh7.5.1 cells since there is no functional RIG-I. 
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5.3: Discussion  
The IFN-β production in Huh7 cells and Huh7.5.1 cells are the most significant results 
here. Huh7.5.1 cells have an inactivating mutation in RIG-I that leads to a defect in IFN 
production. The major effect of the absence of a working RIG-I pathway is an impaired 
response to IFVA ssRNA showing no IRF3 signalling and diminished IFNα/β 
production. However when CVB3 and CVB3 ssRNA or RF-RNA were used there was 
no major difference in IFNα/β production or in signalling, as IRF3 and P-IκB 
production remained unaffected.  
As stated earlier there is  the possibility that the VPg group that usually prevents RIG-I 
binding ssRNA in Picornaviruses is removed during Coxsackievirus replication. 
Whether this occurs or not is still debatable, however regardless of this it does not play 
a role in RLR recognition of ssRNA as neither the whole virus, nor the isolated ssRNA 
create an immune response through RIG-I. As the isolated ssRNA is not bound by RIG-
I it would seem likely that it is a structural trait of the RNA, not another factor created ii 
the life cycle of the virus, that prevents RIG-Is binding, thus it would seem likely that it 
is the VPg group preventing RIG-I creating an immune response to Coxsackievirus. 
Neither of the dsRNA intermediates create a response through RIG-I either, suggesting 
that the structures are too long for RIG-I to bind. It also suggests that the nascent 
ssRNA in the RI is not a suitable ligand for RIG-I. 
This evidence supports the hypothesis that RIG-I does not create an innate immune 
response to Picornaviruses, particularily Coxsackieviruses and suggests that as with 
other Picornaviruses the VPg end group prevents Coxsackievirus recognition. 
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CHAPTER 6: RLR DIMERISATION 
6.1: Introduction   
Once a viral ligand has been detected and bound by RIG-I and MDA5, both signal 
downstream through their CARDs to activate IRF3/7 and NF-κB indirectly, via the 
protein intermediate MAVS [329]. After interaction with RIG-I and MDA5, MAVS 
goes on to recruit and activate a variety of other proteins, including TRAF2, TRAF3, 
and TRAF6 [330-332]. These TRAF proteins then signal further downstream to the IκB 
kinase (IKK) family members, to activate the transcription factors IRF3/7 and NF-κB, 
and initiate an immune response.  
RIG-I, MDA5, and LGP2 have been proposed to homo- and heterodimerise upon viral 
ligand detection. This process involves the C-terminal RD, which is important for 
controlling RLR-mediated IFN responses. RIG-I has two states; an inactive (closed) one 
and an active (open) one. In the inactive state, the CARDs and the helicase domain are 
repressed by the RD. Once a viral ligand binds to the RD, a conformational change 
occurs, converting RIG-I to the active state. This results in the dimerisation of RIG-I 
and the initiation of downstream signalling via the CARDs. Without the RD, RIG-I 
constitutively activates downstream signalling, whilst over-expression of the RD 
inhibits the antiviral response [333].  
Dimerisation of the RLRs is essential for them to function correctly. LGP2 has been 
suggested as a negative regulator of the RIG-I- and MDA5-mediated antiviral response, 
as its over-expression inhibits virus-induced IRF3 and NF-κB activation [334-336]. 
LGP2 has been proven to be a regulator for RIG-I- and MDA5-dependent signalling via 
its RD. Although it was previously thought that LGP2 inhibits dimerisation of RIG-I 
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and its interaction with MAVs, it has now been shown that LGP2 augments MDA5-
dependent signalling [337]. 
Recently it has been shown that MAVS requires homo-dimerisation through its CARD 
domain as part of its requirements for signalling [338], it would seem very possible that 
the same is true of RIG-I and MDA5 both through their CARD domains as well. It is 
already established that TLRs form homodimers or heterodimers in order to induce 
signalling [108] as well as NLRs forming oligomers in the form of the inflammasome. 
Oligomerisation of PRRs appears to be a crucial role in the induction of an immune 
response in creating signalling platforms. To establish whether the same is true of the 
RLRs, immunoprecipitation was used in order to determine whether MDA5 or RIG-I 
formed homodimers, and whether they also formed heterodimers with each other or 
LGP2. 
To test whether RIG-I, MDA5, and LGP2 homo- or heterodimerise together, 
immunoprecipitation experiments were performed. Immunoprecipitation is a technique 
used to precipitate a protein out of a lysate using an antibody specific for that protein 
coupled with beads specific for the antibody. The technique can be used to isolate and 
concentrate a particular protein, as well as determine if dimerisation between two 
proteins has occurred. 
In this project, RIG-I, MDA5, or LGP2 antibodies were used to precipitate out their 
respective protein, and western blotting was then used to detect a different protein, i.e. 
precipitate out MDA5 and then perform western blotting to detect LGP2.  
RIG-I is 110 KDa, MDA5 is 117 KDa, while LGP2 is smaller and is around 60 KDa. 
Thus a dimer of RIG-I should be roughly 200 KDa, as should an MDA5 dimer, while a 
RIG-I/MDA5 with LGP2 dimer should be around 170 KDa. The results obtained are in 
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three sets, those precipitated for RIG-I, MDA5 and LGP2 and each set contains a 
control which is a boiled sample. Each precipitation/gel contains an unstimulated 
sample and CVB3 stimulations at 1, 2, 4 and 6 hours. 
6.2: Results   
6.2.1: MDA5 Homodimerisation  
Cardiac cells were stimulated with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, 
and an MDA5 Goat pAb was used to precipitate MDA5 out of the cell lysate. The 
western blot results after incubating with MDA5 Rabbit pAb and detecting using 
polyclonal Swine anti-Rabbit Ig HRP are shown in Figure 6.1.  
 
Figure 6.1 - Homodimerisation of MDA5. Cardiac cells were stimulated with CVB3 
for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-cleared twice 
with PAS beads. Incubation with MDA5 Goat pAb and PAS beads followed, to 
precipitate MDA5 out of the lysate. The resulting pellets were washed in lysis buffer 
and analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing Sample Buffer) 
and western blotting with MDA5 Rabbit pAb primary antibody followed by polyclonal 
Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to visualise the 
protein bands. kDa: kiloDalton.  
 
MDA5-dimers 
~200 kDa 
MDA5 Monomers 
~110 kDa 
 
MDA5-LGP2 
dimers ~170 kDa 
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The gel where the cell lysate was precipitated for MDA5 and subsequent western blot 
performed for MDA5 shows bands around 200 kDa for all the time points suggesting 
that MDA5 does indeed form a dimer. There are also bands around 170kDa which could 
be an MDA5-LGP2 dimer as well as a band at around 110kDa which is most likely the 
MDA5 monomer.  
As a control cardiac cells were stimulated with CVB3 for 1, 2, 4, or 6 hours, or left 
unstimulated, and an MDA5 Goat pAb was used to precipitate MDA5 out of the cell 
lysate. The samples were analysed via reducing conditions as a control to determine if 
the dimer could be disrupted. Western blot results after incubating with MDA5 Rabbit 
pAb and detecting using polyclonal Swine anti-Rabbit Ig HRP are shown in Figure 6.2.  
 
Figure 6.2 - Homodimerisation of MDA5 under reducing conditions. Cardiac cells 
were stimulated with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell 
lysate was pre-cleared twice with PAS beads. Incubation with MDA5 Goat pAb and 
PAS beads followed, to precipitate MDA5 out of the lysate. The resulting pellets were 
washed in lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE -Reducing 
Sample Buffer) and western blotting with MDA5 Rabbit pAb primary antibody 
followed by polyclonal Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was 
used to visualise the protein bands. kDa: kiloDalton.  
MDA5 Monomers 
~110 kDa 
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The data showed that the 200 kDa dimer was disrupted and broke down into monomers 
with a Mw of 110 kDa. 
6.2.2: MDA5 – LGP2 Interactions 
Western blotting was performed using a LGP2 Rabbit pAb followed by a polyclonal 
Swine anti-Rabbit Ig HRP (Figure 6.3). Faint higher bands approximately 170 kDa can 
be seen, possibly suggesting the presence of a MDA5- LGP2 dimer. A strong band of 
60 kDa was also seen, which is most likely the LGP2 monomers.  
 
Figure 6.3 - Association between MDA5 and LGP2. Cardiac cells were stimulated 
with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-
cleared twice with PAS beads. Incubation with MDA5 Goat pAb and PAS beads 
followed, to precipitate MDA5 out of the lysate. The resulting pellets were washed in 
lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing 
Sample Buffer) and western blotting with LGP2 Rabbit pAb primary antibody followed 
by polyclonal Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to 
visualise the protein bands. kDa: kiloDalton 
 
 
MDA5-LGP2 dimers 
~170 kDa 
 
 
~16000kDa 
LGP2 monomers ~60 
kDa 
 
 
~16000kDa 
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6.2.3: RIG-I Homodimerisation  
Cardiac cells were stimulated with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, 
and a RIG-I Goat pAb was used to precipitate RIG-I out of the cell lysate. The western 
blot results after incubating with RIG-I Rabbit pAb and detecting using polyclonal 
Swine anti-Rabbit Ig HRP are shown in Figure 6.4. A boiled control using X2 SDS-
PAGE Reducing Sample Buffer was performed to illustrate that reducing conditions 
disrupt protein structure (figure 6.5).  
  
 
 
Figure 6.4 - Homodimerisation of RIG-I. Cardiac cells were stimulated with CVB3 
for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-cleared twice 
with PAS beads. Incubation with RIG-I Goat pAb and PAS beads followed, to 
precipitate RIG-I out of the lysate. The resulting pellets were washed in lysis buffer and 
analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing Sample Buffer) and 
western blotting with RIG-I Rabbit pAb primary antibody followed by polyclonal 
Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to visualise the 
protein bands. kDa: kiloDalton.  
 
RIG-I Monomers 
~110 kDa 
 
RIG-I Dimers~190 
kDa 
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In this instance it was shown that bands of around 190 kDa were present at all time 
points after stimulation with CVB3 suggesting the presence of a RIG-I dimer. RIG-I 
even appears to be a dimer in unstimulated cells, which is not consistent with a study 
performed by Cui et al., 2008. A band at around 110 kDa showing RIG-I monomers can 
also be seen.  
 
Figure 6.5 - Homodimerisation of RIG-I under reducing conditions.. Cardiac cells 
were stimulated with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell 
lysate was pre-cleared twice with PAS beads. Incubation with RIG-I Goat pAb and PAS 
beads followed, to precipitate RIG-I out of the lysate. The resulting pellets were washed 
in lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE -Reducing Sample 
Buffer) and western blotting with RIG-I Rabbit pAb primary antibody followed by 
polyclonal Swine anti-Rabbit Ig HRP. A boiled control using X2 SDS-PAGE Reducing 
Sample Buffer was also performed. Enhanced chemiluminescence was used to visualise 
the protein bands. kDa: kiloDalton.  
 
As expected under reducing conditions the RIG-I dimer is disrupted and we can detect 
RIG-I monomers as seen in Figure 6.5.  
  
RIG-I Monomers 
~110 kDa 
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6.2.4: RIG-I – LGP2 Interactions   
The association between LGP2 and RIG-I can be seen in Figure 6.6, showing the 
western blot results after incubating with LGP2 Rabbit pAb and detecting using 
polyclonal Swine anti-Rabbit Ig HRP. 
 
 
Figure 6.6 - Association between RIG-I and LGP2. Cardiac cells were stimulated 
with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-
cleared twice with PAS beads. Incubation with RIG-I Goat pAb and PAS beads 
followed, to precipitate RIG-I out of the lysate. The resulting pellets were washed in 
lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing 
Sample Buffer) and western blotting with LGP2 Rabbit pAb primary antibody followed 
by polyclonal Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to 
visualise the protein bands. kDa: kiloDalton.  
 
The gel shows a band around 170 kDa which is the RIG-I –LGP2 heterodimer as well 
as a 60 kDa, which is an LGP2 monomer. Thus verifying LGP2 and RIG-I associations. 
 
LGP2 Monomers 
~60 kDa 
 
RIG-I-LGP2 
Dimers ~170 kDa 
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6.2.5: LGP2 Homodimerisation 
In order to determine whether LGP2 also homodimerises, cardiac cells were stimulated 
with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and an LGP2 Goat pAb was 
used to precipitate LGP2 out of the cell lysate. The western blot results after incubating 
with LGP2 Rabbit pAb and detecting using polyclonal Swine anti-Rabbit Ig HRP can be 
seen in Figure 6.7.  
 
 
 
Figure 6.7 - Dimers and Monomers of LGP2. Cardiac cells were stimulated with 
CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-cleared 
twice with PAS beads. Incubation with LGP2 Goat pAb and PAS beads followed, to 
precipitate LGP2 out of the lysate. The resulting pellets were washed in lysis buffer and 
analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing Sample Buffer) and 
western blotting with LGP2 Rabbit pAb primary antibody followed by polyclonal 
Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to visualise the 
protein bands. kDa: kiloDalton.  
 
 
LGP2-RLR Dimers 
~160 kDa 
 
LGP2 Monomers 
~60 kDa 
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The results showed that there were two bands for each time point, one at around 170 
kDa which is most likely an LGP2 heterodimer with either RIG-I or MDA5. The other 
band is around 60 kDa showing LGP2 monomers at all time points. It should be noted 
that while LGP2 appears to dimerise with RIG-I and MDA5 it clearly does not under 
these conditions homodimerise. 
Samples were also run under reducing conditions see figure 6.8. The results showed that 
the LGP2-RLR heterodimer was disrupted under reducing conditions and broke down 
into monomers and smaller fragments. 
 
Figure 6.8 - Monomers of LGP2. Cardiac cells were stimulated with CVB3 for 1, 2, 4, 
or 6 hours, or left unstimulated, and the cell lysate was pre-cleared twice with PAS 
beads. Incubation with LGP2 Goat pAb and PAS beads followed, to precipitate LGP2 
out of the lysate. The resulting pellets were washed in lysis buffer and analysed using 
SDS-PAGE (using X2 SDS-PAGE -Reducing Sample Buffer) and western blotting with 
LGP2 Rabbit pAb primary antibody followed by polyclonal Swine anti-Rabbit Ig HRP. 
Enhanced chemiluminescence was used to visualise the protein bands. kDa: kiloDalton.  
 
 
LGP2 Monomers 
~60 kDa 
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6.2.6: LGP2 – MDA5 Interactions  
Heterodimerisation between LGP2 and MDA5 appears to occur at all time points, 
indicated by the bands appearing near the 170 kDa mark. The bands around the 110 kDa 
mark imply that MDA5 monomers are also present. It seems that only a percentage of 
LGP2 is required to associate with MDA5, as MDA5 appears as a monomer as well. 
Treatment with SDS could have disrupted the bond between LGP2 and MDA5, thereby 
allowing the detection of MDA5 monomers.  
 
 
 
Figure 6.9 - Association between LGP2 and MDA5. Cardiac cells were stimulated 
with CVB3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-
cleared twice with PAS beads. Incubation with LGP2 Goat pAb and PAS beads 
followed, to precipitate LGP2 out of the lysate. The resulting pellets were washed in 
lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing 
Sample Buffer) and western blotting with MDA5 Rabbit pAb primary antibody 
followed by polyclonal Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was 
used to visualise the protein bands. kDa: kiloDalton.  
 
MDA5 Monomers 
~110 kDa 
 
MDA5-LGP2 
dimers ~170 kDa 
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6.2.7: LGP2 – RIG-I Interactions   
Similarly, heterodimerisation between LGP2 and RIG-I can be seen at all time points, 
indicated by the top bands near the 170 kDa mark. Monomers of RIG-I can also be 
seen, as indicated by the bands around the 110 kDa mark. 
 
 
 
Figure 6.10 - Association between LGP2 and RIG-I. Cardiac cells were stimulated 
with CBV3 for 1, 2, 4, or 6 hours, or left unstimulated, and the cell lysate was pre-
cleared twice with PAS beads. Incubation with LGP2 Goat pAb and PAS beads 
followed, to precipitate LGP2 out of the lysate. The resulting pellets were washed in 
lysis buffer and analysed using SDS-PAGE (using X2 SDS-PAGE Non-Reducing 
Sample Buffer) and western blotting with RIG-I Rabbit pAb primary antibody followed 
by polyclonal Swine anti-Rabbit Ig HRP. Enhanced chemiluminescence was used to 
visualise the protein bands. kDa: kiloDalton.  
 
 
 
 
RIG-I-LGP2 
Dimers ~170 kDa 
 
RIG-I Monomers 
~110 kDa 
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6.3: Discussion  
Both MDA5 and RIG-I are capable of forming homodimers as well as heterodimers 
with LGP2. It would appear that in the native state both RIG-I and MDA5 form 
heterodimers with LGP2, possibly to prevent signalling without the presence of a 
pathogen. Upon CVB3 infection the MDA5-LGP2 dimer no longer occurs and an 
MDA5-MDA5 homodimer forms that can cause a signalling cascade. As RIG-I does not 
recognise the virus it remains as a heterodimer with LGP2 at all time points and does 
not form a homodimer.  It should be noted that there is no evidence of LGP2 forming a 
homodimer. There also does not appear to be any cleavage of the RLRs even at the 6 
hour time point.  
The function and mechanism of LGP2 in innate immunity is still puzzling. So far, it is 
known that the LGP2 RD can regulate RIG-I and MDA5-dependent signalling. This 
study aimed to determine whether the RLRs dimerise. It can be seen that RIG-I and 
MDA5 exist primarily as homodimers, but also as monomers, in cardiac cells, whilst 
LGP2 exists as a monomer. RIG-I and MDA5 can also heterodimerise with a 
percentage of LGP2. The perplexing question is that although heterodimers between 
LGP2 and RIG-I or MDA5 are present in the LGP2 immunoprecipitations, in the 
MDA5 or RIG-I immunoprecipitations, LGP2 presence is only detected as a monomer. 
These results could be due to the higher affinity of the LGP2 RD with the other RLRs, 
enabling it to bind and precipitate RIG-I or MDA5, whereas MDA5 or RIG-I have a 
lower affinity, and may therefore not be able to bind a detectable percentage of higher 
LGP2 aggregates.  
There are both advantages and disadvantages to using immunoprecipitation in order to 
determine interaction between two molecules. The proteins pulled through will be in 
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their native state and concentration and due to the small quantities of protein involved, 
procedures such as mass spectrometry are not possible. Western blotting is highly 
specific  so still gives an exact result as to whether the two proteins interact. The 
downside is that it only detects stable interactions and does not elucidate whether the 
interactions are direct or whether other proteins have been pulled through in the 
complex. However, by working out the Rf (relative mobility) of the proteins it is 
possible to determine the molecular weight of the complex and this determine the likely 
components. In order to make sure unspecific binding to the sepharose beads was not 
occuring pre-clears were performed and removes the posibility of non-specific binding 
to the beads.  
It still needs to be determined whether these are direct interactions occuring. Due to the 
molecular weights being detected it would seem likely however other small moleculaes 
may be in the complex and aid interaction between the RLRs. An interesting route for 
further study would be to determine the specific proteins in the complex precipitated 
and to explore the nature of interaction between the RLRs. 
Overall, this study concludes that LGP2 and RIG-I or MDA5 associate in cardiac cells, 
and that there is a synergistic mechanism of RLR association for viral detection.  
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CHAPTER 7: DISCUSSION 
 
Coxsackieviruses can cause serious infection particularly in children leading to severe 
inflammatory disorders of the heart, pancreas and CNS. The main disorders associated 
with CVB3 are myocarditis, pancreatitis, aseptic meningitis and encephalitis as well as 
complications that can occur such as myocarditis leading to chronic dilated 
cardiomyopathy in persistent infections [12;339]. Myocarditis occurs due to persistent 
infection causing an immune response that damages the cells, with lesions that occur on 
the heart tissue being due to viral lesion and the immune response [340]. Pancreatitis is 
similarly caused by both the viral factors and the hosts immune response [341]. 
Understanding the immune response therefore is crucial to developing a way of 
preventing the damage caused by the host immune response, as well as clearing the 
infection.  
The immune system, consisting of two main branches of immunity (innate and 
acquired), defends the human body against invading pathogens. Innate immunity is the 
first line of defence against pathogens, and responds rapidly to invading microbes. It 
does this via pattern recognition receptors (PRRs) which can distinguish self from non-
self, and recognise certain microbial components, termed pathogen-associated 
molecular patterns (PAMPs), to initiate an appropriate immune response. Recognition 
of PAMPs by PRRs leads to the rapid activation of latent transcription factors (such as 
NF-κB and IRF3) to stimulate the expression of antimicrobial genes and the production 
of type I interferons (IFN) [342].  
The Toll-like receptors (TLRs) are an important class of PPRs. The 13 currently known 
members within the TLR family recognise a wide range of different PAMPs, and 
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initiate appropriate downstream signalling (via two different pathways: the MyD88-
dependent pathway; and the MyD88-independent (TRIF-dependent) pathway) to 
activate the innate and adaptive immune response. Several TLRs are important for the 
recognition of different viruses, including TLR2, TLR3, TLR4, TLR7/8, and TLR9.  
Along with the TLRs, several new TLR-independent PRRs have been discovered, 
including the Retinoic-acid Inducible Gene-I (RIG-I)-Like Receptor (RLR) family. 
There are three known members: RIG-I [343], Melanoma Differentiation-Associated 
gene 5 (MDA5) [344], and Laboratory of Genetics and Physiology 2 (LGP2) [345]. The 
RLRs detect cytoplasmic viral RNA during viral replication, and preferentially 
recognise different viruses, triggering the host‟s Interferon response.  
RIG-I has been shown to detect a number of both positive and negative stranded 
viruses, as well as several different viral PAMPs, whilst MDA5 has been shown to be 
critical for Picornaviridae detection, including CVB3. Despite the wealth of research on 
identifying the RLR ligands, the precise PAMPs recognised by each RLR are, as yet, 
still undetermined.  
The structure of Coxsackieviruses is relatively simple, consisting of a viral capsid 
containing the single positive stranded RNA genome [346]. The nucleic acid takes on 
several forms throughout the viral life cycle. 
The native state of the RNA genome is a single stranded positive sense RNA and 
therefore would most likely to be recognised by TLRs 7 or 8 and RIG-I 
[108;109;347;348]. However for RIG-I, the all important 5‟ppp group at the end of the 
ssRNA is replaced or blocked by the CVB3 VPg [349;350]. There is evidence that the 
VPg molecule can be removed by the hosts “unlinking enzyme” so RIG-Is involvement 
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cannot be ruled out completely. TLR 7 and 8 have already been shown to be crucial in 
CVB3 mediated inflammatory response in the myocardium by Triantafilou et al [351]. 
Two forms of dsRNA are also present during the CVB3 life cycle. The first is the 
replicative intermediate (RI), a positive sense ssRNA to which 6 to 8 nascent negative 
strands are attached, which form double stranded sections where the main full length 
RNA and nascent chains join. VPg molecules are usually found on the end of the 
nascent chains so the RI is unlikely to be recognised by RIG-I. The second form is the 
replicative form (RF), a dsRNA intermediate with one full copy of both a positive and 
negative chain attached [352;353]. The RF seems the most likely ligand in CVB3 for 
MDA5 recognition. Finberg et al [354] showed the importance of MDA5 and the RLR 
adaptor molecule MAVS in the Type I IFN response to CVB3 in mice but did not reveal 
the specific RNA structure which MDA5 recognises.  
It has been shown that RIG-I recognizes single-stranded RNA (ssRNA) containing a 
terminal 5 -triphosphate (ppp), as well as linear dsRNA no longer than 23 nucleotides. 
MDA5 recognition is less clear, since it does not sense viral genomic ssRNA. It seems 
to recognise long strands of dsRNA but the mechanism by which this occurs has not 
been revealed. Pichlmair et al [289] using mainly biochemical methods had suggested 
that MDA5 senses high order structured RNA containing ssRNA and dsRNA, however 
that fails to explain why MDA5 can sense Poly:I:C, which is a synthetic long dsRNA or 
dsRNA viruses such as Reoviruses [286] or why it cannot sense Picornavirus genomic 
ssRNA that contains highly ordered secondary structures and tertiary RNA structures in 
the 3‟ and 5‟UTR regions. The inherent problem with the study by Pichlmair et al is that 
they rely on immunoprecipitations with a dsRNA-specific antibody in order to isolate 
RNA/MDA5 complexes. Using this method they demonstrated that infected cells 
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contained not only dsRNA but also ssRNA of high molecular weight, which was found 
to be immunostimulatory. The problem is that such biochemical isolations rely 
exclusively on the specificity of the antibody used and they are prone to artefactual 
associations. Under these conditions, weak or transient receptor-ligand associations 
might be lost and artefactual associations might be retained. Therefore although 
Pichlmair et al have given us a clue on what the MDA5 ligand might be, by saying that 
it is most likely an RNA web rather than simply long molecules of dsRNA, they have 
left us with a lot of questions regarding the exact MDA5 ligand.  
In this regard, this project aims to enhance the current knowledge on whether the RNA 
helicase RIG-I or MDA5 is the primary detector of Coxsackieviruses. Is it simply the 
double stranded structure of the RNA or are there other structures within the RNA that 
are required for recognition? How important a role does MDA5 play in the immune 
response to CAV9 and CVB3? Does RIG-I play any role in Coxsackievirus 
recognition? Do the RLRs oligomerise or co-localise with the virus during infection? 
The goal of the present study was to determine whether RIG-I or MDA5 participate in 
the induction of type I IFN in response to Coxsackievirus infection and to determine the 
specific RNA ligand that was recognized and activated these sensors using non-invasive 
methods. 
Coxsackieviruses Group A (CAV) and Group B (CVB) are positive ssRNA viruses 
therefore in addition to their ssRNA genome there are also substantial amounts of 
cytosolic dsRNA produced during the replicative life cycle of these positive ssRNA 
viruses. Thus during a CAV or CVB infection, there is a pool of viral RNA that trigger 
the host‟s innate immune response, raising the question of which viral RNA species is 
responsible for MDA5 activation. In this study, for the first time, viral ssRNA as well as 
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the replicative intermediate dsRNA (RF) and the high order replicative intermediate 
(RI), which is basically a dsRNA RF with a nascent ssRNA viral strand, were isolated.  
A negative ssRNA virus such as Influenza A virus was also used as a control since it is 
well established that RIG-I acts as a sensor triggering interferon production in the 
presence of negative ssRNA virus such as Influenza A virus [285]. 
The experiments showed that there was no interaction of MDA5 with the positive sense 
genomic ssRNA. However MDA5 recognised the dsRNA produced during the CVA 
and CVB replication as well as RI-RNA which has a dsRNA core, highlighting the 
importance of dsRNA in MDA5 recognition. Using fluorescent imaging methods, the 
association of MDA5 with the replicative form of enteroviruses was visualised. This is 
the first report of the visualization of dsRNA and MDA5, which provides unique 
evidence between the relationship of viral dsRNA and MDA5 and proves without a 
doubt that the dsRNA replicative intermediate form of positive sense ssRNA viruses is 
the effective agonist recognised by MDA5. 
Furthermore when synthetic dsRNA was used with either 5‟OH ends or 5‟ ppp ends 
they both elicited IFNα/β response, however dsRNA with 5‟OH ends was more 
immunostimulatory in HEK/MDA5 cells revealing that MDA5 could have a higher 
affinity for 5‟OH dsRNA. 
It seems that MDA5 is an essential sensor of the innate response that unlike TLRs or 
RIG-I is not involved in the initial steps of ssRNA viral infection but detects and 
activates the interferon response only when the RNA viruses begin to replicate 
generating replicative intermediates thus posing a threat for the host cell.  
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A very recent study by Peisley et al supports our findings of dsRNA viral recognition 
by MDA5. This study revealed the MDA5 mechanism of ligand recognition. They have 
shown MDA5 assembly into oligomers composed of segmental arrangement of MDA5 
dimers along the length of dsRNA [355]. They propose a role of ATP hydrolysis as a 
conformational switch for MDA5 activation and signalling.  
These new insights should pave the way for the development of future antiviral 
therapeutics. An increased understanding of the complex mechanisms of viral host 
defence will eventually helps us design new targets for viral infections.    
To verify these findings Huh7 and Huh7.5.1 cells were used to determine the role of 
RIG-I in infection by CVB3. Huh7.5.1 have a mutation within the RIG-I gene so the 
RIG-I pathway is inactive in the cell line. Huh7 have a working RIG-I pathway and 
both Huh7 and Huh7.5.1 cells have an otherwise full active set of PRRs including 
functional MDA5.  
CBV3 ssRNA and dsRNA as well as synthetic dsRNA poly(I:C) was used to stimulate 
Huh cells. What is clear from this data is that despite RIG-Is ability to recognise 
Influenza ssRNA and create an immune response it can‟t recognise CVB3 ssRNA or 
dsRNA. This confirms that RIG-I does not contribute in the IFNα/β host response 
during an infection with Picornaviridae. 
Pattern recognition receptors have a well established tendency towards forming dimeric 
or oligomeric structures within the cell, both in hetero and homo form. TLRs form 
homodimers, with the exception of TLR2 which forms a heterodimer with either TLR1 
or TLR6, to create a strong signalling platform to recruit MyD88, TRIF, TRAM and 
TIRAP [108]. Recruitment and dimerisation both occur through the TIR domain on the 
TLRs and downstream molecules. It is the binding of their ligand that causes 
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dimerisation of TLRs and brings together the TIR domains creating a stable platform for 
interaction with downstream factors [116].  
NLRs form larger oligomeric structures called inflammasomes with other molecules 
such as ASC, binding through PYDs or CARDs depending on the NLR. As with TLRs, 
binding their ligands causes conformational changes in NLRs resulting in the nuclear 
binding domain becoming available for ATP or NTP binding which in turn frees the 
CARD/PYD for oligomerisation [356].  
In the RLR pathway both RIG-I and MDA5 form complexes with MAVS through their 
CARD domains and MAVS has been shown to form a homodimer, again through the 
CARD domain [357]. As with TLRs and NLRs binding of the RLRs to their ligands 
causes conformational change and this releases the CARD domains for homotypic 
interactions with other CARD domains [358;359].  
While CARD-CARD interactions have been shown for RLRs with MAVS, there is little 
in terms of evidence as to dimers or oligomers forming between the RLRs. Homodimers 
(or oligomers) in CARD containing receptors has already been shown to be possible 
through the NLR inflammasomes and MAVS. And in many PRRs dimerisation has 
been shown to be a crucial step in creating a stable signalling platform for downstream 
signalling upon ligand binding. Therefore it would seem likely that once the RLRs have 
bound their specific PAMP a dimer would form and create a binding platform for 
MAVS and perhaps other signalling accessory molecules as well. As well as 
homodimers, as can be seen through TLR2, it may also be possible for heterodimers 
between the RLRs to occur. 
Immunoprecipitation was used to determine whether the RLRs formed complexes with 
themselves or other the RLRs by precipitating for a particular RLR and then running the 
164 
 
precipitate through gel electrophoresis and probing for either the same RLR or a 
different one. If MDA5 or RIG-I forms a homodimer then a band will appear at 
approximately twice the known molecular weight of that RLR, while a heterodimer with 
LGP2 would form a band at a slightly lower molecular weight as LGP2 has a lower 
molecular weight.  
The results showed clearly that for MDA5, a heterodimer with LGP2 exists in the 
unstimulated state. Upon infection with CVB3 this heterodimer disappears and is 
replaced by an MDA5 homodimer. RIG-I differs to MDA5 in that while it forms a 
heterodimer with LGP2, this does not disappear upon CVB3 infection. There is also 
some evidence that RIG-I is capable of forming a homodimer, however it appears that 
the RIG-I-LGP2 dimer predominates. Precipitates for LGP2 show that while LGP2 can 
form a dimer with RIG-I and MDA5, it does not appear to homodimerise.  
Through this data it can be proposed that LGP2 is bound to both RIG-I and MDA5 in an 
inactive state, perhaps keeping them inactive as negative regulation in the absence of 
infection. With the presence of a ligand LGP2 releases the RLR (in this case MDA5 in 
the presence of CVB3 dsRNA) allowing it to homodimerise and form a signalling 
platform through which it can interact with MAVS and initiate an immune response. As 
LGP2 does not contain a CARD domain it must dimerise using a different method and 
could suggest that the same is true of RIG-I and MDA5 allowing the CARDs to remain 
free for MAVS binding. Further work needs to be carried out to determine the exact 
nature of the dimers being formed. 
Overall it can be seen that MDA5 forms a crucial part of the innate immune response to 
CVB3 alongside the TLRs and NLRs. The idea of a trinity of PRRs seems very valid in 
the case of CVB3 infection with MDA5 being crucial in the Type- IFN response, while 
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TLRs 4, and 7/8 are responsible for the main cytokine response and TLR3 for part of 
the Type-I IFN response and also the Type-II IFN response. The NLRs respond by 
inducing caspase-1 to cleave molecules such as Pro-IL-1β into IL-1β creating a further 
step in the immune response. CVB3 requires a complement of PRRs from the 3 family 
members of the trinity to create a full immune response. 
This study has clearly shown that of the RLRs it is MDA5 that responds to and 
recognises CVB3. It has also shown that MDA5 specifically binds to the dsRNA of 
CVB3 that is formed during viral replication and known as the Replicative Form. End 
structures such as the 5‟ppp group preferred as a ligand by RIG-I are not favoured by 
MDA5 and it is most likely that the most crucial structural factor in MDA5 binding is 
the presence of long double stranded RNA. There is also clear evidence to suggest that 
LGP2 acts in a regulatory role by forming a dimer with RIG-I or MDA5 in a cells 
natural state and releases them upon ligand binding allowing signalling activation.  
Further work to be carried out include deterining the exact way in which the RLRs 
dimerise. If LGP2 does not contain a CARD region nthen how does it dimerise with 
MDA5 and RIG-I? Are there other molecules that form a part of the receptor complex 
and would it be possible to run further tests on precipitate to determine the exact 
contents and the proteins present? It would also be of great interest to determine 
MDA5s role within myocarditis. In a disease where the damage contributation largely 
comes from presistant inflmmation would preventing MDA5 from binding CVB or the 
dsRNA intermediate alleviate some of the damage caused by the infection? Or would it 
simply prevent viral recognition and inhibit the immune response from protecting the 
host from the virus. Mouse models could be a fascinating step forward in understanding 
MDA5s role in disease.  
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Recognition of CVB by TLRs and RLRs is becoming well understood, but to better 
understand the relationship between the PRRs in creating an innate immune response, 
CVB3s recognition by NLRs should be explored. 
A model can be suggested where Coxsackieviruses infect the host cell by inserting 
positive-sense ssRNA into the cytoplasm. During replication of its RNA a dsRNA 
intermediate occurs that acts as a ligand for MDA5. MDA5 in an inactive heterodimer 
with LGP2 undergoes a conformational change once bound to the dsRNA intermediate 
and is released from LGP2, allowing it form a homodimer. This creates a stable 
platform for the recruitment of MAVS and further downstream signalling to occur 
leading to the expression of Type-I IFNs and the expression of ISGs. Along with the 
response from TLRs and NLRs this forms crucial part of the innate immune response to 
Coxsackieviruses. 
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CHAPTER 8: APPENDIX 
 
X10 PBS 
 100 g NaCl 
 2.5 g KCl 
 14.4 g Na2HPO4 (or 18.0 g Na2HPO4 2H2O) 
 2.5 g KH2PO4 
 Add distilled water to 1000 ml 
 
For PBS Tween add 10 ml of Tween 20 and rinse tip in buffer. 
 
X1 PBS 
 50 ml from X10 stock 
 Raise to 500 ml with distilled water (add 450 ml). 
 
X2 PBS 
 100 ml from X10 stock 
 Raise to 500 ml with distilled water (add 400 ml). 
 
4% PFA  
 8.0 g of formaldehyde to 80ml distilled water 
 Heat to 60°C in fume hood 
 Add a few drops of 1 M NaOH to help dissolve (until clear). 
 Top up to 100 ml with distilled water. 
 Once the solid has dissolved, cool to RT and add 100 ml of X2 PBS. 
 
X1 PBS/0.02%BSA/0.02%NaN3/0.02%saponin 
 0.02% = 0.02g in 100 ml 
 In 500 ml 0.1 needed. 
 0.1 g of each added to 500 ml (sodium azide, saponin and albumin bovine 
serum) 
 
10% SDS 
 10 g SDS 
 In 100 ml of distilled water 
 
0.5 M Tris-HCl pH 6.8 (500 ml) 
 30.28 g Tris 
 500 ml distilled water 
 pH to 6.8 using concentrated HCl 
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1.5 M Tris-HCl pH 8.8 (500 ml) 
 90.85 g Tris 
 500 ml distilled water 
 pH to 8.8 using concentrated HCl 
 
X2 Reducing sample buffer 
 For 40 ml use 20 ml 0.5 M Tris pH 6.8 
 16 ml 10% SDS 
 10 g Glycerol 
 4ml 14.3 M β-mercaptoethanol 
 Small spatula full of bromophenol blue  
 
10% Resolving Gel (for 2 gels) 
 4.02 ml distilled water 
 2.5 ml 1.5 M Tris-HCl pH 8.8 
 100 µl 10% SDS 
 3.33 ml acrylamide/bis (wear gloves) 
 
To polymerise add: 
 50 µl 10% APS 
 5 µl TEMED 
 
4% Stacking Gel (for 2 gels) 
 6.1 ml distilled water 
 2.5 ml 0.5 M Tris-HCl pH 6.8 
 100 µl 10% SDS 
 1.3 ml acrylamide/bis 
 
To polymerise add: 
 100 µl 10% APS 
 30 µl TEMED 
 
X2 Transfer buffer 
 4.88 g Tris 
 20 ml 10% SDS 
 400ml isopropanol 
 pH to 8.3 with acetic acid 
 Make up to 1000 ml distilled water 
 
Running Buffer 
 100 ml x10 Running buffer 
 Make up to 1000 ml with distilled water 
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PBS Tween (2 litres) 
 200 ml x10 PBS in 1000 ml beaker. 
 Top up to 1000 ml with distilled water. 
 Add 2 ml of PBS Tween 20, dropping the tips into the PBS and using magnetic 
stirrer until mixed. 
 Decant 500 ml into another 1000 ml beaker and top both up to 1000 ml. 
 
Blocking Reagent 
 2 g Milk powder 
 In 40 ml PBS Tween 
 
Stripping Buffer 
 1.4 ml Mercaptoethanol (10 0mM) 
 40 ml 10% SDS (2%) 
 1.52 g Tris-HCl (62.5 mM) pH 6.7 
 Top up to 200 ml with PBS-Tween. 
 
NET Buffer (100 ml) pH 8.0 
 6.056 g Tris-HCl (500 mM) 
 8.768 g NaCl (1.5 M) 
 1.86 g EDTA (50 mM) 
 Make up to 100 ml with dH2O 
 
10mM Iodoacetamide (50ml) 
 92.5mg (0.0925g) in 50ml dH2O 
 
10% (w/v) NP-40 (50 ml) 
 5 g in 50 ml dH2O 
 
PMSF Stock (100 ml) 
 1.74 g PMSF in 100 ml ethanol 
 
Lysis Buffer (50 ml) 
 5 ml NET buffer 
 500 µl Iodoacetamide 
 5 ml NP-40 
 25 µl PMSF 
 2 Protease Tablets (We used 20 µl protease inhibitor) 
 Make up to 50 ml with dH2O.  
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Protein A – Sepharose 
 0.1 g in 1ml lysis buffer 
 Leave for atleast one hour to swell or overnight (in fridge). 
 
X2 Non-Reducing Sample Buffer 
 20 ml 0.5 M Tris pH 6.8 
 16 ml 10% SDS 
 10 g Glycerol 
 Small spatula full of bromophenol blue  
 
Lysis buffer for RNA Extraction 
 1.5 g TrisHCl (50 mM) 
 2.0 g NaCl (140 mM) 
 0.074 g MgCl2 (1.5 mM) 
 1.25 ml V/V NP4O (0.5%) 
 In 250 ml distilled water. 
 pH to 8.0 
 
Digestion buffer for T1 enzyme 
 50 mM TrisHCl – 0.6 g 
 1 mM EDTA     - 0.037 g 
 In 100 ml dH2O 
 pH 7.5 
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8.1: Abbreviations:  
 
5'ppp - 5'triphosphate 
AIM2 - Absent in Melanoma-2 
AP - Alkaline Phosphatase 
ASC - Apoptosis-associated Speck-like protein containing CARD 
BDV - Borna Disease Virus 
BIR - Baculovirus Inhibitor Repeat 
CAR - Coxsackie-Adenovirus Receptor 
CARD - Caspase Recruitment Domain 
CBA - Cytometric Bead Array 
CCHFV - Crimean Congo Hemorrhagic Gever Virus 
CHO - Chinese Hamster Ovary 
CNS - Central Nervous System 
CT - C-Terminal 
CTD - D-terminal Domain  
CVA - Coxsackievirus A 
CVB - Coxsackievirus B 
DAF - Decay Accelerating Factor 
DAMP - Danger Associated Molecular Pattern 
DAP - Diaminopimelic Acid 
DC - Dendritic Cell 
DD - Death Domain 
dsRNA - double stranded RNA 
ECL - Electrochemiluminescence 
EMCV - Ecephalomyocarditis virus 
ER - Endoplasmic Reticulum 
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ERK - Extracellular signal Related Kinases  
FADD - Fas-Associated Death Domain 
FCS - Fetal Calf Serum 
FITC - Fluorescein Isothiocyanate 
HCV - Hepatitis Virus C 
HEK - Human Embryonic Kidney 
HRP - Horseradish Peroxidase 
HTNV - Hantaan Virus 
HUH - Human Hepatocellular 
IFN - Interferon 
IFVA - Influenzavirus A 
IG - Immunoglobulin 
IL - Interleukin 
IKK - IκB Kinase 
IRAK - IL-1 Receptor-Associated Kinase 
IRF - Interferon Regulatory Factor 
ISG - Interferon-induced Genes 
JNK - Jun Kinases 
kDa - kiloDalton 
LGP2 - Lboratory of Genetics and Physiology 2 
LLC - Lewis Lung Carcinoma 
LPS - Lipopolysaccharide 
LRR - Leucine Rich Repeats 
LTA - Lipotechoic Acid 
MAPK - Mitogen Activated Protein kinase 
MAVS - Mitochondrial AntiViral Signalling 
MDA5 - Melanoma Differentiation Associated-gene 5  
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MDP - Muramyl Dipeptide 
MHC - Major Histocompatibility Complex 
MyD88 - Myeloid Differentiation primary response gene-88 
NBD - Nucleotide Binding Domain 
NDV - Newcastle Disease Virus 
NEMO - NF-κB Essential Modulator 
NF-κB - Nuclear Factor kappa-light-chain enhancer of activated B cells 
NLR - Nod-Like Receptor 
NOD - Nucleotide-binding Oligomerisation Domain-containing 
NT - N-Terminal 
P-IκB - phospho-IκB 
PAMP - Pathogen Associated Molecular Pattern 
PAS - Protein A Sepharose 
PBS - Phosphate Buffered Saline 
PE - Phycoerythrin 
PKR - Protein Kinase R 
PMT - Photomultiplier Tube 
PRR - Pattern Recognition Receptor 
PYD - Pyrin Domain 
RD - Rhabdo-myosarcoma or Regulatory Domain 
RF - Replicative Form (dsRNA) 
RI - Replicative Intermediate (dsRNA) 
RIG-I - Retinoic-acid Inducible Gene-I 
RIP - Receptor-Interacting Protein 
RLR - RIG-Like Receptor 
ROS - Reactive Oxygen Species 
RSV - Respiratory Syncitial Virus 
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RT - Room Temperature 
SCR - Short Consensus Repeats 
SDS-PAGE - Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SEAP - Secreted Embryonic Alkaline Phosphatase 
SeV - Sendai Virus 
ssRNA - single stranded RNA 
STING - Stimulator of Interferon Genes 
T-IκB - Total-IκB 
TAK - TGF-β  Activated Kinase 
TBK - TANK-Binding Kinase 
TC - Tissue Culture 
TIM - TRAF Interacting Motif 
TIR - Toll-Interleukin-1 Receptor 
TIRAP - TIR-domain containing Adaptor Protein  
TLR - Toll-Like Receptor 
TNF - Tumour Necrosis Factor  
TRADD - TNFR-Associated Death Domain 
TRAF - TNF Receptor Associated Factor 
TRAM - TRIF Related Adaptor Molecule 
TRIF - TIR domain-containing adaptor-inducing Interferon β 
UPS - Ubiquitin/Proteosome Sytem 
VP - Viral Protein 
VPg - Viral Protein genome-linked 
VSV - Vesicular Stomatitis Virus 
wt - Wild Type 
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